



CONTENTS

Variation of closing times	2524
Special information	2526
Legislation	2527
Government Departments	2529
Special Gazettes Nos S 351, S 352, and S 353 are herewith	



The date of publication of this Gazette is 23 November 1988.

**ADVERTISING RATES FOR
GOVERNMENT NOTICES**

These rates will be:

- \$345.00 per typeset page
- \$115.00 per camera-ready page
- \$225.00 per altered magnetic tape page
- \$150.00 per unaltered magnetic tape page

For further information contact Don Kime on (062) 95 4657.

**ADVERTISING RATES FOR
SPECIAL GAZETTES**

Government Notices rates plus \$100.00 per issue.

**ADVERTISING RATES FOR
PERIODIC GAZETTES**

Notices submitted for publication will be charged at the rate of \$260.00 per typeset page plus \$200.00 per issue. Material supplied as camera-ready copy and magnetic tape (altered and unaltered) will be charged at the respective Government Notices rates.

Variation of closing times

CHRISTMAS/NEW YEAR PERIOD

Commonwealth of Australia Gazette

The last regular *Gazette* for 1988 will be the Public Service issue to be published on 22 December 1988 with normal closing times. There will be no regular issues of the *Gazette* on 27 December 1988, 28 December 1988, 29 December 1988, 3 January 1989, 4 January 1989 and 5 January 1989.

The Government Notices Issue of 11 January 1989 will have normal closing times.

Friday, 6 January 1989 at 10.00 a.m.

Departments are requested to note the dates upon which regular issues will not appear and to make every effort to avoid the need for *Special Issues* during the holiday period by making arrangements for all necessary administrative and executive material to be gazetted by Wednesday 21 December 1988. Where possible all other material should be held over until the first regular issue of 1989.

N.N.—8878067

GENERAL INFORMATION

IMPORTANT COPYRIGHT NOTICE

© Commonwealth of Australia

This work is copyright. Apart from any use as permitted under the *Copyright Act 1968*, no part may be reproduced by any process without written permission from the Director Publishing and Marketing AGPS. Inquiries should be directed to the Manager, AGPS Press, Australian Government Publishing Service, GPO Box 84, Canberra ACT 2601.

Government Notices issues, published each Wednesday, containing all legislation, proclamations, special information and government departments notices and are sold at \$5.95 each or on subscription of \$290.00 (50 issues), \$150.00 (25 issues) or \$75.00 (12 issues).

NOTICES FOR PUBLICATION and related correspondence should be addressed to:

Gazette Officer, Australian Government Publishing Service, GPO Box 4007, Canberra ACT 2601. Telephone (062) 95 4656

or lodged at AGPS, Government Printing Office Building, Wentworth Avenue, Kingston. Notices are accepted for publication in the next available issue, unless otherwise specified.

Except where a standard form is used, all notices for publication must have a covering instruction setting out requirements. A typewritten original or good copies are to be provided, wherever possible double-spaced, with a margin surrounding the typewritten matter. Copy is to be confined to one side of the paper, sheets are to be of uniform size (preferably A4), numbered consecutively and fastened securely together. Dates, proper names and signatures particularly are to be shown clearly.

Copy will be returned unpublished if not submitted in accordance with these requirements.

CLOSING TIMES. Notices for publication should be lodged at AGPS, Government Printing Office Building, unless otherwise specified, by the following times (except at holiday periods for which special advice of earlier closing times will be given).

Government Notices Gazette all copy: Friday at 10.00 a.m. in the week before publication.

PRIVATE NOTICES

The rates of charge and conditions applying to acceptance of copy for private notices are as follows:

- (a) minimum charge up to 125 words \$58.00;
- (b) each 25 words (or part thereof) thereafter \$12.00.

Remittances must be forwarded with a copy of the notice for publication unless prior credit approval has been granted for account customers. Account customers are reminded that payment is due immediately on presentation of invoice. Should payment not be received within twenty-eight days of the invoice date, credit privileges will be withdrawn.

Notices received without payment or from account customers whose credit privileges have been withdrawn will be returned unpublished.

SUBSCRIPTIONS are payable in advance and are accepted for a maximum period of one year. All subscriptions are on a firm basis and refunds for cancellations will not be given. Rates include surface postage in Australia and overseas. Other carriage rates are available on application.

AVAILABILITY. The *Gazette* may be purchased by mail from:

Mail Order Sales, Australian Government Publishing Service, GPO Box 84, Canberra ACT 2601

or over the counter from Commonwealth Government Bookshops at:

Adelaide: 55 Currie St, tel. (08) 237 6955
Brisbane: 294 Adelaide St, tel. (07) 229 6822
Canberra: 70 Alinga St, tel. (062) 47 7211
Hobart: 162 Macquarie St, tel. (002) 23 7151
Melbourne: 347 Swanston St, tel. (03) 663 3010
Perth: 200 St George's Tce, tel. (09) 322 4737
Sydney: 120 Clarence St, tel. (02) 29 1940

Commonwealth Acts and Statutory Rules, Australian Capital Territory Ordinances and Regulations, and other Commonwealth Government publications may also be purchased at these addresses.

ALL REMITTANCES should be made payable to: Collector of Public Moneys, Australia Government Publishing Service.

OTHER ISSUES OF THE GAZETTE

Public Service issues contain notices concerning administrative matters, including examinations, vacancies, transfers and promotions within the Australian Public Service and the Services of the Australian Postal Commission, Australian Telecommunications Commission, Commonwealth Teaching Service and Defence Force appointments etc. These issues are published weekly at 10.30 a.m. on Thursday, and sold at \$8.95 each or on subscription of \$395.00 (50 issues), \$206.00 (25 issues) or \$103.00 (12 issues).

Business issues, published each Tuesday, containing Notices under the Co-operative Companies and Securities Scheme, Bankruptcy Act and Private Notices and sold at \$3.95 each or on subscription of \$220.00 (50 issues), \$116.00 (25 issues) or \$58.00 (12 issues).

Special issues include notices which require urgent publication. All costs associated with producing Specials will be borne by the responsible department or authority. A limited number of *Special Gazettes* will be made available for sale from the Commonwealth Government Bookshop, Canberra, on the day of publication. General distribution of these notices will be by their inclusion in the next published issue of the Government Notices *Gazette* or *Business Gazette* as well as in the next published issue of the series of the *Gazette* in which the notice would normally have been published.

Tariff concessions issues contain notices of tariff concessions proposed, granted or revoked in accordance with the provisions of Part XVA of the *Customs Act 1901*. These issues are published each Wednesday and are sold at \$1.95 or on subscription only at \$115.00 for 50 issues including surface postage.

Periodic issues contain lengthy notices of a non-urgent nature, including the following: certificates of Australian citizenship; registered tax agents; authorised celebrants; unclaimed deposits and moneys; Australian Public Service conditions of entry and advancement; appointments to the Australian Public Service; holders of import licences and tariff quotas. Issues are made at irregular intervals as required, at individual prices according to size. Advice of availability is given in the Government Notices, Business and Public Service issues immediately following the day of publication. Periodic issues are not available on subscription, but standing orders are accepted for all selected issues.

Purchasing and Disposals issues of the *Gazette* provide information on Commonwealth purchases and disposals and other matters of general interest to persons buying from or

selling to the Commonwealth. These issues are published each Wednesday and sold at \$3.95 or on subscription of \$200.00 including postage for 50 issues.

Index issues contain references to entries in the Government Notices issues and entries in the Orders in Council, Notices under the Superannuation Act, Notices under the Public Service Act, and Determinations under the Public Service Act sections of the Public Service issues. Index issues are published quarterly, are available over the counter from Commonwealth Government Bookshops and are supplied without charge to annual subscribers to the Government Notices issues.

N.N.—8878068

ISSUE OF PERIODIC GAZETTES

The following Periodic issues of the *Gazette* have been published.

Copies may be purchased from Commonwealth government bookshops or by mail from the relevant address given on the front page of this *Gazette*.

<i>Gazette number</i>	<i>Date of publication</i>	<i>Subject</i>
P1	18.1.88	Tariff Quotas—Transfer of Quota Allocations—1 January 1987 to 30 November 1987
P2	5.2.88	Australian Customs Service—Import Licences
P3	19.2.88	Tariff Quotas—Motor vehicles multiple period tender quota allocations—1 December 1987 to 31 January 1989
P4	22.2.88	Tariff Quotas—Motor vehicles multiple period tender quota allocations—1 October 1987 to 31 March 1989
P5	23.2.88	Tariff Quotas—Motor vehicles tender quota allocations—1 October 1987 to 31 March 1989
P6	26.2.88	Tariff Quotas—Textile, clothing, footwear quota allocations—1 January 1988 to 28 February
P7	16.3.88	<i>Wildlife Protection (Regulation of Exports and Imports) Act 1982</i>
P8	14.3.88	Tariff Quotas—1988 Base Quota Allocations—Listing of tariff quota holders
P9	24.3.88	Customs (Import Licensing) Regulations Exception Notice No. M68
P10	6.4.88	Tariff Quotas—Base Motor Vehicles Quota Allocations—Listing of tariff quota holders
P11	27.4.88	Tariff Quotas—Quota transactions for the period 871201 to 880331
P12	13.5.88	Tariff Quotas—Textiles, clothing and footwear allocations of 1988 residual tender by ballot
P13	27.5.88	Great Barrier Reef Marine Park Regulations (1987)
P14	24.6.88	Australian Capital Territory, <i>Unclaimed Moneys Ordinance 1950</i> , Petros NL (formerly Offshore Oil NL)
P15	24.6.88	Tariff Quotas—Cheese Quota Allocations—1 July 1988 to 30 June 1989—Listing of Tariff Quota Holders
P16	24.6.88	Tariff Quotas—Developing Country Quota Allocations—1 July 1988 to 28 February 1989—List of Quota Holders
P17	1.7.88	<i>Wildlife Protection (Regulation of Exports and Imports) Act 1982</i>
P18	30.6.88	<i>Life Insurance Act 1945</i> —Return of Unclaimed Moneys as at 31 December 1987
P19	15.7.88	Amendment No. 1 to the National Health and Medical Research Council Food Standards Code
P20	30.6.88	Statement of Unclaimed Money Deposits and Money for Year Ended 31.12.87
P21	22.7.88	Import Licences—Issued under the Customs (Import Licensing) Regulations for used, second hand or disposals earthmoving, construction and materials handling machinery and equipment—January to June 1988
P22	8.8.88	<i>Great Barrier Reef Marine Park Act 1975</i> —Permits granted, refused, suspended or revoked
P23	18.8.88	Tariff Quotas—Quota Transactions for the period 1 April 1988 to 30 June 1988
P24	12.9.88	<i>Wildlife Protection (Regulation of Exports and Imports) Act 1982</i>
P25	31.8.88	<i>National Memorials Ordinance 1928</i> —Determination of Nomenclature
P26	26.10.88	Tariff Quotas—Textiles, Clothing and Footwear Base quota allocations for the Period 1 December 1988 to 28 February 1989—List of quota Holders
P27	27.10.88	Tariff Quotas—Quota Transactions for the Period 1 July 1988 to 30 September 1988
P28	11.11.88	<i>Great Barrier Reef Marine Park Act 1975</i> Particulars of Permits Granted, Refused Suspended or Revoked for the Period 1 July 1988 to 30 September 1988

N.N.—8878069

Special Information

PROCLAMATION

Commonwealth of
Australia
N. M. STEPHEN
Governor-General

By His Excellency the
Governor-General of
the Commonwealth of
Australia

I, SIR NINIAN MARTIN STEPHEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and under subsection 358A (3) of the *Crimes Act 1900* of the State of New South Wales in the application of that Act to the Australian Capital Territory by virtue of subsection 6 (1) of the *Seat of Government Acceptance Act 1909*, hereby declare each of the following enactments to be a corresponding law:

- (a) *Search Warrants Act 1985*, of the State of New South Wales;

- (b) Part 11A of the *Crimes Act 1958*, of the State of Victoria.
(c) *Criminal Investigation (Extra-territorial Offences) Act 1987*, of the State of Western Australia;
(d) *Criminal Investigation (Extraterritorial Offences) Act 1984*, of the State of South Australia;
(e) *Criminal Investigation (Extra-Territorial Offences) Act 1987*, of the State of Tasmania; and
(f) *Criminal Investigation (Extra-territorial Offences) Act 1985*, of the Northern Territory.

(L.S.) GIVEN under my hand and the Great Seal of Australia on 14 November 1988.

By His Excellency's Command,
LIONEL BOWEN
Attorney-General

GOD SAVE THE QUEEN!

N.N.—8878070

NOTICES UNDER THE INDEPENDENT AIR FARES COMMITTEE ACT 1981

COST ALLOCATION REVIEW

EAST-WEST AIRLINES (OPERATIONS) LIMITED

In accordance with the provisions of section 13 of the *Independent Air Fares Committee Act 1981*, the Minister for Transport and Communications has requested the Independent Air Fares Committee to conduct a Cost allocation review in relation to air services provided by East-West Airlines (Operations) Limited over all its routes. A previous such review for the airline was completed in July 1985, and copies of the Committee's report are available from the IAFIC office.

The members of the Committee are Mr K. F. Wraith (Chairman), Dr D. W. Zink, A.M. and Mr A. Oliver, C.M.G.

For this cost allocation review, the Committee plans to hold public hearings during February and March 1989 in Brisbane, Cairns, Hobart and Sydney. Notices will be placed in the *Gazette* and relevant daily newspapers in December 1988 giving information about the dates and locations of the hearings.

Purpose of review

When conducting a cost allocation review, the Committee is required by the Act to determine the manner in which all costs incurred by the operator in providing regular public transport air services are to be recorded from the 'flag-fall' and 'distance' components of passenger fares. As part of a review, the Committee also takes public evidence concerning guidelines and principles to be applied in approving domestic air fares.

In the circumstances of this Cost allocation review, the Committee does not propose to completely re-examine all matters, but rather to concentrate on establishing what changes are appropriate to the previous cost allocations and fare setting guidelines so far as East-West is concerned.

Public Submissions

Interested persons, organisations and associations are invited to submit in writing any views they consider should be taken into account in the Cost allocation review for East-West Airlines. They should also indicate whether they wish to give oral evidence at the hearings.

An information paper, which includes details of matters the Committee wishes to consider during the review, can be obtained by telephoning the office of the IAFIC (03) 629 7174 or making a request in writing to the Secretary at the address set out below.

The closing date for written submissions is Friday, 20 January 1989. Two copies of all submissions would be appreciated, and should be addressed to the Secretary, Independent Air Fares Committee, GPO Box 94A, Melbourne Vic. 3001. Facsimile (03) 629 1853. Telex 38145.

<i>Operator and reference</i>	<i>Section of Act</i>	<i>Date notified</i>
Determination		
AIRLINES OF TASMANIA (C4/88)	25	16.11.88
In response to an application by the operator under section 25 of the IAFIC Act, determination of the following one-way economy air fares effective from 16 November 1988:		
Launceston-Flinders Is	\$60	Launceston-King Is \$93
being the same as those approved by Transport Tasmania.		
Decision		
EAST-WEST AIRLINES (D199/88)	17 (4)	10.11.88

Approval to offer, during the period 29 April 1989 to 28 April 1990, fixed price holiday discount air fares at discounts ranging from nil to 32.5 per cent off the approved economy air fares at 1.11.88 depending on route and season, and available under specified conditions as proposed by the operator including that fares must be used in conjunction with authorised package holidays.

Approved on basis of estimates provided by the operator that the discount fares will generate additional traffic and improve profitability.

ANSETT AIRLINES OF AUSTRALIA (D200/88)

17 (4) 10.11.88

Approval to offer a 30 per cent discount return fare during periods of low activity from 19 November 1988 to 18 November 1989 inclusive, under specified conditions as proposed by the operator including seven days advance purchase and three nights minimum stay away requirements, and limited seat availability on specific flights over selected routes.

Approved on basis of estimates provided by the operator that the discount fare will generate additional traffic and improve profitability. The Committee intends to closely monitor operating results of this fare.

AUSTRALIAN AIRLINES (D202/88)

17 (4) 10.11.88

Approval to offer an Australian Originating Add-on fare at 25 per cent discount (was 30 per cent) off the normal economy fare from 1 January 1989 to 31 October 1990 under specified conditions as proposed by the operator available to passengers ticketed on international promotional air fares for travel commencing and terminating in Australia.

Approved on basis of estimates provided by the operator that the discount fare will generate additional traffic and improve profitability.

AIR NSW (D201/88)

17 (4) 16.11.88

Approval to offer, during the period 29 April 1989 to 27 April 1990, fixed price holiday discount air fares at 21.0 per cent off the approved economy air fares as at 1 September 1988, under specified conditions as proposed by the operator. A surcharge level of 6.0 per cent on the economy fare as at 1.9.88 is applicable at specified peak periods, but the air fare component cannot be higher than the relevant economy fare in force at the time of ticketing. The fares must be used in conjunction with an authorised package holiday.

Approved on basis of estimates provided by the operator that the discount fares will generate additional traffic and improve profitability.

N.N.—8878071

NOTICE OF CESSATION OF A STATUTORY LIEN IN RESPECT OF CERTAIN AIRCRAFT

NOTICE is hereby given that pursuant to section 75 (1) of the *Civil Aviation Act 1988*, a statutory lien vested in the Authority ceased to have effect in respect of each of the aircraft described hereunder.

<i>Lien No.</i>	<i>Aircraft description and registration mark</i>	<i>Date on which the Lien ceased to have effect</i>
00474	Piper PA-30, VH-KNT	26 October 1988
00698	Beech 58, VH-PRH	3 November 1988

Dated this 17th day of November 1988.

K. L. CLAYTON
Registrar of Statutory Liens

N.N.—8878072

Legislation

Acts of Parliament assented to

IT IS HEREBY NOTIFIED, for general information, that His Excellency the Governor-General, in the name of Her Majesty, assented, on 8 November 1988 to the undermentioned Acts passed by the Senate and the House of Representatives in Parliament assembled, viz.:

No. 86 of 1988—An Act relating to the prevention and settlement of certain industrial disputes, and for other purposes (*Industrial Relations Act 1988*).

No. 87 of 1988—An Act to enact certain transitional provisions, and to repeal certain Acts and amend certain Acts, in consequence of the enactment of the *Industrial Relations Act 1988*, and for other purposes (*Industrial Relations (Consequential Provisions) Act 1988*).

A. R. BROWNING
Clerk of the House of Representatives

N.N.—8878073

Regulations

AUSTRALIAN CAPITAL TERRITORY

NOTIFICATION OF THE MAKING OF A REGULATION

NOTICE is hereby given that the undermentioned Regulation of the Australian Capital Territory has been made. Copies of the Regulation may be purchased at the Commonwealth government bookshop, 70 Alinga St, Canberra City Australian Capital Territory.

<i>Ordinance under which the Regulation was made</i>	<i>Description of Regulation</i>	<i>Number and year of Regulation</i>
<i>Gaming Machine Ordinance 1987</i>	Gaming Machine Regulations (Amendment)	1988 No. 20

N.N.—8878074

Orders**NOTIFICATION OF THE MAKING OF ORDERS
UNDER THE EXPORT CONTROL (ORDERS)
REGULATIONS**

NOTICE is hereby given that the undermentioned orders under the Export Control (Orders) Regulations have been made. Copies of the orders can be purchased over the counter from the Commonwealth government bookshop at 70 Alinga St, Canberra City ACT 2600, or by mail from Mail Order Sales, GPO Box 84, Canberra 2601.

<i>Number of Orders</i>	<i>Description of Orders</i>
No. 17 of 1988	Export Control (Fresh Fruits and Vegetables) Orders

N.N.—8878075

**NOTIFICATION OF THE MAKING OF ORDERS
UNDER THE CIVIL AVIATION REGULATIONS**

NOTICE is hereby given that an amendment to Civil Aviation Orders Part 105, was made on 14 November 1988 and is effective from 18 November 1988.

AD/Cessna 303/7: NLG Actuator attach fitting.

Copies of the Order are available for inspection and may be purchased over the counter from the Civil Aviation Authority, 607 Swanston St, Carlton South Vic. 3053 or by mail from the Civil Aviation Authority, Publications Centre, GPO Box 1986, Carlton South Vic. 3053.

N.N.—8878076

By-laws**AUSTRALIAN TELECOMMUNICATIONS COMMISSION****NOTIFICATION OF THE MAKING OF BY-LAWS**

NOTICE is hereby given that the Australian Telecommunications Commission has made the undermentioned By-laws on 9 November 1988.

Copies can be obtained from the Corporate Secretary, Telecom Australia, 17th Floor, 199 William St, Melbourne Vic. 3000.

<i>Act under which By-laws were made</i>	<i>Description of By-laws</i>
<i>Telecommunications Act 1975</i>	Telecommunications (General) By-laws—Amendment No. 52

CA03T040 CR\$

N.N.—8878077

FEDERAL AIRPORTS CORPORATION**NOTIFICATION OF THE MAKING OF BY-LAWS**

NOTICE is hereby given that the undermentioned By-laws have been made. Copies of the By-laws can be purchased from the Commonwealth Government Bookshop, 70 Alinga St, Canberra City ACT.

<i>Act under which the By-laws were made</i>	<i>No. of By-laws (or form of individual for By-laws)</i>	<i>Description of By-laws</i>
<i>Federal Airports Corporation Act 1986</i>	2.1	Part I—Preliminary Amended
	15D.1—15E.2	Part IVC Regulation of building and engineering works on federal airports Part IVD Regulations for the security of federal airports
	15F.1—15F.5	

CA03F082 CR\$

N.N.—8878078

CORRIGENDUM

GAZETTE NO. GN 43, 16 NOVEMBER 1988

FEDERAL AIRPORTS CORPORATION

Insert '1986' in column 1 after the word 'Act'.

Delete from column 2 '3.1' and delete the wording in column 3 opposite that entry.

Insert after the entry in column 2 '3.2.3.13' and the wording in column 3 opposite that entry, words and figures as follows:

in column 2

'8.3A

'8.4

'9.1

in column 3

Removal of abandoned vehicles

Additional reference to 8.3A

Additional reference to 8.3A'

Delete from column 3 the word and symbol 'Part IVA' (second occurring) and substitute the word and symbol 'Part IVB'.

N.N.—8878111

Determinations

Commonwealth Teaching Service Act 1972

NOTICE OF THE MAKING OF DETERMINATION UNDER SECTIONS 20 AND 23

NOTICE is hereby given that the following determination has been made under sections 20 and 23 of the Commonwealth Teaching Service Act. Copies can be obtained from the Department of Industrial Relations, 1 Farrell Pl, Canberra City ACT (062) 43 7154.

<i>Number and year of Determination</i>	<i>Description of Determination</i>	<i>Date made</i>
No. 4 of 1988	Amendment to Determination 44—Canberra Institute of the Arts Second tier salary increases	19.10.88

N.N.—8878079

Government Departments

Administrative Services

AUSTRALIAN ELECTORAL COMMISSION

I HAVE ascertained and set out in the schedule for each State and Territory the number of electors enrolled in each Division as at the date indicated and for each State and the Australian Capital Territory have determined the average divisional enrolment and the extent to which the number of electors enrolled in each Division differs from the average divisional enrolment.

THE SCHEDULE

New South Wales as at 23 September 1988:

Average Divisional Enrolment 70 033

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Banks	67 953	-2.97
Barton	71 346	1.87
Bennelong	70 312	0.40
Berowra	70 622	0.84
Blaxland	68 141	-2.70
Bradfield	68 468	-2.23
Calare	71 307	1.82
Charlton	69 665	-0.53
Chifley	70 007	-0.04
Cook	69 679	-0.51
Cowper	75 116	7.26
Cunningham	66 496	-5.05
Dobell	74 071	5.77
Dundas	68 293	-2.48
Eden-Monaro	70 647	0.88
Farrer	71 759	2.46
Fowler	69 569	-0.66
Gilmore	68 524	-2.15
Grayndler	69 508	-0.75
Greenway	66 444	-5.12
Gwydir	69 195	-1.20
Hughes	70 835	1.15
Hume	69 429	-0.86
Hunter	70 787	1.08
Kingsford-Smith	70 825	1.13
Lindsay	70 927	1.28
Lowe	69 519	-0.73
Lyne	75 141	7.29
Macarthur	67 979	-2.93
Mackellar	70 259	0.32
Macquarie	67 758	-3.25
Mitchell	71 096	1.52

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Newcastle	67 147	-4.12
New England	71 748	2.45
North Sydney	67 677	-3.36
Page	70 636	0.86
Parkes	67 722	-3.30
Parramatta	69 000	-1.48
Phillip	70 675	0.92
Prospect	75 492	7.79
Reid	70 799	1.09
Richmond	68 297	-2.48
Riverina-Darling	65 385	-6.64
Robertson	73 915	5.54
St George	70 348	0.45
Shortland	71 877	2.63
Sydney	69 545	-0.70
Throsby	66 596	-4.91
Warringah	69 298	-1.05
Wentworth	66 501	-5.04
Werriwa	77 358	10.46

State Total 3 571 693

Victoria as at 23 September 1988:

Average Divisional Enrolment 70 266

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Aston	72 592	3.31
Ballarat	73 148	4.10
Batman	64 862	-7.69
Bendigo	73 303	4.32
Bruce	65 937	-6.16
Burke	77 691	10.57
Calwell	72 149	2.68
Casey	72 919	3.78
Chisolm	69 460	-1.15
Corangamite	74 940	6.65
Corio	69 076	-1.69
Deakin	68 473	-2.55
Dunkley	69 119	-1.63
Flinders	77 314	10.03
Gellibrand	68 923	-1.91
Gippsland	73 535	4.65
Goldstein	69 511	-1.07
Henty	67 161	-4.42
Higgins	66 844	-4.87
Holt	67 778	-3.54
Hotham	70 657	0.56
Indi	74 904	6.60

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Isaacs	68 354	-2.72
Jagajaga	64 346	-8.43
Kooyong	68 193	-2.95
Lalor	78 330	11.48
La Trobe	71 607	1.91
McEwen	73 433	4.51
McMillan	69 052	-1.73
Mallee	71 597	1.89
Maribyrnong	66 793	-4.94
Melbourne	69 110	-1.65
Melbourne Ports	67 103	-4.50
Menzies	69 424	-1.20
Murray	71 138	1.24
Scullin	63 381	-9.80
Streecon	69 970	-0.42
Wannon	70 401	0.19
Wills	67 829	-3.47
State Total	2 740 357	

Queensland as at 26 September 1988:
Average Divisional Enrolment 71 122

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Bowman	73 707	3.63
Brisbane	68 472	-3.73
Capricornia	68 950	-3.05
Dawson	71 275	0.22
Fadden	66 564	-6.41
Fairfax	74 015	4.07
Fisher	77 765	9.34
Forde	66 403	-6.64
Griffith	68 490	-3.70
Groom	72 408	1.81
Herbert	73 468	3.30
Hinkler	69 721	-1.97
Kennedy	70 127	-1.40
Leichhardt	70 800	-0.45
Lilley	68 836	-3.21
McPherson	82 301	15.72
Maranoa	69 498	-2.28
Moncrieff	76 054	6.93
Moreton	67 113	-5.64
Oxley	67 056	-5.72
Petrie	72 522	1.97
Rankin	69 052	-2.91
Ryan	74 130	4.23
Wide Bay	68 206	-4.10
State Total	1 706 933	

State of Western Australia as at 27 September 1988:
Average Divisional Enrolment 72 264

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Brand	74 733	3.42
Canning	69 760	-3.47
Cowan	76 042	5.23
Curtin	71 339	-1.28
Forrest	72 538	0.38
Fremantle	73 368	1.53
Kalgoorlie	72 311	0.07
Moore	75 343	4.26
O'Connor	71 025	-1.71

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Perth	71 148	-1.54
Stirling	68 831	-4.75
Swan	69 091	-4.39
Tangney	73 902	2.27
State Total	939 431	

South Australia as at 29 September 1988:
Average Divisional Enrolment 72 857

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Adelaide	74 245	1.92
Barker	72 101	-1.04
Bonython	72 893	0.05
Boothby	73 795	1.29
Grey	70 062	-3.84
Hawker	71 694	-1.60
Hindmarsh	72 895	0.05
Kingston	71 877	-1.35
Makin	71 872	-1.35
Mayo	75 455	3.57
Port Adelaide	73 232	0.51
Sturt	72 163	0.95
Wakefield	74 860	2.75
State Total	947 144	

State of Tasmania as at 23 September 1988:
Average Divisional Enrolment 60 875

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Bass	60 778	-0.16
Braddon	61 371	0.81
Denison	60 349	-0.86
Franklin	60 689	-0.31
Lyons	61 189	0.52
State Total	304 376	

Australian Capital Territory as at 23 September 1988:
Average Divisional Enrolment 83 481

<i>Division</i>	<i>Enrolment</i>	<i>% Deviation from average divisional enrolment</i>
Canberra	81 748	-2.08
Fraser	85 214	2.08
Territory Total	166 962	

Northern Territory as at 27 September 1988:
Average Divisional Enrolment 75 231

Total for Australia 10 452 127

COLIN A. HUGHES
Electoral Commissioner

The Arts, Sport, the Environment, Tourism and Territories

AUSTRALIAN CAPITAL TERRITORY

Trading Hours Ordinance 1962

APPLICATION OF ORDINANCE

Under section 6 (1) of the *Trading Hours Ordinance 1962* 'the Ordinance', I, hereby declare that the Ordinance shall not apply in the part of the Australian Capital Territory being the area occupied by the store known as Grace Bros on levels 1, 2 and 3 of the Westfield Shopping Centre located on Block 1, Section 52, Division of Belconnen for the period of time starting at 6.00 p.m. and finishing at 8.00 p.m. on Wednesday, 30 November 1988.

Dated 16 November 1988.

WILLIAM JOHN HARRIS
ACT Administration
Delegate of the Minister of State
for the Arts and Territories

N.N.—8878080

AUSTRALIAN CAPITAL TERRITORY

Canberra Theatre Trust Ordinance 1965

APPOINTMENT

Under section 6 (1) of the *Canberra Theatre Trust Ordinance 1965* I appoint:

Anthony Lewis Hayward
Joan Margaret Taggart

to be Trustees of the Canberra Theatre Trust for the period of three years commencing on the date of this instrument.

Dated 10 November 1988.

WILLIAM JOHN HARRIS
ACT Administration
Delegate of the Minister of State
for the Arts and Territories

N.N.—8878081

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Peter Neil Gowland and Valerie Mary Gowland ('the Applicant') carrying on the profession trade occupation or calling of venison and game distributors and ecological consultant ('the business') on Block 27, Section 25, Division of Hawker known as 9 Mataranka St, Hawker ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

- (1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;
- (2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;
- (3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the

National Capital Development Commission and the Building Controller;

- (4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the *City Area Leases Ordinance* unless otherwise stipulated in this Instrument;
- (5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;
- (6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;
- (7) that the Applicant will not employ any assistants for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;
- (8) that deliveries to the land by commercial vehicles be restricted to two per week;
- (9) that this approval relates to the provision of office accommodation and garaging of a refrigerated vehicle;
- (10) that this approval will terminate on the thirty-first day of October 1989 or on such earlier date as the Minister determines in accordance with condition 11;
- (11) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 9th day of November 1988.

P. R. GRIFFITHS
Delegate of the Minister of State
for the Arts and Territories

N.N.—8878082

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Ronald Edward Cochran ('the Applicant') carrying on the profession trade occupation or calling of medical practitioner ('the business') on Block 8, Section 1, Division of Melba known as 103 Kingsford Smith Drv, Melba ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

- (1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;
- (2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;
- (3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the National Capital Development Commission and the Building Controller;
- (4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the *City Area Leases Ordinance* unless otherwise stipulated in this Instrument;

2532 *Government departments*

- (5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;
- (6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;
- (7) that the Applicant will not without the prior approval of the Minister employ any more than two assistants for the purpose of conducting or carrying on the business on the land and those assistants shall be employed only in the capacity of a nurse and receptionist;
- (8) that the business will only be conducted on the land between the hours of 9.00 a.m. and 6.00 p.m. Monday to Friday and 9.00 a.m. and 12.00 noon Saturdays except in the case of an emergency;
- (9) that this approval will terminate on the thirty-first day of October 1989 or on such earlier date as the Minister determines in accordance with condition 10;
- (10) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 9th day of November 1988.

P. R. GRIFFITHS

Delegate of the Minister of State
for the Arts and Territories

N.N.—8878083

- (6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;
- (7) that the Applicant will not employ any assistants for the purpose of conducting or carrying on the business on the land without the prior approval of the Minister;
- (8) that only one room in the house be used for the conduct of the business;
- (9) that the business will only be conducted on the land seven days per week;
- (10) that all equipment and materials shall be stored in the carport only;
- (11) that this approval will terminate on the thirtieth day of September 1989 or on such earlier date as the Minister determines in accordance with condition 12;
- (12) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 9th day of November 1988.

P. R. GRIFFITHS

Delegate of the Minister of State
for the Arts and Territories

N.N.—8878084

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of David Lindsay Barnes ('the Applicant') carrying on the profession trade occupation or calling of plumber and drainer ('the business') on Block 2, Section 17, Division of Scullin known as 27 Leven St, Scullin ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

- (1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;
- (2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;
- (3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the National Capital Development Commission and the Building Controller;
- (4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the *City Area Leases Ordinance* unless otherwise stipulated in this Instrument;
- (5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;

AUSTRALIAN CAPITAL TERRITORY

City Area Leases Ordinance 1936

INSTRUMENT OF APPROVAL UNDER SECTION 10

In pursuance of section 10 of the *City Area Leases Ordinance 1936*, I, PETER ROBERT GRIFFITHS being the officer for the time being occupying an office to the occupant of which the Minister has by instrument in writing under section 12C of the *Seat of Government (Administration) Act 1910* delegated his powers under section 10 of the said Ordinance hereby approve of Ricky Allen Flavell and Laurelle June Flavell ('the Applicant') carrying on the profession trade occupation or calling of freelance graphic design and publishing ('the business') on Block 1, Section 282, Division of Kambah known as 12 Kathleens Park, 17 Pinkerton Cct, Kambah ('the land') subject to the following conditions relating to the use of the land being observed by the Applicant in carrying on the business:

- (1) that this approval will remain valid only while the Applicant continues to be a bona fide resident of the land;
- (2) that the Applicant will ensure that the conduct of the business does not cause an annoyance, a nuisance or danger and is not offensive to any tenants or occupiers of adjoining lands;
- (3) that the Applicant will not erect or permit or suffer to be displayed or erected upon the land or any building thereon any advertising sign or hoarding whatever without the consent in writing of the National Capital Development Commission and the Building Controller;
- (4) that the Applicant will conduct the business strictly in accordance with the application made by the Applicant under section 10 of the *City Area Leases Ordinance* unless otherwise stipulated in this Instrument;
- (5) that no person other than the Applicant will conduct or in any way carry on the business on the land without the prior approval of the Minister;
- (6) that the Applicant will ensure that all residence and business related vehicles are parked within the confines of the land;

- (7) that the applicant may employ the equivalent of one full-time assistant in the conduct of the business on the land between 8.30 a.m. and 5.30 p.m., with no more than one person assisting in the business on the land at any one time;
- (8) that Clause 7 does not prevent the Applicant accepting up to two school students per year to be engaged in the business to gain work experience for a maximum of two weeks per year per student;
- (9) that the hours of operation for the business do not extend beyond 11.00 p.m.
- (10) that the Applicant will conduct the business strictly by appointment, and that such appointments will be organised to ensure that not more than two clients are in attendance at any one time;

- (11) that this approval will terminate on the thirty-first day of August 1989 or on such earlier date as the Minister determines in accordance with condition 12;
- (12) upon any failure to comply with any or all of the foregoing conditions the Minister or his Delegate under the said Ordinance may give written notice requiring the Applicant to show cause within a period of fourteen days why this approval should not be revoked. At the expiration of this period the Minister or his Delegate may revoke the approval.

Dated this 9th day of November 1988.

P. R. GRIFFITHS

Delegate of the Minister of State
for the Arts and Territories

N.N.—8878085

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 11

DECLARATION OF APPROVED INSTITUTIONS

I, JOHN DERRICK OVINGTON, the Designated Authority under subsection 18 (1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, in pursuance of subsection 11 (1) of the Act, hereby declare each of the organisations specified in Column 2 of the Schedule, in an item in the Schedule, to be an approved institution in relation to the class, or classes, of specimens specified in Column 3 of the Schedule in that item.

Dated this eighteenth day of November 1988.

J. D. OVINGTON

Designated authority

SCHEDULE

Column 1 Item	Column 2 Name and country of approved institution	Column 3 Approved class, or classes, of specimens
1	Lionel E. Campion Little Moe River Road Yarragon Vic. 3823	<i>Cervus elaphus</i>
2	Zoo Berlin Hardenbergplatz 8 D-1000 Berlin 30 West Germany	<i>Dacelo</i> spp
3	Geoffrey A. Hemmings 44 Spurwood Rd Warrimoo NSW 2774	<i>Agapornis</i> spp
4	Keith Voss 'Olveston', 22 Hastings Rd Hawera, South Taranaki New Zealand	<i>Agapornis</i> spp
5	San Diego Zoo 2920 Zoo Drv San Diego, CA 92103, USA	<i>Saguinus imperator</i>

N.N.—8878086

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 12

DECLARATION OF APPROVED ZOOLOGICAL ORGANISATIONS

I, JOHN DERRICK OVINGTON, the Designated Authority under subsection 18 (1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, in pursuance of subsection 12 (1) of that Act, hereby declare each of the zoological organisations specified in column 2 of the Schedule, in an item in the Schedule, to be an approved zoological organisation in relation to the class, or classes, of specimens specified in Column 3 of the Schedule in that item.

Dated this eighteenth day of November 1988.

J. D. OVINGTON

Designated Authority

SCHEDULE

Column 1 Item	Column 2 Name and country of zoo	Column 3 Approved class, or classes, of specimens
1	Zoo Berlin Hardenbergplatz 8 D-1000 Berlin 30 West Germany	<i>Dacelo</i> spp
2	San Diego Zoo 2920 Zoo Drive San Diego, CA 92103, USA	<i>Saguinus imperator</i>

N.N.—8878087

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 44

NOTICE

I, GRAHAM FREDERICK RICHARDSON, the Minister of State for the Arts, Sport, the Environment, Tourism and Territories in pursuance of subsection 44 (1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, hereby notify that I am considering giving the following person authority under section 44 of the Act to export over a period of six months, the specimens specified below, on condition that prior to export of each consignment, the exporter obtains the permission of the Director of National Parks and Wildlife Service or his nominee.

The person and specimens are as follows:

Person	Specimens
H. N. Mighell	<i>Caustis blakei</i> —cut stems
PO Box 185	collected from 5ha of private
Tin Can Bay	property and 20ha of State
	Forest under licence.

Qld 4580

In accordance with paragraph 44 (1) (f) of that Act, I invite interested persons to lodge with me comments in writing on the desirability of giving this authority. Such comments should be lodged at the following address not later than ten days after the date of publication of this Notice:

The Director
Australian National Parks and Wildlife Service
GPO Box 636
Canberra ACT 2601

Attention: Wildlife Protection Section

Dated this 10th day of November 1988.

GRAHAM RICHARDSON

Minister of State
for the Arts, Sport, the Environment,
Tourism and Territories

N.N.—8878088

Dated this 9th day of November 1988.

GRAHAM RICHARDSON

Minister of State
for the Arts, Sport, the Environment,
Tourism and Territories
N.N.—8878089

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 44

NOTICE

I, SENATOR GRAHAM RICHARDSON, the Minister of State for the Arts, Sport, the Environment, Tourism and Territories, in pursuance of subsection 44 (1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, hereby notify that I am considering renewing the authority issued to B. Gunderson of Ravensbourne, Qld, under section 44 of the Act to export over a period of six months fronds of *Macrozamia miquellii* harvested in Queensland from areas of State Forests 451 and 915 on condition that prior to export of each consignment, the exporter obtains the permission of the Director of National Parks and Wildlife Service or his nominee.

In accordance with paragraph 44 (1) (f) of that Act I invite interested persons to lodge with me comments in writing on the desirability of giving this authority. Such comments should be lodged at the following address not later than ten days after the date of publication of this notice:

The Director
Australian National Parks and Wildlife Service
GPO Box 636
Canberra ACT 2601

Attention: Wildlife Protection Section

Dated this 9th day of November 1988.

GRAHAM RICHARDSON

Minister of State
for the Arts, Sport, the Environment,
Tourism and Territories
N.N.—8878090

COMMONWEALTH OF AUSTRALIA

Wildlife Protection (Regulation of Exports and Imports) Act 1982

Section 44

NOTICE

I, GRAHAM FREDERICK RICHARDSON, the Minister of State for the Arts, Sport, the Environment, Tourism and Territories in pursuance of subsection 44 (1) of the *Wildlife Protection (Regulation of Exports and Imports) Act 1982*, hereby notify that I am considering giving Andrew Edinger, 14 Lake St, Esperance WA 6450, authority under section 44 of the Act to export over a period of six months, consignments of shells of native Australian molluscs on condition that prior to export of each consignment, the exporter obtains the permission of the Director of Australian National Parks and Wildlife Service or his nominee.

In accordance with paragraph 44 (1) (f) of that Act, I invite interested persons to lodge with me comments in writing on the desirability of giving this authority. Such comments should be lodged at the following address not later than ten days after the date of publication of this Notice:

The Director
Australian National Parks and Wildlife Service
GPO Box 636
Canberra ACT 2601

Attention: Wildlife Protection Section

AUSTRALIAN CAPITAL TERRITORY

Electricity and Water Ordinance 1988

DETERMINATION

The Australian Capital Territory Electricity and Water Authority (ACTEW) under section 48 of the *Electricity and Water Ordinance 1988*, makes the following determination fixing the charge that is to be payable to ACTEW for the bulk supply of water to Queanbeyan City Council for the financial year 1988-1989.

1. Charge

For the sale of water to Queanbeyan City Council—16.6 cents per kilolitre.

N.N.—8878091

PHYSIOTHERAPISTS BOARD OF THE
AUSTRALIAN CAPITAL TERRITORY
ELECTION OF DEPUTY CHAIRMAN OF THE
BOARD

Pursuant to paragraph 6 (2) (b) of the *Health Professions Boards (Procedures) Ordinance 1981*, it is hereby notified that Patricia Levick was on 15 November 1988, unanimously elected by the Physiotherapists Board to be Deputy Chairman of the Board for twelve months from and including 21 November 1988.

Dated the sixteenth day of November 1988.

N. BAXTER

Chairman of the Board
N.N.—8878092

Attorney-General

PUBLICATIONS CLASSIFIED UNDER THE ACT CLASSIFICATION OF PUBLICATIONS ORDINANCE 1983 FOR WEEK ENDING 4.11.88

Publications classified under the A.C.T. Ordinance would attract the following classifications under the N.S.W. *Indecent Articles and Classified Publications Act 1975* and the N.T. *Classification of Publications Act 1979*: U/R—Unrestricted; Category 1—Restricted; Category 2—Direct Sale; Refused—Includes Child Pornography (CP) may not be sold.

Title	Edition	Author/Publisher	Decision flagging
<i>Busen</i>	No. 29	Pleasure Verlagsgesellschaft GmbH, Germany	Category 2
<i>Busen</i>	No. 29	Pleasure Verlags, W. Germany	Category 2
<i>Club International</i>	Vol. 17 No. 11 (C) 1988	Paul Raymond Publications, UK	Category 1
<i>Club Pour Hommes</i>	No. 20, May 1988	Paul Raymond Publications Ltd, UK	Refused
<i>Easyriders (Australian)</i>	No. 186, Vol. 18, December 1988	Paisano Publications, USA	Unrestricted
<i>Escort</i>	Vol. 8, No. 11, October 1988	Paul Raymond Publications, UK	Category 1
<i>Fling</i>	Vol. 30 No. 4, Issue 151, November 1988	Relim Publishing, USA	Category 2
<i>Gallery Fantasies</i>	Vol. 3, No. 4, Winter 1988	Montcalm Publishing Co., USA	Category 1
<i>Gentlemans Companion</i>	Vol. 8, No. 10, December 1988	Gentlemas Companion Magazine, USA	Category 2
<i>Hot Dreams (The best of human digest)</i>	Vol. 4, No. 6, December 1988	Thomaston Publications, USA	Category 2
<i>Inside Foxy Lady</i>	Vol. 7 No. 32	Verlag, Teresa Orlowski, W. Germany	Category 2
<i>Knave</i>	Vol. 20, No. 11 (C) 1988	Galaxy Publications, UK	Category 1
<i>Live (Best of)</i>	Vol. 8 No. 8 Winter 1988 collectors edition No. 5	Live Periodicals Inc., USA	Category 2
<i>Lolitas Anal</i>	No. 3	Silwa Film, W. Germany	Category 2
<i>Mayfair</i>	Vol. 23, No. 11	Fisk Publishing Co., UK	Unrestricted
<i>Penthouse (French Edition)</i>	No. 46, November 1988	Filipacchi Editée Par editions, France	Category 2
<i>Penthouse (The Girls of)</i>	November/December 1988	Penthouse International, USA	Category 1
<i>Penthouse Forum</i>	Vol. 18, No. 4, December 1988	Forum International, USA	Category 1
<i>Penthouse Variations</i>	Vol. 10, No. 12, November 1988	Viva International, USA	Category 1
<i>Playboy (US)</i>	Vol. 35, No. 12, December 1988	Playboy, USA	Unrestricted
<i>Playboy's Book of Lingerie</i>	November/December 1988	Playboy Press, USA	Unrestricted
<i>Playgirl</i>	Vol. XVI, No. 7 (Vol. 16, No. 7) December 1988	Playgirl Inc., USA	Unrestricted
<i>Seventeen Special</i>	No. 17	Coer'est Holland	Category 2
<i>Seventeen Special</i>	No. 17 (C) 1988	Coer'est Holland	Category 2
<i>Sex Bizarre</i>	No. 46, October 1988	Color-Climax Corp., Denmark	Category 2
<i>Super Neger</i>	No. 6, March 1988	COQ International, Denmark	Category 2
<i>Topsy Special</i>	No. 6, September 1988	Silva Film, West Germany	Category 2

Flags

- (1) Brought to the attention of the Victorian Government.
- (2) Brought to the attention of the SA Government.
- (3) Brought to the attention of the WA Government.
- (CP) Child Pornography.
- (*) Decision subject of an appeal.

FILM CENSORSHIP BOARD
OCTOBER 1988

Films examined in terms of the Customs (Cinematograph Films) Regulations and State's film censorship legislation are listed below.

An explanatory key to reasons for classifying non-'G' films appears hereunder:

	Frequency		Explicitness/Intensity			Purpose	
	Infrequent	Frequent	Low	Medium	High	Justified	Gratuitous
S (Sex)	i	f	l	m	h	j	g
V (Violence)	i	f	l	m	h	j	g
L (Language)	i	f	l	m	h	j	g
O (Other)							

*** Films Board of Review Decision

Title	Producer	Country	Submitted length (mins)	Applicant	Reason for decision
For general exhibition—'G' Suitable for all ages					
<i>Blowpipes and Bulldozers</i>	J. Kendell/P. Tait	Australia	60	Gaia Films	
<i>Matter of Heart</i>	M. Whitney	USA	102	Ronin Films	
<i>Story of Jiro, The</i>	Seiyu, Gakushu Kenkyusha Kinema Tokyo Productions	Japan	106	Japan Information and Culture Centre	
Parental guidance—'PG' Parental guidance recommended for children under 15 years					
<i>Campus Man</i>	P. Fowler/J. Landau	USA	93	Vestron Pictures	L (i-l-g) V (i-l-g) O (adult concepts)
<i>Contradictions</i>	D. Knaus	Australia	57	Film Australia	O (adult concepts)
<i>Crossing Delancey</i>	M. Nozik	USA	96	Village Roadshow Corporation	O (sexual allusions adult concepts)
<i>Deciduous Tree</i> (main title not shown in English)	Marui Kobun Company/Kindas Ega Kyokai	Japan	102	Japan Information and Culture Centre	O (nudity adult concepts)
<i>La Leggenda del Santo Bevitore</i>	V. De Leo/R. Cicutto/M. Cecchi Gori/V. Cecchi Gori	Italy	130	Ente Autonomo di Gestione per il Cinema	O (adult concepts)
<i>Mother vs Mother</i>	Lau Tin Chi	Hong Kong	96	Vacole	L (i-l-g) O (adult concepts)
<i>Ngati</i>	J. O'Shea	New Zealand	91	Australian Film Institute (Sydney)	L (f-l-j)
<i>Qualcuno in Ascolto (High Frequency)</i>	G. Piccioli/G. Leopardi	Italy	105	Ente Autonomo di Gestione per il Cinema	V (i-l-j) O (adult concepts)
<i>Things Change</i>	M. Hausman	USA	100	Fox Columbia Film Distributors	L (i-l-j) O (adult concepts)
<i>Without a Clue</i>	M. Stirdivant	UK	106	Filmpac Holdings	V (i-m-j)
<i>Young Einstein</i> (edited version)	Y. Serious/W. Ross/D. Roach	Australia	91	Village Roadshow Corporation	O (adult concepts)
For mature audiences—'M' Recommended as suitable for persons 15 years and over					
<i>Consuming Passions</i>	W. Cartlidge	UK	98	Vestron Pictures	O (sexual allusions adult concepts)
<i>Dark Night</i>	Lo Wai	Hong Kong	97	Golden Reel Films	S (f-m-j) O (adult theme)
<i>Deceivers, The</i>	I. Merchant	UK/India	102	Vestron Pictures	V (f-m-g)
<i>Distant Thunder</i>	R. Schaffel	Canada/USA	113	United International Pictures	L (f-m-g) V (i-m-g)
<i>Distant Voices, Still Lives</i>	J. Howarth	UK	81	Dendy Cinema	O (adult concepts) L (i-m-g)

Title	Producer	Country	Submitted length (mins)	Applicant	Reason for decision
<i>Evil Angels</i>	V. Lambert	Australia	121	Village Roadshow Corporation	L (i-m-j) O (adult concepts)
<i>Fatal Love</i>	R. Wong	Hong Kong	82	Chinatown Cinema	V (i-m-g) S (i-m-g)
<i>Film d'Amore e d'Anarchia</i>	R. Cardarelli	Italy	123	Ente Autonomo di Gestione per il Cinema	O (nudity, sexual allusions)
<i>Heart to Hearts</i>	S. Shin	Hong Kong	94	Chinatown Cinema	O (adult concepts)
<i>How to Pick Girls Up!?</i>	Lau Tin Chi	Hong Kong	98	Vacole	V (i-m-g) O (adult concepts)
<i>Imagine—John Lennon</i>	D. Wolper/A. Solt	USA	105	Village Roadshow Corporation	L (i-m-j) O (adult concepts)
<i>Io e Mia Sorella (Me and My Sister)</i>	M. Cecchi Gori/ V. Cecchi Gori	Italy	111	Ente Autonomo Di Gestione Per il Cinema	S (i-m-j) O (adult concepts)
<i>L'Ami De Mon Amie</i>	M. Menegoz	France	100	Newvision Film Distributors	L (i-m-j)
<i>Mignon E' Partita (Mignon has Left)</i>	L. Pescarolo/G. De Laurentiis	Italy/France	99	Ente Autonomo Di Gestione Per Il Cinema	O (adult concepts)
<i>Mimi Metallurgico</i>	Euro International	Italy	115	Ente Autonomo Di Gestione Per Il Cinema	O (adult concepts) V (i-m-j)
<i>P.I. Private Investigations</i>	S. Colin/ S. Sighvatsson	USA	91	Vestron Pictures	V (i-m-g) L (i-m-g)
<i>Pasqualino Settebellezze (A.K.A. Seven Beauties)</i>	Medusa Distribuzione	Italy	120	Ente Autonomo Di Gestione Per Il Cinema	O (adult concepts) V (i-m-j) S (i-m-j)
<i>Prayer for the Dying, A</i>	P. Snell	UK/USA	107	Vestron Pictures	L (i-m-j) V (i-m-j)
<i>Spellbinder</i>	J. Wizan/B. Russell	USA	96	United International Pictures	L (i-m-g) O (occult theme)
<i>Sposi (Brides and Bridegrooms)</i>	A. Avanti/ C. Bonivento	Italy	97	Ente Autonomo Di Gestione Per Il Cinema	L (i-m-g) O (adult concepts)
<i>U2—Rattle and Hum</i>	M. Hamlyn	USA	99	United International Pictures	L (i-m-g)
<i>Un Complicato Intrigo Di Donne Vicoli e Delitti</i>	F. Lucisano	Italy	107	Ente Autonomo Di Gestione Per Il Cinema	V (i-m-j) L (f-m-j) O (adult concepts)
<i>Vroom</i>	P. Lister	UK	88	Hoyts Distribution	L (i-m-j) O (adult concepts)
For Restricted Exhibition—"R" Persons 2 years of age and over, and under 18 years of age, are not admitted					
<i>Bet on Fire (main title not shown in English)</i>	Not shown	Hong Kong	95	Chinatown Cinema	V (i-m-g)
<i>Blue Jean Cop (a)</i>	J. Harman	USA	95	Hoyts Distribution	V (i-m-g) O (adult concepts anti-social theme)
<i>Blue Velvet</i>	F. Caruso	USA	119	Hoyts Distribution	S (i-m-j) V (i-m-j) L (f-m-g)
<i>Call Me</i>	J. Quill/K. Martel	USA	98	Vestron Pictures	L (f-m-g) S (i-m-g)
<i>Crazy Love</i>	E. Provoost/ A. Keysman	Belgium	87	Dendy Cinema	S (i-m-j) O (adult concepts)
<i>Travolti Da un Insolito Destino</i>	R. Cardarelli	Italy	114	Ente Autonomo Di Gestione Per Il Cinema	S (i-m-j) O (sexual concepts)

(a) *Blue Jean Cop* was inadvertently omitted from 'Films Registered Without Deletions' For Restricted Exhibition—"R" on September 1988 list.

<i>Title</i>	<i>Producer</i>	<i>Country</i>	<i>Submitted length (mins)</i>	<i>Applicant</i>	<i>Reason for decision</i>
Special Conditions:					
<i>Fatto Di Sanguie Tra Due Uomini</i>	H. Colombo	UK	118	Ente Autonomo Di Gestione Per Il Cinema	
<i>La Fine Del Mondo Nel Nostro Solito Letto</i>	G. Shiva	Italy	108	Ente Autonomo Di Gestione Per Il Cinema	

N.N.—8876533

FILM CENSORSHIP BOARD

WEEK ENDING 28 OCTOBER 1988

Classifications assigned to films for sale/hire pursuant to the Australian Capital Territory *Classification of Publications Ordinance 1983*; the Northern Territory *Classification of Publications Act 1985*; the New South Wales *Film and Video Tape Classification Act 1984*; the Queensland *Censorship of Films Act 1947-1984*; the Tasmania *Classification of Publications Act 1984*; the Western Australia *Video Tapes Classification and Control Act 1987*.

An explanatory key to reasons for classifying non-'G' films appears hereunder:

	<i>Frequency</i>		<i>Explicitness/Intensity</i>			<i>Purpose</i>	
	<i>Infrequent</i>	<i>Frequent</i>	<i>Low</i>	<i>Medium</i>	<i>High</i>	<i>Justified</i>	<i>Gratuitous</i>
S (Sex)	i	f	l	m	h	j	g
V (Violence)	i	f	l	m	h	j	g
L (Language)	i	f	l	m	h	j	g
O (Other)							

* Films Board of Review

Decision

** Code reasons unavailable for films originally classified before 1972

<i>Title</i>	<i>Producer</i>	<i>Country</i>	<i>Submitted length (mins)</i>	<i>Applicant</i>	<i>Reason for decision</i>
'G'—Suitable for general exhibition					
<i>Australia—Take a Bow</i>	B. Morris	Australian	101	Hoyts Polygram Video	
<i>Monster Madness</i>	Halcon Days Productions	USA	30	Majestic Products	
<i>Never Give a Sucker An Even Break/ You're Telling Me</i>	E. Cline/E. Kenton	USA	69	Marieth Investments	
<i>Pro Football Funnies</i>	M. Ehuoin	USA	30	Majestic Products	
<i>Skydiving—The Ultimate Sport</i>	Norman Kent Productions	USA	30	Majestic Products	
<i>Truckin'—The 1987 European Truck Racing Organization Championship Season</i>	Hay Fisher Productions	UK	55	Majestic Products	
<i>Ultimate Home Fitness Club</i>	Not shown	Australia	49	Rob Gild Productions	
'PG'—Parental guidance required for those under 15					
<i>Bagdad Cafe</i>	E. Adlon/P. Adlon	USA/West Germany	91	Communications and Entertainment	L (i-l-j) O (adult concepts)
<i>Bingo Bongo</i>	M. Cecchi Gori/V. Cecchi Gori	Italy	102	RCA/Columbia Pictures/Hoyts Video	O (adult concepts)
<i>Boggy Creek II</i>	C. Pierce	USA	94	Key United Home Video	L (i-l-j) V (i-l-g)
<i>Bonanza—The Next Generation</i>	D. Dortort	USA	93	Taft Hardie Group	V (i-l-j) O (adult concepts)
'M'—Mature (not recommended for viewing by persons under 15)					
<i>Against Her Will (a)</i>	D. Karew	USA	90	CBS/Fox Video	V (i-m-g) O (adult concepts)
<i>Australian Made</i>	J. McLean	Australia	79	Hoyts Polygram Video	L (i-m-g)

Title	Producer	Country	Submitted length (mins)	Applicant	Reason for decision
<i>Beach Balls</i>	M. Leipzig	USA	75	RCA/Columbia Pictures/Hoyts Video	L (i-m-g) S (i-m-g)
<i>Buy & Cell</i>	F. Yablans	USA/Italy	91	Roadshow Home Video	L (i-m-g) V (i-m-g) O (nudity)
<i>Cat Squad: Python Wolf Daddy</i>	D. Salven	Canada	93	Filmpac Holdings	V (f-m-g)
<i>Distant Thunder</i>	R. Florio/H. Frey	USA	93	Communications and Entertainment	O (adult concepts)
<i>Dracula A.D. 1972</i>	R. Schaffel	Canada/USA	113	United International Pictures	L (f-m-g) V (i-m-g)
<i>Evil Angels</i>	J. Douglas	UK	92	Corporate Video	V (i-m-j)
	V. Lambert	Australia	121	Warner Home Video	L (i-m-j) O (adult concepts)
<i>Horror House on Highway Five</i>	Vistar International Productions	USA	89	Popular Home Products	L (i-m-g) V (f-m-g) O (drug use)
<i>Imagine—John Lennon</i>	D. Wolper/A. Solt	USA	105	Warner Home Video	L (i-m-j) O (adult concepts)
<i>In Dangerous Company</i>	R. Preuss/R. Newell	USA	91	Roadshow Home Video	V (i-m-g) O (i-m-g) S (i-m-g)
<i>Jack's Back</i>	T. Moore/C. Elwes	USA	97	CBS/Fox Video	L (i-m-g) O (adult concepts) V (i-m-j)
<i>My Stepmother is an Alien</i>	Not shown	Not shown	98	Hoyts Distribution	O (sexual allusions)
<i>Philip Marlowe Private Eye—Blackmailers Don't Shoot/Spanish Blood</i>	J. Slan	Canada	97	CBS/Fox Video	V (i-m-g) O (drug use)
<i>Sonney and Jed</i>	R. Loyola	Italy	91	Popular Home Products	L (f-m-g) V (i-m-g) O (adult concepts)
<i>Trident Force</i>	Anna Films International	Not shown	86	Roadshow Home Video	V (i-m-g) L (i-m-g) O (sexual allusions)

(a) Title changed from *Hostage* shown on 26 July 1988 gazette list.

'R'—Restricted (not to be sold or hire or delivered to minors or displayed in a public place unless container bears prescribed markings)

<i>Adult Party Games</i>	Electric Blue	U.K.	57	Video Ray	O (exploitative nudity) S (i-m-g)
<i>Blonde, The (edited version)</i>	Not shown	U.S.A.	64	Mareith Investments	S (f-m-g)
<i>Lair of the White Worm, The</i>	K. Russell	U.K.	93	Outland Promotions	O (horror adult concepts)
<i>Manifesto</i>	M. Golan/Y. Globus	USA/ Yugoslavia	90	Hoyts Distribution	S (i-m-g) O (adult concepts)
<i>Playboy's Farmers Daughters</i>	D. Kellogg/G. Moskowitz	U.S.A.	41	Palace Entertainment Corporation	O (exploitative nudity)
<i>Playboy's Video Centerfold—Luann Lee</i>	M. Trikilis	U.S.A.	27	Palace Entertainment Corporation	O (exploitative nudity)

'X'—Extra Restricted (not to be sold or hired or delivered to minors or displayed except in a restricted publications area and bearing prescribed markings)

<i>Behind Ginger</i>	Vivid Video	U.S.A.	28	Capital Duplicators	S (f-h-g)
<i>Blonde, The</i>	Not shown	U.S.A.	68	Mareith Investments	S (f-h-g)
<i>Brat on the Run</i>	P. Thomas	U.S.A.	81	Leisuremail	S (f-h-g)
<i>Crocodile Blondee Part II</i>	The Jellyroll Company	U.S.A.	83	Leisuremail	S (f-h-g)

<i>Title</i>	<i>Producer</i>	<i>Country</i>	<i>Submitted length (mins)</i>	<i>Applicant</i>	<i>Reason for decision</i>
<i>Debbie Does Dallas IV</i>	M. Curtis	U.S.A.	73	Leisuremail	S (f-h-g)
<i>Nightmare on Porn Street</i>	Moonlight Entertainment	U.S.A.	74	Leisuremail	S (f-h-g)
<i>Sex Asylum II—Sheer Bedlam</i>	B. Seven	U.S.A.	87	Leisuremail	S (f-h-g) O (mild fetish)
<i>Surf's Up</i>	Ocean Productions	U.S.A.	85	Leisuremail	S (f-h-g)
Refused Classification					
<i>Pop's Oasis</i>	H. Hope/N. Hope	U.S.A.	94	Hoyts Distribution	O (gratuitous sexual violence)

N.N.—8876534

Community Services and Health

COMMONWEALTH OF AUSTRALIA
NATIONAL HEALTH ACT 1953
PHARMACEUTICAL BENEFITS
DETERMINATION UNDER SECTION 93

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to section 93 of the National Health Act 1953, hereby make the following Determination:


1. This Determination shall come into operation on the first day of December 1988.
2. The Determination under section 93 of the National Health Act made on 18 July 1988 with effect from 1 August 1988 is hereby revoked.
3. The pharmaceutical benefits referred to in this Determination shall be those contained in the Schedule to this Determination.
4. A medical practitioner is authorised for the purpose of section 93 of the Act to supply any of the pharmaceutical benefits obtained by the medical practitioner, or by another medical practitioner for whom the first-named medical practitioner is temporarily acting as a locum, in pursuance of this Determination.
5. Subject to this Determination, the maximum quantity or number of units of a pharmaceutical benefit that may be obtained by a medical practitioner in any one month for the purpose of section 93 of the Act is the number or quantity specified in the Schedule to this Determination in relation to the pharmaceutical benefit.
6. Where a medical practitioner has obtained a pharmaceutical benefit for the purpose of section 93 of the Act, that medical practitioner is not entitled to obtain a further quantity or number of units of that pharmaceutical benefit for that purpose whilst in possession of a quantity or number of units of the pharmaceutical benefit obtained by the medical practitioner equal to or greater than the maximum quantity or number of units allowed for the pharmaceutical benefit by paragraph 5.
7. A medical practitioner is not entitled to obtain a pharmaceutical benefit for the purpose of section 93 of the Act more often than twice in any two months.

THE SCHEDULE

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Maximum quantity
Adrenaline Injection B.P.	Adrenaline, 1 in 1,000, 1 mL	5
Aminophylline Injection B.P.	Ampoule, 250 mg in 10 mL	5
Atropine Sulphate Injection B.P.	Ampoule, 600 micrograms in 1 mL	5
Chlorpromazine Injection B.P.	Ampoule, 50 mg in 2 mL	10
OR		
Haloperidol B.P.	Injection, 5 mg in 1 mL amp.	10
Diazepam Injection B.P.	10 mg in 2 mL	5
Digoxin Injection B.P.	Ampoule, 500 micrograms in 2 mL	5
Diphtheria and Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	10
Diphtheria and Tetanus Vaccine, Adsorbed B.P., Diluted	Injection, 0.5 mL amp.	10
Ergometrine Injection B.P.	Ampoule, 250 micrograms in 1 mL	5
Erythromycin Ethyl Succinate B.P.	Injection, 100 mg (base) in 2 mL	5
Frusemide Injection B.P.	Ampoule, 20 mg in 2 mL	5
Glucose Intravenous Infusion B.P.	Ampoule, 5 g in 10 mL	5
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 100 mg hydrocortisone and 2 mL solvent	2
OR		
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 250 mg hydrocortisone and 2 mL solvent	1
OR		
Dexamethasone Sodium Phosphate B.P.	Injection, 1 mL amp. containing equivalent of 4 mg dexamethasone phosphate	5
Lignocaine Hydrochloride B.P.	Injection, 100 mg in 5 mL	4
OR		
Lignocaine Hydrochloride Injection B.P.	Syringe, disposable, 300 mg in 3 mL	1

Metoclopramide Injection B.P.	Ampoule, 10 mg in 2 mL	10
OR		
Prochlorperazine Edisylate	Injection, 12.5 mg in 1 mL	10
OR		
Prochlorperazine Injection B.P.	Ampoule, 12.5 mg in 1 mL	10
Morphine Sulphate Injection B.P.	Ampoule, 15 mg in 1 mL	5
OR		
Morphine Sulphate Injection B.P.	Ampoule, 30 mg in 1 mL	5
Naloxone Hydrochloride	Injection, 2 mg in 5 mL disposable injection set	2
Pethidine Injection B.P.	Ampoule, 100 mg in 2 mL	5
Procaine Penicillin Injection B.P.	Syringe, disposable, 1.5 g	10
OR		
Benzylpenicillin Potassium B.P. with any determined brand of Water for Injections	Injection, 600 mg vial (with ampoule, 2 mL)	10
Promethazine Hydrochloride Injection B.P.	Ampoule, 50 mg in 2 mL	10
Terbutaline Sulphate B.P.	Injection, 100 micrograms in 1 mL amp.	5
OR		
Terbutaline Sulphate B.P.	Injection, 500 micrograms in 1 mL amp.	5
Verapamil Hydrochloride Injection B.P.	Ampoule, 5 mg in 2 mL	5

Dated this 16th day of November 1988.



JOHN DEEBLE
ACTING FIRST ASSISTANT SECRETARY
HEALTH BENEFITS DIVISION
DELEGATE OF THE MINISTER OF STATE FOR COMMUNITY SERVICES AND HEALTH

COMMONWEALTH OF AUSTRALIA
NATIONAL HEALTH ACT 1953
PHARMACEUTICAL BENEFITS
DECLARATION UNDER SUB-SECTION 85(2AA)

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sub-section 85(2AA) of the National Health Act 1953, hereby make the following Declaration:


1. This Declaration shall come into operation on 1 December 1988.
2. The drugs and medicinal preparations contained in the Schedule to this Declaration shall cease to be drugs and medicinal preparations to which Part VII of the National Health Act 1953 applies.

THE SCHEDULE

Atropine Methonitrate B.P.
Benzocaine B.P. with Adrenaline B.P.
Cholera Vaccine B.P.
Cloxacillin Sodium B.P. with Purified Water B.P.
Dapsone Tablets B.P.
Epicillin
Ergotamine Tartrate B.P. with Caffeine B.P. and Cyclizine Hydrochloride B.P.
Ergotamine Tartrate B.P. with Caffeine Citrate B.P.C. 1959 and
Diphenhydramine Hydrochloride B.P.
Flucloxacillin Sodium B.P. with Purified Water B.P.
Natamycin
Norethisterone Acetate B.P. with Ethinyloestradiol B.P.
Ornidazole
Phenytoin Injection B.P.
Plague Vaccine B.P. 1973
Pyridostigmine Injection B.P.
Sodium Calciumedetate B.P.
Sodium Salicylate B.P.
Stilboestrol Tablets B.P.
Sulphamethizole B.P.
"Teric" N8 with Lauryldimethylbenzyl Ammonium Chloride
Trimetaphan Camsylate B.P. 1968
Typhoid Vaccine B.P.
Typhoid Vaccine, Oral
Typhus Vaccine B.P.
Anthrax Antiserum
Anthrax Vaccine
Antirabies Immunoglobulin Injection B.P.
Bacillus Calmette-Guérin Vaccine B.P.
Bacillus Calmette-Guérin Vaccine, Percutaneous B.P.
Black Snake Antivenom
Botulinum Antitoxin B.P.
Box Jellyfish Antivenom
Brown Snake Antivenom
Death Adder Antivenom
Formaldehyde Solution B.P.
Funnel-Web Spider Antivenom

Haemodialysis Solutions B.P.
Haemodialysis Solutions B.P.C. 1973
Haemodialysis Solutions, Concentrated B.P.
Haemodialysis Solutions, Concentrated B.P.C. 1973
Intraperitoneal Dialysis Solutions, Concentrated
Pituitary Gonadotrophin, Human
Pituitary Growth Hormone, Human
Rabies Vaccine B.P.
Snake Bite Antivenom, Polyvalent
Sodium Hypochlorite Solution, Strong B.P.
Sodium Hypochlorite Solution 52.5 mg per mL
Stone Fish Antivenom
Taipan Antivenom
Tiger Snake Antivenom
Tuberculin Purified Protein Derivative B.P.
Tuberculin Purified Protein Derivatives, Atypical

Dated this 16th day of November 1988.



JOHN DEEBLE
ACTING FIRST ASSISTANT SECRETARY
HEALTH BENEFITS DIVISION
DELEGATE OF THE MINISTER OF STATE FOR COMMUNITY SERVICES AND HEALTH

N.N.-8878561

COMMONWEALTH OF AUSTRALIA
NATIONAL HEALTH ACT 1953
PHARMACEUTICAL BENEFITS
DETERMINATION UNDER SUB-SECTION 84C(7)

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sub-section 84C(7) of the National Health Act 1953, hereby make the following Determination:

1. This Determination shall come into operation on the first day of December 1988.
2. The Determination under sub-section 84C(7) of the National Health Act made on 1 November 1986 with effect from 1 November 1986, as amended, is, in this Determination, referred to as the Principal Determination.
3. Sub-paragraphs 10(a), 10(b) and 10(c) of the Principal Determination are amended by omitting "\$0.62" (wherever occurring) and substituting "\$0.63".
4. Sub-paragraphs 10(a), 10(c), 20(d), 38(c) and 38(d) of the Principal Determination are amended by omitting "\$0.90" (wherever occurring) and substituting "\$0.91".


Dated this

16th

day of

November

1988.



JOHN DEEBLE
ACTING FIRST ASSISTANT SECRETARY
HEALTH BENEFITS DIVISION
DELEGATE OF THE MINISTER OF STATE FOR COMMUNITY SERVICES AND HEALTH

COMMONWEALTH OF AUSTRALIA

National Health Act 1953

PHARMACEUTICAL BENEFITS

DECLARATION UNDER SUB-SECTION 85 (2)

No. PB 5 of 1988

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sub-section 85 (2) of the *National Health Act 1953*, hereby make the following Declaration:

1. This Declaration shall come into operation on 1 December 1988.
2. Declaration No. PB 3 under sub-section 85 (2) of the Act made with effect from 1 August 1988, as amended by Declaration No. PB 4 with effect from 1 August 1988, is hereby revoked.
3. In this Declaration:
 - "the Act" means the *National Health Act 1953*;
 - "approved pharmacist" has the same meaning as in sub-section 84 (1) of the Act;
 - "ready-prepared pharmaceutical benefit" means a drug or medicinal preparation in respect of which there is in force a determination under sub-section 85 (6) of the Act;
 - "extemporaneously-prepared pharmaceutical benefit" means a pharmaceutical benefit other than a ready-prepared pharmaceutical benefit.
4. Part VII of the Act applies in relation to each of the drugs and medicinal preparations as are specified in Schedule 1.
5. A medicinal preparation composed of a compound that includes a pharmaceutical benefit specified in column 1 of Schedule 2, other than a compound specified in column 2 of that Schedule opposite to that pharmaceutical benefit, is not a medicinal preparation to which Part VII of the Act applies, unless that pharmaceutical benefit is also specified in Schedule 3, in which case the provisions of paragraphs 7 and 8 apply.
6. Part VII of the Act does not apply in relation to a medicinal preparation composed of a compound that includes a ready-prepared pharmaceutical benefit, other than Water for Injections or a pharmaceutical benefit specified in column 1 of Schedule 2.
7. Part VII of the Act applies in relation to medicinal preparations composed of one or more of the drugs or medicinal preparations specified in Schedule 3.
8. Part VII of the Act applies in relation to medicinal preparations composed of one or more of the drugs or medicinal preparations specified in Schedule 3 with the addition of one or more of the substances specified in Schedule 4.
9. The substances specified in Schedule 4 are additives for the purposes of paragraph 85 (2) (b) of the Act.
10. Part VII of the Act applies in relation to each of the drugs and medicinal preparations as are specified in Schedule 5.
11. The drugs and medicinal preparations specified in Schedule 5 are additional pharmaceutical benefits made available under arrangements provided for by section 100 of the Act.
12. Where circumstances are specified in column 2 of Schedule 1 or Schedule 3 opposite the name of a pharmaceutical benefit specified in column 1 of either of those Schedules, that pharmaceutical benefit is a relevant pharmaceutical benefit for the purposes of section 88A of the Act.
13. Where circumstances are specified in column 2 of Schedule 3 opposite the name of a pharmaceutical benefit specified in column 1 of that Schedule, those circumstances are also specified in relation to any medicinal preparation containing that pharmaceutical benefit.
14. The following circumstances are specified in relation to each relevant pharmaceutical benefit for the purposes of section 88A of the Act:
 - (a) Where a class of persons is specified in column 2 of Schedule 1 or Schedule 3—that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;
 - (b) Where a disease or condition is specified in column 2 of Schedule 1 or Schedule 3—
 - (i) if sub-sub-paragraph (ii) does not apply—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or
 - (ii) if the disease or condition is specified in relation to a specified class of persons—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;
 - (c) Where a purpose is specified in column 2 of Schedule 1 or Schedule 3—that the pharmaceutical benefit is to be supplied for that purpose;
 - (d) Where it is specified in column 2 of Schedule 1 or Schedule 3 that compliance with authority procedures set out in sub-paragraph 14 (d) is required—
 - (i) that an application for the written authority of the Secretary in relation to the supply of the pharmaceutical benefit has been made by a medical practitioner, on a form approved by the Secretary, and has been forwarded to the Secretary by that medical practitioner or on behalf of that medical practitioner by a person other than an approved pharmacist, and the Secretary has approved the application; or
 - (ii) where the medical practitioner believes that the supply of the pharmaceutical benefit is required urgently—that the medical practitioner has prepared an Authority Prescription on a form approved by the Secretary and has:
 - (A) issued the original and duplicate of the form to the person for whom the pharmaceutical benefit is to be supplied;
 - (B) on the departmental copy of the form declared that the circumstances specified in column 2 of Schedule 1 or Schedule 3 apply and signed that copy in the medical practitioner's handwriting; and

(C) forwarded the departmental copy to reach the Secretary within 7 days from the date on which the original and duplicate were issued to the person for whom the pharmaceutical benefit is to be supplied.

15. Where a medical practitioner makes an application under sub-paragraph 14 (d) and the Secretary approves the application, the Secretary shall record the approval on a numbered authority and—
- (a) where, in the approval, the Secretary requires the medical practitioner to vary the prescription for the supply of the pharmaceutical benefit—return the approval to the medical practitioner; or
 - (b) in any other case—return the approval to the medical practitioner or, if the medical practitioner so requests, forward the approval to the person to whom the pharmaceutical benefit is to be supplied.

SCHEDULE 1

Ready-prepared pharmaceutical benefits

Column 1	Column 2
Pharmaceutical benefit	Circumstances (if any) specified for the purposes of section 88A of the Act
Acetazolamide B.P.	—
Acetazolamide Sodium	—
Acetazolamide Tablets B.P.	—
Acetylcysteine	Bronchiectasis Cystic fibrosis (mucoviscidosis) Ileostomy or colostomy conditions
Acrylic Resin	In respect of the eye ointment: Eye infections caused by herpes simplex virus
Acyclovir	In respect of the tablet, 200 mg: In compliance with authority procedures set out in sub-paragraph 14 (d): Moderate to severe initial genital herpes, complicated by severe pain, systemic symptoms or urinary retention In respect of the tablet, 400 mg: In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment of patients with herpes zoster with severe pain who are over 60 years of age and in whom the duration of rash is less than 72 hours
Adrenaline B.P.	—
Adrenaline Hydrochloride	—
Adrenaline Injection B.P.	—
"Albumaid XP"	Phenylketonuria
"Albumaid XPXT"	Tyrosinaemia
"Alfaré"	In compliance with authority procedures set out in sub-paragraph 14 (d): Biliary atresia Chyloascites Chylothorax Cystic fibrosis Enterokinase deficiency Intolerance to both milk protein and soya protein Severe diarrhoea of greater than two weeks duration in infants under the age of 4 months
Allopurinol B.P.	—
Allopurinol Tablets B.P.	—
Alprenolol Tablets B.P.	—
Aluminium Hydroxide and Magnesium Carbonate Co-dried Gel	—
Aluminium Hydroxide, Dried B.P.	—
Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P.	—
Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P.	—
Aluminium Hydroxide Mixture B.P.	—
Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P.	—
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P.	—
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine	—
Amantadine Hydrochloride	The treatment of Parkinson's disease caused otherwise than by treatment with a drug
Amibenonium Chloride	—
Amiloride Hydrochloride Tablets B.P.	—
Aminacrine Hydrochloride B.P. 1968	—
Aminogluthethimide	In compliance with authority procedures set out in sub-paragraph 14 (d): Post-menopausal metastatic breast cancer in patients who have failed to respond adequately to endocrine manipulation Cushing's syndrome

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
"Aminogran Food Supplement"	Phenylketonuria
"Aminogran Mineral Mixture"	Phenylketonuria
Aminophylline B.P.	—
Aminophylline Injection B.P.	—
Aminophylline Tablets B.P.	—
Amiodarone Hydrochloride	In compliance with authority procedures set out in sub-paragraph 14 (d): For the continuing treatment of severe refractory cardiac arrhythmias where treatment with amiodarone hydrochloride was initiated in a hospital (in-patient or out-patient)
Amitriptyline Tablets B.P.	—
Ammonium Chloride B.P.	—
Amoxycillin Capsules B.P.	—
Amoxycillin Sodium	—
Amoxycillin Trihydrate B.P.	—
Amoxycillin Trihydrate B.P. with Potassium Clavulanate	—
Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P.	—
Amoxycillin Trihydrate B.P. with Purified Water B.P.	—
Amphotericin B.P.	—
Amphotericin Lozenges B.P.	—
Ampicillin Capsules B.P.	—
Ampicillin Sodium B.P.	—
Ampicillin Trihydrate B.P. with Purified Water B.P.	—
Amylobarbitone Sodium B.P.	Epilepsy
Antazoline Phosphate with Naphazoline Hydrochloride	—
Antazoline Sulphate with Naphazoline Nitrate B.P.	—
Aspirin B.P.	—
Aspirin Tablets B.P.	—
Aspirin Tablets, Dispersible B.P.	—
Atenolol	—
Atropine Eye Ointment B.P.	—
Atropine Sulphate B.P.	—
Atropine Sulphate Injection B.P.	—
Atropine Sulphate Tablets B.P.	—
Auranofin	—
Aurothioglucose	—
Azathioprine Tablets B.P.	—
Baclofen Tablets B.P.	—
"Banish"	Ileostomy or colostomy conditions
Beclomethasone Dipropionate B.P.	In respect of the capsules and the sprays, metered aerosol, 50 micrograms per dose, 200 doses, 20.4 g and 100 micrograms per dose, 200 doses, 20.4 g: Asthma In respect of the spray, metered aerosol, 250 micrograms per dose, 200 doses, 20.4 g: In compliance with authority procedures set out in sub-paragraph 14 (d): Severe chronic asthma not responding to lower doses of beclomethasone dipropionate aerosol
Bendrofluazide Tablets B.P.	—
Benzathine Penicillin B.P.	—
Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections	—
Benzhexol Tablets B.P.	—
Benzoin Tincture, Compound B.P.	Ileostomy or colostomy conditions
Benztropine Injection B.P.	—
Benztropine Tablets B.P.	—

Column 1	Column 2
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Benzyl Benzoate Application B.P.	—
Benzyl Benzoate B.P.	—
Benzylpenicillin Potassium B.P.	—
Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.	Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid Necrobiosis lipoidica Uveitis
Betamethasone Dipropionate	—
Betamethasone Tablets B.P.	—
Betamethasone Valerate B.P.	—
Betamethasone Valerate Cream B.P.	—
Betamethasone Valerate Ointment B.P.	—
Bethanechol Chloride	—
Biperiden Hydrochloride	—
Bisacodyl B.P.	Any disease or condition in a paraplegic or quadriplegic patient
Bisacodyl Suppositories B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Bisacodyl Tablets B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Bismuth Subcitrate	—
Bleomycin Sulphate	Germ cell neoplasms Lymphoma Squamous cell carcinoma
Bromocriptine Mesylate Capsules B.P.	In compliance with authority procedures set out in subparagraph 14 (d): Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution
Bromocriptine Mesylate Tablets B.P.	Urgent suppression of physiological lactation In compliance with authority procedures set out in subparagraph 14 (d): Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution
Bumetanide	—
Busulphan Tablets B.P.	—
Butyl Monoester Polymer with Ethanol B.P.	Ileostomy or colostomy conditions
Butyl Monoester Polymer with Isopropyl Alcohol B.P.	Ileostomy or colostomy conditions
Calciferol Tablets, High-Strength B.P.	Hypocalcaemia Hypoparathyroidism Osteomalacia following gastrectomy, severe steatorrhoea or renal failure Vitamin D-resistant rickets

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Calcitonin (Human)—Synthetic	In compliance with authority procedures set out in subparagraph 14 (d): Proven active Paget's disease of bone, or hypercalcaemia, in patients unable to tolerate both pork and salmon calcitonin or who are resistant to treatment with either pork or salmon calcitonin
Calcitonin (Pork) B.P.	In compliance with authority procedures set out in subparagraph 14 (d): Proven active Paget's disease of bone causing pain or disability Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia For the continuation of treatment of patients already established on calcitonin under arrangements provided for by section 100 of the Act
Calcitriol	In compliance with authority procedures set out in subparagraph 14 (d): Hypocalcaemia due to renal disease Hypoparathyroidism Hypophosphataemic rickets Vitamin D-resistant rickets
Calcium Carbonate B.P.	Hypocalcaemia Osteoporosis Proven malabsorption
Calcium Carbonate B.P. with Calcium Lactate-Gluconate	Hypocalcaemia Osteoporosis Proven malabsorption
Calcium Folate	Antidote to folic acid antagonists
Calcium Glubionate	—
Captopril	In compliance with authority procedures set out in subparagraph 14 (d): For the continuing treatment of severe refractory cardiac failure where treatment with captopril was initiated in a hospital (in-patient or out-patient) Hypertension where other drug therapy has failed or is inappropriate
Carbachol B.P. 1973	—
Carbamazepine B.P.	—
Carbamazepine Tablets B.P.	—
Carbimazole Tablets B.P.	—
Carboplatin	In compliance with authority procedures set out in subparagraph 14 (d): Advanced stage ovarian carcinoma
Carmellose Sodium B.P. with Pectin and Gelatin B.P.	Ileostomy or colostomy conditions
Cefotaxime Sodium	In compliance with authority procedures set out in subparagraph 14 (d): Infections where positive bacteriological evidence confirms that cefotaxime sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Ceftriaxone Sodium	In compliance with authority procedures set out in subparagraph 14 (d): Infections where positive bacteriological evidence confirms that ceftriaxone sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Cephalexin B.P. with Purified Water B.P.	—
Cephalexin Capsules B.P.	—
Cephalothin Sodium B.P.	—
Cephazolin Sodium	In compliance with authority procedures set out in subparagraph 14 (d): Infections where positive bacteriological evidence confirms that cephazolin sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Charcoal, Activated B.P.	Ileostomy or colostomy conditions

Column 1	Column 2
Pharmaceutical benefit	Circumstances (if any) specified for the purposes of section 88A of the Act
Chloral Hydrate B.P.	—
Chlorambucil Tablets B.P.	—
Chloramphenicol B.P.	—
Chloramphenicol B.P. with Polymyxin B Sulphate B.P.	—
Chloramphenicol Capsules B.P.	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chloramphenicol Eye Drops B.P.	—
Chloramphenicol Eye Ointment B.P.	—
Chloramphenicol Palmitate Mixture B.P.	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chloramphenicol Sodium Succinate B.P.	Bacterial meningitis Intracranial bacterial infections Intraocular infections Rickettsioses Typhoid Other serious infections where positive bacteriological evidence confirms that chloramphenicol is the only appropriate antibiotic
Chlorhexidine Gluconate	—
Chlormethiazole Capsules B.P.	In compliance with authority procedures set out in subparagraph 14 (d): Short-term alcohol or drug withdrawal therapy in a hospital or approved centre Status epilepticus
Chlormethiazole Edisylate B.P.	Short-term alcohol or drug withdrawal therapy in a hospital or approved centre Status epilepticus
Chloroquine Phosphate Tablets B.P.	—
Chloroquine Sulphate B.P.	—
Chlorothiazide Tablets B.P.	—
Chlorpromazine Elixir B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Chlorpromazine Injection B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Chlorpromazine Suppositories B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Chlorpromazine Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Chlorpropamide Tablets B.P.	—
Chlorthalidone Tablets B.P.	—
Cholestyramine	In compliance with authority procedures set out in subparagraph 14 (d): Bile salt malabsorption Hypercholesterolaemia Pruritus associated with partial biliary obstruction not responding to other therapy Severe diarrhoea associated with pelvic irradiation
Choline Theophyllinate B.P.	—
Chorionic Gonadotrophin B.P.	In respect of the injection set containing 1 ampoule powder for injection 5,000 units and 1 ampoule solvent 1mL: In compliance with authority procedures set out in subparagraph 14 (d): For use with bromocriptine mesylate in infertility associated with hyperprolactinaemia In respect of the other injection sets: In compliance with authority procedures set out in subparagraph 14 (d): For the treatment of anovulatory infertility in females under 41 years of age with no more than 2 live children by their present union For the treatment of infertility in males due to hypogonadotrophic hypogonadism For the treatment of infertility in males associated with isolated luteinizing hormone deficiency For the treatment of males who have combined deficiency of human growth hormone and gonadotrophins and in whom the absence of secondary sexual characteristics indicates a lag in maturation For the treatment of males over the age of 16 years who show clinical evidence of hypogonadism or delayed puberty
Cimetidine	In respect of the tablets, 200 mg and 400 mg: In compliance with authority procedures set out in subparagraph 14 (d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous two years Scleroderma oesophagus Severe ulcerating (erosive) oesophagitis, proven by endoscopy and unresponsive to other measures Zollinger-Ellison syndrome In respect of the tablet, 800 mg:

Column 1	Column 2
Pharmaceutical benefit	Circumstances (if any) specified for the purposes of section 88A of the Act
	In compliance with authority procedures set out in sub-paragraph 14 (d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous two years Zollinger-Ellison syndrome
Ciprofloxacin Hydrochloride	In compliance with authority procedures set out in sub-paragraph 14 (d): Serious infections for which no other antimicrobial agent is appropriate
Clindamycin Capsules B.P.	Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Gram-positive coccal infections where the infection cannot be safely and effectively treated with penicillin or a derivative of penicillin
Clioquinol B.P.	—
Clofibrate Capsules B.P.	Hypertriglyceridaemia Hypercholesterolaemia
Clomiphene Tablets B.P.	Anovulatory infertility Patients undergoing in-vitro fertilisation
Clomipramine Hydrochloride B.P.	Cataplexy associated with narcolepsy Obsessive compulsive disorders
Clonazepam	—
Clonidine Hydrochloride Tablets B.P.	—
Clopidamide	—
Clotrimazole B.P.	—
Cloxacillin Capsules B.P.	—
Cloxacillin Sodium B.P.	—
Codeine Phosphate B.P. with Aspirin B.P.	—
Codeine Phosphate B.P. with Paracetamol B.P.	—
Codeine Phosphate Tablets B.P.	—
Colchicine Tablets B.P.	—
Colestipol Hydrochloride	In compliance with authority procedures set out in sub-paragraph 14 (d): Hypercholesterolaemia
Colistin Sulphate B.P. with Neomycin Sulphate B.P.	—
Colistin Sulphomethate Sodium B.P.	—
Copper Sulphate B.P.C. 1973	—
Cortisone Tablets B.P.	—
Co-trimoxazole Mixture, Paediatric B.P.	—
Co-trimoxazole Tablets B.P.	—
Cyclopenthiiazide Tablets B.P.	—
Cyclophosphamide B.P.	—
Cyclophosphamide Tablets B.P.	—
Cyproheptadine Tablets B.P.	Prevention of migraine
Cytarabine B.P.	—
Danazol	In compliance with authority procedures set out in sub-paragraph 14 (d): Endometriosis, proven by visual means Hereditary angio-oedema Menorrhagia, intractable primary
Dantrolene Sodium	Treatment of chronic spasticity
Debrisoquine Tablets B.P.	—
"De-Lact Infant"	Acute gastro-enteritis complicated by lactose intolerance in infants under the age of 12 months Proven lactose intolerance in infants under the age of 12 months
Demeclocycline Capsules B.P.	Syndrome of inappropriate antidiuretic hormone secretion, caused otherwise than by treatment with a drug
Desipramine Tablets B.P.	—

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Desmopressin	—
Dexamethasone B.P.	—
Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin	—
Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin	—
Dexamethasone Sodium Phosphate B.P.	In respect of the injection, 5 mL vial containing equivalent of 120 mg dexamethasone phosphate: For use in a hospital In respect of the other injections: —
Dexamethasone Tablets B.P.	—
Dexamphetamine Tablets B.P.	In compliance with authority procedures set out in subparagraph 14 (d): For the treatment of a patient under the age of 21 years and who is hyperkinetic as a result of brain damage Narcolepsy
Dextran 40 Intravenous Infusion B.P. with Glucose B.P.	—
Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P.	—
Dextran 70 Intravenous Infusion B.P. with Glucose B.P.	—
Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P.	—
Diazepam B.P.	—
Diazepam Injection B.P.	—
Diazepam Tablets B.P.	—
Diazoxide Injection B.P.	—
Dichlorphenamide Tablets B.P.	—
Diclofenac Sodium	—
Dienoestrol B.P.	—
Difenoxin Hydrochloride with Atropine Sulphate B.P.	—
Diffunisal Tablets B.P.	—
"Digestelact"	In compliance with authority procedures set out in subparagraph 14 (d): Lactose intolerance
Digoxin Elixir, Paediatric B.P.	—
Digoxin Injection B.P.	—
Digoxin Tablets B.P.	—
Dihydroergotamine Mesylate B.P.	—
Dihydrotachysterol B.P.	In compliance with authority procedures set out in subparagraph 14 (d): Hypoparathyroidism Osteomalacia following gastrectomy, severe steatorrhoea or renal failure Vitamin D-resistant rickets
Diloxanide Furoate Tablets B.P.	—
Diltiazem Hydrochloride	In compliance with authority procedures set out in subparagraph 14 (d): Angina where treatment with verapamil hydrochloride or nifedipine has failed or is inappropriate
Dimercaprol Injection B.P.	—
Dimethicones B.P.	Ileostomy or colostomy conditions
Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P.	—
Diphtheria and Tetanus Vaccine, Adsorbed B.P.	—
Diphtheria and Tetanus Vaccine, Adsorbed B.P., Diluted	—
Diphtheria Antitoxin B.P.	—
Diphtheria, Tetanus and Pertussis Vaccine, Adsorbed B.P.	—
Diphtheria Vaccine, Adsorbed B.P.	—
Diphtheria Vaccine, Adsorbed B.P., Diluted	—
Dipivefrine Hydrochloride	—

Column 1	Column 2
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Disodium Etidronate	In compliance with authority procedures set out in subparagraph 14 (d): Active Paget's disease of bone when calcitonin has been found to be unsatisfactory due to lack of efficacy or unacceptable side effects
Disopyramide Capsules B.P.	—
Disopyramide Phosphate Capsules B.P.	—
Docusate Sodium B.P. with Bisacodyl B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Domperidone	—
Dothiepin Capsules B.P.	—
Dothiepin Hydrochloride B.P.	—
Doxepin Capsules B.P.	—
Doxepin Hydrochloride B.P.	—
Doxorubicin Hydrochloride	—
Doxycycline Capsules B.P.	—
Doxycycline Hydrochloride B.P.	In respect of the capsules, 50 mg (base) (containing enteric coated pellets) and the tablets, 50 mg (base): Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne In respect of the other capsules and tablets: —
Dydrogesterone Tablets B.P.	In compliance with authority procedures set out in subparagraph 14 (d): Endometriosis, proven by visual means
Econazole Nitrate B.P.	—
Econazole Nitrate Cream B.P.	—
Econazole Nitrate Pessaries B.P.	—
Ecothiopate Iodide B.P.	—
Enalapril Maleate	In compliance with authority procedures set out in subparagraph 14 (d): For the continuing treatment of severe refractory cardiac failure where treatment with enalapril maleate was initiated in a hospital (in-patient or out-patient) Hypertension where other drug therapy has failed or is inappropriate
Ergometrine and Oxytocin Injection B.P.	—
Ergometrine Injection B.P.	—
Ergometrine Tablets B.P.	—
Ergotamine Tablets B.P.	—
Ergotamine Tartrate B.P. with Caffeine B.P.	—
Erythromycin B.P.	—
Erythromycin Estolate B.P.	—
Erythromycin Ethyl Succinate B.P.	—
Erythromycin Ethyl Succinate B.P. with Purified Water B.P.	—
Erythromycin Lactobionate	—
Erythromycin Stearate	—
Erythromycin Stearate Tablets B.P.	—
Erythromycin Tablets B.P.	—
Ethacrynic Acid Tablets B.P.	Patients who are hypersensitive to other oral diuretics
Ethinylloestradiol Tablets B.P.	—
Ethosuximide Capsules B.P.	—
Ethosuximide Elixir B.P.	—
Ethylloestrenol Tablets B.P.	In compliance with authority procedures set out in subparagraph 14 (d): Osteoporosis Patients on long-term treatment with corticosteroids

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Ethinodiol Diacetate B.P. with Ethinyloestradiol B.P.	—
Etretnate	In compliance with authority procedures set out in sub-paragraph 14 (d): Darier's disease Erythrokeratoderma Pityriasis rubra pilaris Severe congenital ichthyosis (lamellar, bullous and sex linked) Severe intractable psoriasis Severe lichen planus Severe palmo-plantar keratoderma
Famotidine	In compliance with authority procedures set out in sub-paragraph 14 (d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous two years Zollinger-Ellison syndrome
Felodipine	In compliance with authority procedures set out in sub-paragraph 14 (d): Treatment where less costly alternative therapy is inappropriate
Fenoterol Hydrobromide B.P.	—
Ferrous Aminoacetosulphate	—
Ferrous Gluconate B.P.	—
Ferrous Gluconate Tablets B.P.	—
Ferrous Sulphate, Dried B.P.	—
Ferrous Sulphate, Dried B.P. with Folic Acid B.P.	—
Flecainide Acetate	In compliance with authority procedures set out in sub-paragraph 14 (d): For the continuing treatment of cardiac arrhythmias where treatment with flecainide acetate was initiated in a hospital (in-patient or out-patient)
Fluclorolone Acetonide B.P.	—
Flucloxacillin Capsules B.P.	—
Flucloxacillin Magnesium B.P. with Purified Water B.P.	—
Flucloxacillin Sodium B.P.	—
Flucytosine Tablets B.P.	Invasive or systemic fungal infections such as candidiasis, cryptococcosis and chromoblastomycosis
Fludrocortisone Tablets B.P.	—
Flumethasone Pivalate with Clioquinol B.P.	—
Fluocortolone Pivalate and Fluocortolone Hexanoate Cream B.P.	—
Fluocortolone Pivalate and Fluocortolone Hexanoate Ointment B.P.	—
Fluorometholone	—
Fluorouracil Injection B.P.	—
Fluoxymesterone Tablets B.P.	In compliance with authority procedures set out in sub-paragraph 14 (d): Aplastic anaemias, proven Carcinoma of the breast Hypogonadism Osteoporosis
Fluphenazine Decanoate Injection B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness

Column 1	Column 2
Pharmaceutical benefit	Circumstances (if any) specified for the purposes of section 88A of the Act
Fluphenazine Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Folic Acid B.P.	—
Folic Acid Tablets B.P.	—
Fosfestrol Sodium B.P.	Carcinoma of the prostate
Framycetin Sulphate B.P.	—
Frusemide B.P.	—
Frusemide Injection B.P.	—
Frusemide Tablets B.P.	In respect of the 500 mg strength: Renal failure In respect of the other strengths: —
Fusidic Acid Mixture B.P.	In compliance with authority procedures set out in subparagraph 14 (d): For use in combination with another antibiotic in the treatment of serious staphylococcal infections confirmed by bacteriological evidence
Gas-gangrene Antitoxin, Mixed B.P.	—
Gentamicin Eye Drops B.P.	Invasive ocular infection Perioperative use Suspected pseudomonal eye infection
Gentamicin Injection B.P.	—
Glibenclamide Tablets B.P.	—
Gliclazide	—
Glipizide	—
Glucagon Hydrochloride	—
Glucose and Ketone Indicator—Urine	—
Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.	—
Glucose Indicator—Blood	—
Glucose Indicator—Urine	—
Glucose Intravenous Infusion B.P.	—
Glyceryl Trinitrate	—
Glyceryl Trinitrate Tablets B.P.	—
Griseofulvin Tablets B.P.	Kerion Recalcitrant tinea infections
Haloperidol B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Haloperidol Solution B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Haloperidol Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness
Heparin Injection B.P. (Calcium Salt)	—
Heparin Injection B.P. (Sodium Salt)	—
Hexamine Hippurate	—
Hexamine Mandelate	—
Homatropine Hydrobromide B.P.	—
Hydralazine Hydrochloride Tablets B.P.	—
Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P.	—
Hydrochlorothiazide B.P. with Triamterene B.P.	—
Hydrochlorothiazide Tablets B.P.	—
Hydrocortisone B.P.	—
Hydrocortisone Acetate B.P.	In respect of the rectal foam: Proctitis Ulcerative colitis In respect of the other forms: —
Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.	—
Hydrocortisone Acetate Cream B.P.	—
Hydrocortisone Acetate Injection B.P.	Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid
Hydrocortisone Acetate Ointment B.P.	—
Hydrocortisone Sodium Succinate B.P.	In respect of the injection set containing equivalent of 500 mg hydrocortisone and 4 mL solvent: Any disease or condition in a patient receiving treatment in a hospital In respect of the other injection sets: —
Hydroxocobalamin Injection B.P.	Pernicious anaemia and other proven vitamin B12 deficiencies Post-gastrectomy treatment Sub-acute combined degeneration of the cord
Hydroxychloroquine Tablets B.P.	—
Hydroxyurea Capsules B.P.	—
Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	—
Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.	—
Hypromellose 4500 B.P.	—
Hypromellose 4500 B.P. with Dextran 70	—
Ibuprofen Tablets B.P.	—
Idoxuridine B.P.	—
Idoxuridine Eye Drops B.P.	—
Imipramine Hydrochloride B.P.	—
Imipramine Tablets B.P.	—
Indapamide	—
Indomethacin Capsules B.P.	—
Indomethacin Suppositories B.P.	—
Influenza Vaccine (Split Virion), Inactivated B.P.	For prophylaxis of persons at special risk of adverse consequences from infections of the lower respiratory tract

Column 1	Column 2
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Insect Allergen Extract—Honey Bee Venom	—
Insect Allergen Extract—Paper Wasp Venom	—
Insulin Injection, Acid B.P.	—
Insulin Injection, Biphasic B.P.	—
Insulin Injection, Isophane B.P.	—
Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.	—
Insulin Injection, Neutral B.P.	—
Insulin Injection, Protamine Zinc B.P.	—
Insulin Isophane, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Neutral, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Zinc Suspension B.P.	—
Insulin Zinc Suspension (Amorphous) B.P.	—
Insulin Zinc Suspension (Crystalline) B.P.	—
Insulin Zinc Suspension (Crystalline), Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Insulin Zinc Suspension, Human (Synthetic)	Diabetics exhibiting lipoatrophy, lipohypertrophy, local allergy or immunologic resistance Newly diagnosed insulin dependent diabetics
Intraperitoneal Dialysis Solutions B.P.C. 1973	—
Ipratropium Bromide	—
Iron Dextran Injection B.P.	—
Iron Polymaltose Complex	—
Isoconazole Nitrate	—
Isoniazid Tablets B.P.	—
Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.	Ileostomy or colostomy conditions
Isosorbide Dinitrate Tablets B.P.	—
Isotretinoin	In compliance with authority procedures set out in subparagraph 14(d): Severe cystic acne not responsive to other therapy
Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin	—
Ketoconazole	In compliance with authority procedures set out in subparagraph 14(d): Systemic or deep mycoses where other forms of therapy have failed
Ketoprofen B.P.	—
Ketoprofen Capsules B.P.	—
Labetalol Hydrochloride Tablets B.P.	—
Lactulose Solution B.P.	In compliance with authority procedures set out in subparagraph 14(d): Hepatic coma or pre-coma (chronic portosystemic encephalopathy) Terminal malignant neoplasia
Lauramine Oxide with Octoxinol	Ileostomy or colostomy conditions
Leuporelin Acetate	In compliance with authority procedures set out in subparagraph 14 (d): Advanced cancer of the prostate
Levodopa and Carbidopa Tablets B.P.	—
Levodopa B.P. with Benserazide	—
Levodopa Tablets B.P.	—
Levonorgestrel B.P.	—
Levonorgestrel B.P. with Ethinyloestradiol B.P.	—

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Lignocaine Hydrochloride B.P.	—
Lignocaine Hydrochloride Injection B.P.	—
Lincomycin Injection B.P.	—
Lindane B.P.	—
Lindane Cream B.P.	—
Liothyronine Tablets B.P.	—
Lithium Carbonate B.P.	—
Lithium Carbonate Tablets B.P.	—
"Locasol New Formula"	In compliance with authority procedures set out in sub-paragraph 14(d): Hypercalcaemia in children under the age of 2 years Osteopetrosis
"Lofenalac"	Phenylketonuria
Loperamide Hydrochloride	—
Lypressin	In compliance with authority procedures set out in sub-paragraph 14(d): Treatment where less costly alternative therapy is inappropriate
"Maxamaid RVHB"	Pyridoxine non-responsive homocystinuria
"Maxamaid XP"	Phenylketonuria
"Maxamum XP"	Phenylketonuria
Medroxyprogesterone Acetate B.P.	In respect of the injections, 50 mg in 1 mL vial and 500 mg in 2.5 mL vial, the oral suspension and the tablets, 100 mg, 200 mg and 250 mg: Breast cancer Endometrial cancer Renal cell cancer In respect of the injection, 150 mg in 1 mL vial: Breast cancer Endometrial cancer Endometriosis Renal cell cancer In respect of the tablet, 10 mg: — In respect of the tablet, 500 mg: Advanced breast cancer
Medrysone	—
Mefenamic Acid Capsules B.P.	Dysmenorrhoea Menorrhagia
Mefruside	—
Megestrol Acetate B.P.	Breast cancer
Melphalan Tablets B.P.	—
Menopausal Gonadotrophin, Human	In compliance with authority procedures set out in sub-paragraph 14(d): For the treatment of anovulatory infertility in females under 41 years of age with no more than 2 live children by their present union For the treatment of infertility in males due to hypogonadotrophic hypogonadism
Mercaptopurine Tablets B.P.	—
Metformin Tablets B.P.	—
Methacycline Hydrochloride B.P.C. 1973	—
Methadone Injection B.P.	Severe disabling pain not responding to non-narcotic analgesics
Methadone Tablets B.P.	Severe disabling pain not responding to non-narcotic analgesics
Methdilazine Hydrochloride	Prevention of migraine
Methenolone Acetate	In compliance with authority procedures set out in sub-paragraph 14(d): Osteoporosis Patients on long-term treatment with corticosteroids
Methotrexate B.P.	—
Methotrexate Injection B.P.	—

Column 1	Column 2
Pharmaceutical benefit	Circumstances (if any) specified for the purposes of section 88A of the Act
Methotrexate Tablets B.P.	—
Methsuximide	In compliance with authority procedures set out in sub-paragraph 14(d): Treatment where less costly alternative therapy is inappropriate
Methyclothiazide	—
Methyldopa Tablets B.P.	—
Methylphenobarbitone B.P.	Epilepsy
Methylprednisolone Acetate Injection B.P.	For local intra-articular or peri-articular infiltration
Methylprednisolone Sodium Succinate	—
Methyl Salicylate Liniment A.P.F.	—
Methyltestosterone Tablets B.P.	In respect of the 5 mg strength: Hypogonadism in patients under the age of 16 years In respect of the other strengths: Carcinoma of the breast Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Methysergide Tablets B.P.	—
Metoclopramide Hydrochloride B.P.	—
Metoclopramide Injection B.P.	—
Metoclopramide Tablets B.P.	—
Metolazone	—
Metoprolol Tartrate	—
Metronidazole Benzoate	—
Metronidazole B.P.	Prophylaxis in large bowel surgery Treatment, in a hospital, of acute anaerobic sepsis
Metronidazole Suppositories B.P.	—
Metronidazole Tablets B.P.	—
Mexiletine Hydrochloride Capsules B.P.	—
Mianserin Hydrochloride Tablets B.P.	In compliance with authority procedures set out in sub-paragraph 14(d): Depressive illness in persons with cardiovascular disease, bladder neck dysfunction or glaucoma
Miconazole	—
Miconazole Nitrate B.P.	—
Miconazole Nitrate Cream B.P.	—
Minocycline Hydrochloride	—
Minoxidil	In compliance with authority procedures set out in sub-paragraph 14(d): For the continuing treatment of severe refractory hypertensive disease where treatment with minoxidil was initiated in a hospital (in-patient or out-patient) For the continuing treatment of a patient who has already received, for more than 6 months, therapy with minoxidil for severe refractory hypertension
Misoprostol	In compliance with authority procedures set out in sub-paragraph 14(d): Duodenal ulcer (including pyloric and stomal ulcers), proven by x-ray, endoscopy or surgery within 3 months of application Gastric ulcer, proven by x-ray, endoscopy or surgery within 3 months of application
Mithramycin	For use in a hospital for: Inoperable testicular neoplasm Symptomatic hypercalcaemia and hypercalcaemia associated with advanced neoplasia
Mitozantrone Hydrochloride	Metastatic or locally advanced breast cancer
Morphine Sulphate B.P. with Tacrine Hydrochloride	Severe intractable pain
Morphine Sulphate Injection B.P.	—
Morphine Sulphate Tablets B.P.	Severe disabling pain not responding to non-narcotic analgesics
"M.S.U.D. AID"	Maple syrup urine disease

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Mustine Hydrochloride B.P.	—
Nalidixic Acid Tablets B.P.	For use as a urinary antiseptic in patients with neurogenic bladder Urinary tract infections where current clinical and bacteriological evidence confirm that nalidixic acid is an appropriate therapeutic agent
Naloxone Hydrochloride	—
Nandrolone Decanoate Injection B.P.	In compliance with authority procedures set out in subparagraph 14(d): Carcinoma of the breast Osteoporosis Patients on long-term treatment with corticosteroids
Nandrolone Phenylpropionate Injection B.P.	In compliance with authority procedures set out in subparagraph 14(d): Carcinoma of the breast Osteoporosis Patients on long-term treatment with corticosteroids
Naphazoline Hydrochloride	—
Naproxen B.P.	—
Naproxen Tablets B.P.	—
Neomycin Sulphate Eye Drops B.P.	—
Neomycin Tablets B.P.	Acute leukaemia during induction of remission with chemotherapy Bowel sterilisation preparatory to major surgery Encephalopathy, hepatic
Neomycin Undecenoate with Bacitracin Zinc B.P.	—
Neostigmine Injection B.P.	—
Neostigmine Tablets B.P.	—
Niclosamide Tablets B.P.	—
Nicotinic Acid Tablets B.P.	—
Nifedipine	—
Nitrazepam Tablets B.P.	—
Nitrofurantoin B.P.	—
Nitrofurantoin Mixture B.P.	—
Nitrofurantoin Tablets B.P.	—
Norethisterone Acetate B.P.	Carcinoma of the breast Carcinoma of the prostate
Norethisterone B.P. with Ethinyloestradiol B.P.	—
Norethisterone B.P. with Mestranol B.P.	—
Norethisterone Tablets B.P.	—
Norfloxacin	Acute bacterial enterocolitis Urinary tract infection
Nortriptyline Hydrochloride B.P.	—
Nortriptyline Tablets B.P.	—
"Nutramigen"	In compliance with authority procedures set out in subparagraph 14(d): Allergy to both cows' milk and soy protein in children under the age of 2 years Cystic fibrosis (mucoviscidosis) Galactosaemia Glycogen storage disease due to glucose-6-phosphatase deficiency in children under the age of 2 years Homocystinuria Lactose intolerance
Nystatin B.P.	—
Nystatin Mixture B.P.	—
Nystatin Ointment B.P.	—
Nystatin Pessaries B.P.	—
Nystatin Tablets B.P.	—
"Odorgon"	Ileostomy or colostomy conditions
Oestradiol Valerate	—
Oestrogens—Conjugated	—

Column 1	Column 2
Pharmaceutical benefit	Circumstances (if any) specified for the purposes of section 88A of the Act
Oestrone B.P.C. 1954	—
Olsalazine Sodium	In compliance with authority procedures set out in subparagraph 14(d): Inflammatory bowel disease involving the colon in patients with proven hypersensitivity to sulphonamides
Orphenadrine Hydrochloride Tablets B.P.	Parkinsonism
Oxazepam Tablets B.P.	—
Oxprenolol Hydrochloride B.P.	—
Oxprenolol Tablets B.P.	—
Oxycodone Hydrochloride	Severe disabling pain not responding to non-narcotic analgesics
Oxycodone Pectinate	Severe disabling pain not responding to non-narcotic analgesics
Oxymetholone Tablets B.P.	In compliance with authority procedures set out in subparagraph 14(d): Aplastic anaemias, proven Myeloclerosis
Oxytocin Injection B.P.	—
Pancreatin B.P.	Cystic fibrosis (mucoviscidosis) Following pancreatico-duodenectomy Pancreatic steatorrhoea
Pancrelipase	Cystic fibrosis (mucoviscidosis) Following pancreatico-duodenectomy Pancreatic steatorrhoea
Papaveretum B.P.C. 1973	—
Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.	—
Paracetamol B.P.	—
Paracetamol Tablets B.P.	—
Paraffin, Soft White B.P.	Ileostomy or colostomy conditions
Paraffin, Soft White B.P. with Liquid Paraffin B.P.	—
Penicillamine Tablets B.P.	Acute heavy metal intoxication Cystinosis Cystinuria with calculus formation Haemoglobinuria, paroxysmal cold Severe rheumatoid arthritis Wilson's disease (hepatolenticular degeneration)
Perhexiline Maleate	In compliance with authority procedures set out in subparagraph 14(d): Angina not responding to other therapy
Pericyazine	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Pethidine Injection B.P.	—
Pethidine Tablets B.P.	In compliance with authority procedures set out in subparagraph 14(d): Disabling pain associated with proven malignant neoplasia
Phenelzine Tablets B.P.	Depressive illness resistant to treatment with either tricyclic antidepressants or electroconvulsive therapy Phobic states
Phenethicillin Capsules B.P.	—
Phenethicillin Potassium B.P. with Purified Water B.P.	—
Phenethicillin Tablets B.P.	—
Phenindione Tablets B.P.	Patients stabilised on phenindione for more than 6 months
Phenobarbitone Injection B.P.	Epilepsy
Phenobarbitone Tablets B.P.	Epilepsy

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Phenoxybenzamine Capsules B.P.	In compliance with authority procedures set out in sub-paragraph 14(d): Neurogenic urinary retention Phaeochromocytoma
Phenoxymethylpenicillin (Benzathine Salt)	—
Phenoxymethylpenicillin (Hydrabamine Salt)	—
Phenoxymethylpenicillin Potassium Capsules B.P.	—
Phenoxymethylpenicillin Potassium Tablets B.P.	—
Phensuximide B.P.C. 1973	In compliance with authority procedures set out in sub-paragraph 14(d): Treatment where less costly alternative therapy is inappropriate
Phenylephrine Hydrochloride B.P.	—
Phenytol B.P.	—
Phenytol Capsules B.P.	—
Phenytol Mixture B.P.	—
Phytomenadione Injection B.P.	—
Pilocarpine	In compliance with authority procedures set out in sub-paragraph 14(d): Chronic glaucoma when other miotics are not tolerated
Pilocarpine Hydrochloride B.P.	—
Pindolol B.P.	—
Pindolol Tablets B.P.	—
Piperazine Oestrone Sulphate	—
Piroxicam	—
Pizotifen Malate	—
"PK AID I"	Phenylketonuria
"PK AID II"	Phenylketonuria
Pneumococcal Vaccine, Polyvalent	Splenectomised persons over the age of 2 years Persons with Hodgkin's disease Persons at high risk of pneumococcal infections
Polygeline	—
Polyisobutylene	Ileostomy or colostomy conditions
Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P.	—
Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.	—
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin	—
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.	—
Polyvinyl Alcohol	—
Polyvinyl Alcohol with Povidone B.P.	—
Polyvinylpyrrolidone and Vinyl Acetate Copolymer "Portagen"	Ileostomy or colostomy conditions In compliance with authority procedures set out in sub-paragraph 14(d): Chyloascites Chylothorax Patients requiring a ketogenic diet for intractable childhood epilepsy Proven malabsorption
Potassium Chloride B.P.	—
Potassium Chloride B.P. with Potassium Bicarbonate Effervescent Tablets	—
Pralidoxime Iodide	—
Prazosin Hydrochloride	—
Prednisolone Acetate	In respect of the injection: For local intra-articular or peri-articular infiltration In respect of the eye drops: —
Prednisolone Acetate with Phenylephrine Hydrochloride B.P.	Corneal grafts Uveitis

Column 1	Column 2
Pharmaceutical benefit	Circumstances (if any) specified for the purposes of section 88A of the Act
Prednisolone Sodium Phosphate B.P.	In respect of the retention enema: In compliance with authority procedures set out in sub-paragraph 14(d): Proctitis Ulcerative colitis In respect of the suppositories: Proctitis Ulcerative colitis In respect of the eye/ear drops: —
Prednisolone Stearoylglycolate	—
Prednisolone Tablets B.P.	—
Prednisone Tablets B.P.	—
"Pregestimil"	In compliance with authority procedures set out in sub-paragraph 14(d): Biliary atresia Chyloascites Chylothorax Cystic fibrosis Enterokinase deficiency Intolerance to both milk protein and soya protein Severe diarrhoea of greater than two weeks duration in infants under the age of 4 months
Primaquine Tablets B.P.	—
Primidone Tablets B.P.	—
Probenecid Tablets B.P.	—
Probutol	In compliance with authority procedures set out in sub-paragraph 14(d): Familial hypercholesterolaemia inadequately responsive to diet and a cholesterol lowering resin
Procainamide Hydrochloride B.P.	—
Procainamide Injection B.P.	—
Procaine Penicillin Injection B.P.	—
Procarbazine Hydrochloride	—
Prochlorperazine	—
Prochlorperazine Edisylate	—
Prochlorperazine Injection B.P.	—
Prochlorperazine Tablets B.P.	—
Procyclidine Tablets B.P.	—
Promethazine Hydrochloride Injection B.P.	—
Promethazine Theoclate Tablets B.P.	—
Propantheline Tablets B.P.	Chronic neurogenic incontinence of urine
Propranolol Injection B.P.	—
Propranolol Tablets B.P.	—
Propylthiouracil Tablets B.P.	—
Protamine Sulphate Injection B.P.	—
Pyrantel Embonate	—
Pyridostigmine Tablets B.P.	—
Pyridoxine Hydrochloride B.P.	—
Pyridoxine Hydrochloride Tablets B.P.	Anaemia proved to be responsive to pyridoxine Convulsions responsive to pyridoxine Homocystinuria Primary hyperoxaluria Radiation sickness Sideroblastic (refractory) anaemia Treatment and prophylaxis of peripheral neuritis caused or likely to be caused by isoniazid therapy

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Pyrimethamine Tablets B.P.	—
Quinethazone	—
Quinidine Bisulphate B.P.	—
Quinidine Sulphate B.P.	—
Quinidine Sulphate Tablets B.P.	—
Quinine Bisulphate Tablets B.P.	—
Quinine Sulphate Tablets B.P.	—
Ranitidine Hydrochloride	In respect of the tablet, 150 mg (base): In compliance with authority procedures set out in sub-paragraph 14(d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous 2 years Scleroderma oesophagus Severe ulcerating (erosive) oesophagitis, proven by endoscopy and unresponsive to other measures Zollinger-Ellison syndrome
Red-back Spider Antivenom	In respect of the tablet, 300 mg (base): In compliance with authority procedures set out in sub-paragraph 14(d): Duodenal ulcer (including pyloric and stomal ulcers), proven by current or prior x-ray, endoscopy or surgery Gastric ulcer, proven by x-ray, endoscopy or surgery within the previous 2 years Zollinger-Ellison syndrome
Rifampicin B.P.	— Prophylactic treatment of contacts of patients with Haemophilus influenzae type B Prophylaxis of meningococcal disease in close contacts and carriers In compliance with authority procedures set out in sub-paragraph 14(d): Leprosy in adults
Rolitettracycline	—
Salbutamol B.P.	—
Salbutamol Sulphate B.P.	—
Salbutamol Tablets B.P.	—
Salcatonin Injection B.P.	In compliance with authority procedures set out in sub-paragraph 14(d): Proven active Paget's disease of bone causing pain or disability Treatment initiated in a hospital (in-patient or out-patient) of hypercalcaemia For the continuation of treatment of patients already established on calcitonin under arrangements provided for by section 100 of the Act
Semisodium Valproate	—
Silver Sulphadiazine with Chlorhexidine Gluconate	In respect of the cream, 10 mg-2 mg per g, 50 g and the cream, 10 mg-2 mg per g, 100 g: For the prevention and treatment of infection in partial or full skin thickness loss due to burns or epidermolysis bullosa Stasis ulcers In respect of the cream, 10 mg-2 mg per g, 500 g: In compliance with authority procedures set out in sub-paragraph 14(d): Treatment, in a hospital, of burns
Sodium Acid Citrate B.P.	—
Sodium Acid Phosphate B.P.	In compliance with authority procedures set out in sub-paragraph 14(d): Familial hypophosphataemia Hypercalcaemia Hypophosphataemic rickets Vitamin D-resistant rickets

Column 1	Column 2
Pharmaceutical benefit	Circumstances (if any) specified for the purposes of section 88A of the Act
Sodium Aurothiomalate Injection B.P.	—
Sodium Bicarbonate Intravenous Infusion B.P.	—
Sodium Chloride and Glucose Intravenous Infusion B.P.	—
Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections	—
Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.	—
Sodium Chloride Intravenous Infusion B.P.	—
Sodium Citro-Tartrate	—
Sodium Cromoglycate B.P.	In respect of the eye drops: In compliance with authority procedures set out in subparagraph 14(d): Vernal kerato-conjunctivitis In respect of the nebuliser solution: Use in a power-operated nebuliser for prophylaxis of asthma in persons who are unable to use the capsule or metered aerosol spray for oral inhalation In respect of the metered aerosol spray: —
Sodium Cromoglycate Insufflation B.P.	—
Sodium Fusidate B.P.	In compliance with authority procedures set out in subparagraph 14(d): For use in combination with another antibiotic in the treatment of serious staphylococcal infections confirmed by bacteriological evidence
Sodium Lactate Compound Intravenous Infusion B.P.	—
Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.	—
Sodium Nitroprusside B.P.	—
Sodium Valproate B.P.	—
Sodium Valproate Elixir B.P.	—
Sotalol Hydrochloride	In compliance with authority procedures set out in subparagraph 14(d): For the continuing treatment of severe refractory cardiac arrhythmias where treatment with sotalol hydrochloride was initiated in a hospital (in-patient or out-patient)
Spectinomycin Hydrochloride B.P.	—
Spironolactone Tablets B.P.	Female hirsutism Hyperaldosteronism
Staphylococcus Toxoid B.P. 1968	—
Sterculia B.P.	Ileostomy or colostomy conditions
Sterculia B.P. with Frangula Bark B.P.	Any disease or condition in a paraplegic or quadriplegic patient For use by patients who are receiving long-term extensive nursing care in hospitals or nursing homes For use by patients for whose care a Commonwealth Domiciliary Nursing Care Benefit is approved
Streptokinase B.P.	—
Sucralfate	—
Sulindac Tablets B.P.	—
Sulphacetamide Sodium B.P.	—
Sulphadimidine Tablets B.P.	—
Sulphafurazole B.P.	—
Sulphamethizole Tablets B.P.	—
Sulphasalazine	Crohn's disease Rheumatoid arthritis Ulcerative colitis
Sulphinpyrazone Tablets B.P.	Glomerulonephritis Gout Renal transplantation

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Sulthiame Tablets B.P.	—
"Super Banish"	Ileostomy or colostomy conditions
Surgical Cement	Any disease or condition in a paraplegic or quadriplegic patient For use with surgical appliances Ileostomy or colostomy conditions
Surgical Cement Solvent	Any disease or condition in a paraplegic or quadriplegic patient For use with surgical appliances Ileostomy or colostomy conditions
Tamoxifen Citrate Tablets B.P.	Breast cancer in post-menopausal women with positive hormone receptor levels and local lymph node involvement with or without other evidence of metastases Recurrent or metastatic breast cancer
Temazepam	—
Terbutaline Sulphate B.P.	—
Terbutaline Sulphate Tablets B.P.	—
Testosterone Enanthate B.P.	Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P.	Gigantism Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.	Gigantism Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Testosterone Propionate Injection B.P.	Hypogonadism Klinefelter's syndrome (seminiferous tubule dysgenesis)
Tetanus Vaccine, Adsorbed B.P.	—
Terabenazine	Chorea not adequately controlled by other drug therapy
Tetracosactrin Zinc Injection B.P.	In compliance with authority procedures set out in subparagraph 14(d): Hypsarrhythmia Multiple sclerosis, acute exacerbation Treatment of children who need long-term corticosteroid therapy but who are in danger of growth suppression as a result Treatment of patients who are being withdrawn from long-term corticosteroid therapy Ulcerative colitis, proven, not responding to parenteral corticosteroids
Tetracycline B.P. with a buffering agent	—
Tetracycline B.P. with a buffering agent and Nystatin B.P.	—
Tetracycline Capsules B.P.	—
Tetracycline Hydrochloride B.P.	—
Tetracycline Hydrochloride B.P. with Nystatin B.P.	—
Theophylline B.P.	—
Thiabendazole Tablets B.P.	—
Thiamine Hydrochloride Injection B.P.	—
Thiamine Hydrochloride Tablets B.P.	—
Thiethylperazine Malate	—
Thiethylperazine Maleate	—
Thioguanine Tablets B.P.	—
Thiopropazate Hydrochloride Tablets B.P.	Chorea
Thioridazine Hydrochloride B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years

Column 1	Column 2
Pharmaceutical benefit	Circumstances (if any) specified for the purposes of section 88A of the Act
Thioridazine Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Thiotepa B.P.	—
Thyroxine Tablets B.P.	—
Ticarcillin Sodium	In compliance with authority procedures set out in subparagraph 14(d): Infections where positive bacteriological evidence confirms that ticarcillin sodium is an appropriate therapeutic agent Septicaemia, suspected or proven
Timolol Maleate Eye Drops B.P.	—
Timolol Maleate Tablets B.P.	—
Tinidazole	—
Tobramycin B.P.	Invasive ocular infection Perioperative use Suspected pseudomonal eye infection
Tobramycin Injection B.P.	In compliance with authority procedures set out in subparagraph 14(d): Infections where positive bacteriological evidence confirms that tobramycin is an appropriate antibiotic Septicaemia, suspected or proven
Tolazamide Tablets B.P.	—
Tolbutamide Tablets B.P.	—
Tranexamic Acid Tablets B.P.	Hereditary angio-oedema
Tranlycypromine Tablets B.P.	Depressive illness resistant to treatment with either tricyclic antidepressants or electroconvulsive therapy Phobic states
Triamcinolone Acetonide B.P.	Alopecia areata For local intra-articular or peri-articular infiltration Granulomata, dermal Keloid Lichen planus hypertrophic Lichen simplex chronicus Lupus erythematosus, chronic discoid Necrobiosis lipoidica Psoriasis
Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.	—
Triamcinolone Acetonide Cream B.P.	—
Triamcinolone Acetonide Ointment B.P.	—
Triamterene B.P.	—
Trifluoperazine Hydrochloride B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Trifluoperazine Hydrochloride Tablets B.P.	Chorea Hyperactive states of organic or toxic delirium Major psychoses including: Major organic psychoses including arteriopathic dementia Manic depressive disorder—manic phase Paranoid states Schizophrenia Senile dementia Malignant neoplasia (late stage) Radiation sickness Severe conduct disorders in patients under the age of 16 years
Triglycerides Oil, Medium Chain	In compliance with authority procedures set out in subparagraph 14(d): Abetalipoproteinaemia Chyloascites Chylothorax Intestinal lymphangiectasia Intractable childhood epilepsy requiring a ketogenic diet Short-term nutritional support in severe steatorrhoea Steatorrhoea due to distal small bowel resection
Trimethoprim Tablets B.P.	—
Trimipramine	—
Trimipramine Tablets B.P.	—
Trioxysalen	Vitiligo
Urea Cream B.P.	—
Vancomycin Hydrochloride B.P.	In respect of the capsules: In compliance with authority procedures set out in subparagraph 14(d): Antibiotic associated colitis In respect of the injection: In compliance with authority procedures set out in subparagraph 14(d): Any disease or condition in a patient receiving treatment in a hospital Endophthalmitis
Vasopressin Tannate	—
Verapamil Hydrochloride B.P.	—
Verapamil Hydrochloride Injection B.P.	—
Verapamil Hydrochloride Tablets B.P.	—
Vidarabine	Eye infections caused by herpes simplex virus
Vinblastine Sulphate B.P.	—
Vincristine Sulphate B.P.	—
Warfarin Tablets B.P.	—
Water for Injections B.P.	—
Wool Alcohols Ointment B.P.	—
Zinc Oxide B.P.	—
Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.	—

SCHEDULE 2

Allowable compounds of ready-prepared pharmaceutical benefits

Column 1 Pharmaceutical benefit	Column 2 Allowable compounds
Aluminium Hydroxide, Dried B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P.
Aluminium Hydroxide Mixture B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P. and Magnesium Trisilicate B.P. Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine
Amiloride Hydrochloride B.P.	Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P.
Amoxycillin Trihydrate B.P.	Amoxycillin Trihydrate B.P. with Potassium Clavulanate Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P. Amoxycillin Trihydrate B.P. with Purified Water B.P.
Ampicillin Trihydrate B.P.	Ampicillin Trihydrate B.P. with Purified Water B.P.
Antazoline Phosphate	Antazoline Phosphate with Naphazoline Hydrochloride
Antazoline Sulphate	Antazoline Sulphate with Naphazoline Nitrate B.P.
Aspirin B.P.	Codeine Phosphate B.P. with Aspirin B.P.
Atropine Sulphate B.P.	Difenoxin Hydrochloride with Atropine Sulphate B.P. Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P. Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P. Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Bacitracin B.P. 1968	Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P.
Bacitracin Zinc B.P.	Neomycin Undecenoate with Bacitracin Zinc B.P. Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.
Benserazide	Levodopa B.P. with Benserazide
Benzathine Penicillin B.P.	Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections
Benzylpenicillin Potassium B.P.	Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections
Betamethasone Acetate	Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.
Betamethasone Sodium Phosphate B.P.	Betamethasone Acetate with Betamethasone Sodium Phosphate B.P.
Bisacodyl B.P.	Docusate Sodium B.P. with Bisacodyl B.P.
Butyl Monoester Polymer	Butyl Monoester Polymer with Ethanol B.P. Butyl Monoester Polymer with Isopropyl Alcohol B.P.
Caffeine B.P.	Ergotamine Tartrate B.P. with Caffeine B.P.
Calcium Carbonate B.P.	Calcium Carbonate B.P. with Calcium Lactate-Gluconate
Calcium Chloride B.P.	Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections
Calcium Lactate-Gluconate	Calcium Carbonate B.P. with Calcium Lactate-Gluconate
Carmellose Sodium B.P.	Carmellose Sodium B.P. with Pectin and Gelatin B.P.
Cephalexin B.P.	Cephalexin B.P. with Purified Water B.P.
Chloramphenicol B.P.	Chloramphenicol B.P. with Polymyxin B Sulphate B.P.
Chlorhexidine Gluconate	Silver Sulphadiazine with Chlorhexidine Gluconate
Citric Acid B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.
Clindamycin Palmitate Hydrochloride	Clindamycin Palmitate Hydrochloride with Purified Water B.P.
Codeine Phosphate B.P.	Codeine Phosphate B.P. with Aspirin B.P. Codeine Phosphate B.P. with Paracetamol B.P.
Colistin Sulphate B.P.	Colistin Sulphate B.P. with Neomycin Sulphate B.P.
Dexamethasone B.P.	Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin

<i>Column 1</i> <i>Pharmaceutical benefit</i>	<i>Column 2</i> <i>Allowable compounds</i>
Dexamethasone Sodium Metasulphobenzoate	Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin
Dextran 40 Intravenous Infusion B.P.	Dextran 40 Intravenous Infusion B.P. with Glucose B.P. Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P.
Dextran 70	Hypromellose 4500 B.P. with Dextran 70
Dextran 70 Intravenous Infusion B.P.	Dextran 70 Intravenous Infusion B.P. with Glucose B.P. Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P.
Difenoxin Hydrochloride	Difenoxin Hydrochloride with Atropine Sulphate B.P.
Diphenoxylate Hydrochloride B.P.	Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P.
Docusate Sodium B.P.	Docusate Sodium B.P. with Bisacodyl B.P.
Ergotamine Tartrate B.P.	Ergotamine Tartrate B.P. with Caffeine B.P.
Erythromycin Ethyl Succinate B.P.	Erythromycin Ethyl Succinate B.P. with Purified Water B.P.
Ethanol B.P.	Butyl Monoester Polymer with Ethanol B.P.
Ethinylestradiol B.P.	Ethinodiol Diacetate B.P. with Ethinylestradiol B.P. Levonorgestrel B.P. with Ethinylestradiol B.P. Norethisterone B.P. with Ethinylestradiol B.P.
Ethinodiol Diacetate B.P.	Ethinodiol Diacetate B.P. with Ethinylestradiol B.P.
Ferrous Sulphate, Dried B.P.	Ferrous Sulphate, Dried B.P. with Folic Acid B.P.
Flucloxacillin Magnesium B.P.	Flucloxacillin Magnesium B.P. with Purified Water B.P.
Flumethasone Pivalate	Flumethasone Pivalate with Clioquinol B.P.
Folic Acid B.P.	Ferrous Sulphate, Dried B.P. with Folic Acid B.P.
Framycetin Sulphate B.P.	Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin
Frangula Bark B.P.	Sterculia B.P. with Frangula Bark B.P.
Gelatin B.P.	Carmellose Sodium B.P. with Pectin and Gelatin B.P.
Glucose B.P.	Dextran 40 Intravenous Infusion B.P. with Glucose B.P. Dextran 70 Intravenous Infusion B.P. with Glucose B.P.
Glucose, Anhydrous B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P. Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.
Gramicidin	Dexamethasone B.P. with Framycetin Sulphate B.P. and Gramicidin Dexamethasone Sodium Metasulphobenzoate with Framycetin Sulphate B.P. and Gramicidin Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Hydrochlorothiazide B.P.	Hydrochlorothiazide B.P. with Amiloride Hydrochloride B.P. Hydrochlorothiazide B.P. with Triamterene B.P.
Hydrocortisone B.P.	Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.
Hydrocortisone Acetate B.P.	Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.
Hyoscine Hydrobromide B.P.	Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P. Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Hyoscyamine Hydrobromide	Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P. Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Hyoscyamine Sulphate B.P.	Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyoscine Hydrobromide B.P.
Hypromellose 4500 B.P.	Hypromellose 4500 B.P. with Dextran 70
Insulin Injection, Isophane B.P.	Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.
Insulin Injection, Neutral B.P.	Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Allowable compounds</i>
Insulin Isophane, Human (Synthetic)	Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)
Insulin Neutral, Human (Synthetic)	Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)
Isopropyl Alcohol B.P.	Butyl Monoester Polymer with Isopropyl Alcohol B.P. Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.
Isopropyl Monoester Polymer	Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.
Kaolin, Light B.P. or Light Kaolin (Natural) B.P.	Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P. Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin
Lauramine Oxide	Lauramine Oxide with Octoxinol
Levodopa B.P.	Levodopa B.P. with Benserazide
Levonorgestrel B.P.	Levonorgestrel B.P. with Ethinylloestradiol B.P.
Magnesium Chloride B.P.	Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Magnesium Hydroxide B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine
Magnesium Trisilicate B.P.	Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P.
Mestranol B.P.	Norethisterone B.P. with Mestranol B.P.
Morphine Sulphate B.P.	Morphine Sulphate B.P. with Tacrine Hydrochloride B.P.
Naphazoline Hydrochloride	Antazoline Phosphate with Naphazoline Hydrochloride
Naphazoline Nitrate B.P.	Antazoline Sulphate with Naphazoline Nitrate B.P.
Neomycin Sulphate B.P.	Colistin Sulphate B.P. with Neomycin Sulphate B.P. Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P. Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Neomycin Undecenoate	Neomycin Undecenoate with Bacitracin Zinc B.P.
Norethisterone B.P.	Norethisterone B.P. with Ethinylloestradiol B.P. Norethisterone B.P. with Mestranol B.P.
Nystatin B.P.	Tetracycline B.P. with a buffering agent and Nystatin B.P. Tetracycline Hydrochloride B.P. with Nystatin B.P. Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Octoxinol	Lauramine Oxide with Octoxinol
Oxethazaine	Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine
Papaveretum B.P.C. 1973	Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.
Paracetamol B.P.	Codeine Phosphate B.P. with Paracetamol B.P.
Paraffin, Liquid B.P.	Paraffin, Soft White B.P. with Liquid Paraffin B.P.
Paraffin, Soft White B.P.	Paraffin, Soft White B.P. with Liquid Paraffin B.P.
Pectin	Carmellose Sodium B.P. with Pectin and Gelatin B.P. Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin
Phenethicillin Potassium B.P.	Phenethicillin Potassium B.P. with Purified Water B.P.
Phenylephrine Hydrochloride B.P.	Prednisolone Acetate with Phenylephrine Hydrochloride B.P. Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.

<i>Column 1</i> <i>Pharmaceutical benefit</i>	<i>Column 2</i> <i>Allowable compounds</i>
Polymyxin B Sulphate B.P.	Chloramphenicol B.P. with Polymyxin B Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P. Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.
Polyvinyl Alcohol	Polyvinyl Alcohol with Povidone B.P.
Potassium Chloride B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P. Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Potassium Clavulanate	Amoxycillin Trihydrate B.P. with Potassium Clavulanate Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P.
Povidone B.P.	Polyvinyl Alcohol with Povidone B.P.
Prednisolone Acetate	Prednisolone Acetate with Phenylephrine Hydrochloride B.P.
Procaine Penicillin B.P.	Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections
Silver Sulphadiazine	Silver Sulphadiazine with Chlorhexidine Gluconate
Sodium Acetate B.P.	Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Sodium Chloride B.P.	Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P. Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P. Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P. Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Sodium Citrate B.P.	Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.
Sodium Gluconate	Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.
Sodium Lactate Compound Intravenous Infusion B.P.	Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.
Sterculia B.P.	Sterculia B.P. with Frangula Bark B.P.
Tacrine Hydrochloride	Morphine Sulphate B.P. with Tacrine Hydrochloride
Testosterone Decanoate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Testosterone Isocaproate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P. Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Testosterone Phenylpropionate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P. Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.
Testosterone Propionate B.P.	Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P. Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.

<i>Column 1</i> <i>Pharmaceutical benefit</i>	<i>Column 2</i> <i>Allowable compounds</i>
Tetracycline B.P.	Tetracycline B.P. with a buffering agent Tetracycline B.P. with a buffering agent and Nystatin B.P.
Tetracycline Hydrochloride B.P.	Tetracycline Hydrochloride B.P. with Nystatin B.P.
Triamcinolone Acetonide B.P.	Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.
Triamterene B.P.	Hydrochlorothiazide B.P. with Triamterene B.P.
Water, Purified B.P.	Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Purified Water B.P. Amoxycillin Trihydrate B.P. with Purified Water B.P. Ampicillin Trihydrate B.P. with Purified Water B.P. Cephalexin B.P. with Purified Water B.P. Clindamycin Palmitate Hydrochloride with Purified Water B.P. Erythromycin Ethyl Succinate B.P. with Purified Water B.P. Flucloxacillin Magnesium B.P. with Purified Water B.P. Phenethicillin Potassium B.P. with Purified Water B.P.
Zinc Sulphate B.P.	Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.

SCHEDULE 3**Drugs or medicinal preparations which may be used as ingredients of extemporaneously-prepared pharmaceutical benefits**

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Acacia B.P.	—
Acetic Acid (33 per cent) B.P.	—
Acriflavine B.P.C. 1963	—
Adrenaline B.P.	May only be prescribed in eye drops
Alum B.P.	—
Aluminium Acetate Solution B.P.	—
Aminophylline B.P.	—
Ammonia Spirit, Aromatic B.P.	—
Ammoniated Mercury B.P. 1973	—
Ascorbic Acid B.P.	Use as ingredient of Ferrous Sulphate Mixture A.P.F. and Ferrous Sulphate Mixture C.F. A.P.F. 13
Aspirin B.P.	—
Atropine Sulphate B.P.	—
Beeswax, White B.P.	—
Belladonna Tincture B.P.	—
Bentonite B.P.	—
Benzocaine B.P.	—
Benzoic Acid B.P.	—
Benzoin Tincture, Compound B.P.	—
Cade Oil B.P.C. 1973	—
Calamine B.P.	—
Calcium Hydroxide B.P.	—
Camphor Spirit, Compound A.P.F.	—
Cetomacrogol Emulsifying Wax B.P.	—
Cetostearyl Alcohol B.P.	—
Cetrimide B.P.	—
Chlorbutol B.P.	—
Chlorinated Lime B.P.	—
Chlorocresol B.P.	—
Citric Acid Monohydrate B.P.	—
Clioquinol B.P.	—
Coal Tar B.P.	—
Coal Tar, Prepared B.P. 1973	—
Coal Tar Solution B.P.	—
Cocaine Hydrochloride B.P.	—
Coconut Oil B.P.	—
Codeine Phosphate B.P.	—
Collodion, Flexible B.P.	—
Crystal Violet B.P.	—
Dithranol B.P.	—
Emulsifying Wax B.P.	—
Ephedrine Hydrochloride B.P.	May only be prescribed in nasal instillations
Ferrous Sulphate B.P.	—
Ferrous Sulphate, Dried B.P.	—
Formaldehyde Solution B.P.	—
Gentian Infusion, Compound, Concentrated B.P.	—
Glycerol B.P.	—
Hydrochloric Acid B.P.	—
Hyoscyamus Liquid Extract B.P.C. 1973	—
Ichthammol B.P.	—
Iodine B.P.	—
Ipecacuanha Tincture B.P.	—
Kaolin, Light B.P.	—
Kaolin, Light (Natural) B.P.	—

Column 1	Column 2
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Lactic Acid B.P.	—
Lactose B.P.	—
Lavender Oil, Spike B.P.C. 1968	—
Lemon Spirit B.P.	—
Lignocaine Hydrochloride B.P.	—
Liquorice Liquid Extract B.P.	—
Lobelia Tincture, Ethereal B.P.C. 1973	—
Magnesium Carbonate, Light B.P.	—
Magnesium Sulphate B.P.	May only be prescribed for other than oral use
Magnesium Trisilicate B.P.	—
Menthol B.P.	—
Methyl Salicylate B.P.	—
Methyl Salicylate Ointment, Compound A.P.F. 1934	—
Morphine Hydrochloride B.P.	—
Oily Cream A.P.F.	—
Oleic Acid B.P.	—
Opium Tincture B.P.	—
Orange Tincture B.P.	—
Paraffin, Hard B.P.	—
Paraffin, Light Liquid B.P.	—
Paraffin, Liquid B.P.	May only be prescribed for other than oral use
Paraffin, Soft White B.P.	—
Paraffin, Soft Yellow B.P.	—
Phenobarbitone B.P.	May only be prescribed for the treatment of epilepsy
Phenobarbitone Sodium B.P.	May only be prescribed for the treatment of epilepsy
Phenol B.P.	May not be prescribed in ear drops
Phenoxyethanol B.P.	—
Pilocarpine Hydrochloride B.P.	—
Pilocarpine Nitrate B.P.	—
Podophyllum Resin B.P.	—
Potassium Citrate B.P.	—
Potassium Iodide B.P.	—
Potassium Permanganate B.P.	—
Propylene Glycol B.P.	—
Pumilio Pine Oil B.P.	—
Raspberry Syrup B.P.	—
Red Syrup A.P.F.	—
Resorcinol B.P.	—
Salicylic Acid B.P.	—
Siberian Fir Oil B.P.C. 1949	—
Silver Nitrate B.P.	—
Soap, Soft B.P.	—
Sodium Acid Phosphate B.P.	—
Sodium Bicarbonate B.P.	—
Sodium Chloride B.P.	—
Sodium Citrate B.P.	—
Sodium Phosphate B.P.	—
Starch B.P.	—
Stramonium Tincture B.P.	—
Sulphur, Precipitated B.P.	—
Sulphurated Potash B.P.C. 1973	—
Syrup B.P.	—
Talc, Purified B.P., sterilised	—
Testosterone B.P.	May only be prescribed in creams
Theophylline B.P.	—
Thymol B.P.	—
Thymol Mouth Wash, Compound A.P.F.	—

<i>Column 1</i>	<i>Column 2</i>
<i>Pharmaceutical benefit</i>	<i>Circumstances (if any) specified for the purposes of section 88A of the Act</i>
Titanium Dioxide B.P.	---
Tolu Syrup B.P.	—
Tragacanth B.P.	—
Tragacanth Powder, Compound B.P.	—
Trichloroacetic Acid B.P.	—
Triethanolamine B.P.	—
Turpentine Liniment B.P.	—
Water for Injections B.P.	May only be prescribed in eye drops and eye lotions
Water, Purified B.P.	—
Wool Alcohols B.P.	—
Wool Fat B.P.	—
Wool Fat, Hydrous B.P.	—
Zinc Oxide B.P.	—
Zinc Sulphate B.P.	—

SCHEDULE 4

Additives

Acetone B.P.
Anise Water, Concentrated B.P.
Arachis Oil B.P.
Borax B.P.
Boric Acid B.P.
Castor Oil B.P.
Chlorhexidine Acetate B.P.
Chlorhexidine Gluconate Solution B.P.
Chloroform B.P.
Ethanol (96 per cent) B.P.
Ethanol, Dilute B.P.
Ether, Solvent B.P.
Eucalyptus Oil B.P.
Glucose for Oral Use B.P.
Honey, Purified B.P.
Industrial Methylated Spirit B.P.
Olive Oil B.P. 1973
Peppermint Oil B.P.
Peppermint Water, Concentrated A.P.F.
Pholcodine Citrate Syrup B.P.C. 1959
Sodium Thiosulphate B.P.
Turpentine Oil B.P.

SCHEDULE 5

Additional pharmaceutical benefits made available under arrangements provided for by section 100 of the Act

Anti-Haemophilic Factor of Animal Origin

Carmellose Sodium B.P.

Methadone Hydrochloride B.P.

Somatrem

Dated this 16th day of November 1988.

JOHN DEEBLE
Acting First Assistant Secretary
Health Benefits Division
Delegate of the Minister of State for Community Services and Health

N.N.—8852514

National Health Act 1953

PHARMACEUTICAL BENEFITS

**DETERMINATION UNDER SECTIONS 85, 85A
AND 88**

I, JOHN STEWART DEEBLE, Acting First Assistant Secretary, Health Benefits Division, Department of Community Services and Health and Delegate of the Minister of State for Community Services and Health, pursuant to sections 85, 85A and 88 of the *National Health Act 1953*, hereby make the following Determination:

1. This Determination shall come into operation on 1 December 1988.

2. The Determination under sections 85, 85A and 88 of the Act made with effect from 1 August 1988, as amended with effect from 1 October 1988, is hereby revoked.

3. In the Schedules to this Determination:

'amp.' means ampoule;

'fl oz' means fluid ounce of 480 minims;

'g' means gram;

'I.M.' means intramuscular;

'I.U.' means international unit;

'I.V.' means intravenous;

'kg' means kilogram;

'L' means litre;

'lb' means pound of 16 ounces;

'm' means metre;

'mg' means milligram;

'mL' means millilitre;

'mm' means millimetre;

'mmol' means millimole;

'Sch. 2' means the Second Schedule to this Determination.

4. Where the strength, type of unit, size of unit or other particulars of form are specified in the column headed 'Form' in the First Schedule to this Determination in relation to a drug or medicinal preparation referred to in sub-section 85 (2) of the *National Health Act 1953* the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of that Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a pharmaceutical benefit when prescribed by a medical practitioner.

5. Where the strength, type of unit, size of unit or other particulars of form are specified in the column headed 'Form' in the Third Schedule to this Determination in relation to a drug or medicinal preparation referred to in sub-section 85 (2) of the *National Health Act 1953* the name of which is specified in that Schedule, those particulars refer to the form or forms of the drug or medicinal preparation that is or are allowable for the purposes of Part VII of that Act to the effect that the drug or medicinal preparation in that form or in each of those forms is a pharmaceutical benefit referred to in sub-section 88 (1A) of that Act for the supply of which a participating dental practitioner is authorized to write a prescription.

6. The purposes set out in the column headed 'Purposes' in Part 2 of the First Schedule to this Determination are the only purposes for which a medical practitioner may prescribe the maximum quantities and number of repeats specified in that Part in relation to those pharmaceutical benefits specified in that same Part.

7. The manner, if any, in which a pharmaceutical benefit specified in the First and Third Schedules to this Determination is to be administered in relation to the pharmaceutical benefit is set out in those Schedules in the column headed 'Manner of administration'.

8. The maximum quantity or number of units of a pharmaceutical benefit that may, in one prescription, be directed to be supplied on any one occasion is:

(a) where the name of the pharmaceutical benefit is specified—

(i) in Part 1 of the First Schedule to this Determination—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or

(ii) in Part 2 of the First Schedule to this Determination and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes'—the quantity or number, if any, in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or

(iii) if reference is made to the Second Schedule to this Determination in the column headed 'Maximum quantity' in the First Schedule to this Determination, the quantity or number, if any, specified in the column headed 'Maximum quantity' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit; or

(iv) in the Third Schedule to this Determination—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Maximum quantity' in relation to the pharmaceutical benefit; or

(b) in any other case—the quantity or number, if any, specified in the column headed 'Maximum quantity' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit.

9. The maximum number of occasions, if any, on which the supply of a pharmaceutical benefit may, in one prescription, be directed by a medical practitioner to be repeated is:

(a) where the name of the pharmaceutical benefit is specified—

(i) in Part 1 of the First Schedule to this Determination—the quantity or number, if any, specified in that Part of the Schedule in the column headed 'Number of repeats' in relation to the pharmaceutical benefit; or

(ii) in Part 2 of the First Schedule to this Determination and the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes'—the quantity or number, if any, in that Part of the Schedule in the column headed 'Number of repeats' in relation to the pharmaceutical benefit; or

(iii) if reference is made to the Second Schedule to this Determination in the column headed 'Number of repeats' in the First Schedule to this Determination, the quantity or number, if any, specified in the column headed 'Number of repeats' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit; or

(b) in any other case—the number, if any, specified in the column headed 'Number of repeats' in the Second Schedule to this Determination in relation to the form of the pharmaceutical benefit.

10. The following purposes are specified in relation to each pharmaceutical benefit the name of which is specified in Part 2 of the First Schedule to this Determination:

(a) Where a class of persons is specified in the column headed 'Purposes'—that the pharmaceutical benefit is to be supplied for the treatment of a person included in that class of persons;

(b) Where a disease or condition is specified in the column headed 'Purposes'—

(i) if sub-sub-paragraph (ii) does not apply—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in relation to any person; or

- (ii) if the disease or condition is specified in relation to a specified class of persons—that the pharmaceutical benefit is to be supplied for the treatment of that disease or condition in a person included in that class of persons;
 - (c) Where a purpose is specified in the column headed 'Purposes'—that the pharmaceutical benefit is to be supplied for that purpose;
 - (d) Where it is specified in the column headed 'Purposes' that compliance with authority procedures set out in sub-paragraph 10 (d) is required—
 - (i) that an application for the written authority of the Secretary in relation to the supply of the pharmaceutical benefit has been made by a medical practitioner, on a form approved by the Secretary, and has been forwarded to the Secretary by that medical practitioner or on behalf of that medical practitioner by a person other than an approved pharmacist, and the Secretary has approved the application; or
 - (ii) where the medical practitioner believes that the supply of the pharmaceutical benefit is required urgently—that the medical practitioner has prepared an Authority Prescription on a form approved by the Secretary and has:
 - (A) issued the original and duplicate of the form to the person for whom the pharmaceutical benefit is to be supplied;
 - (B) on the departmental copy of the form declared that the pharmaceutical benefit is prescribed in accordance with the provisions of the column headed 'Purposes' and signed that copy in the medical practitioner's handwriting; and
 - (C) forwarded the departmental copy to reach the Secretary within seven days from the date on which the original and duplicate were issued to the person for whom the pharmaceutical benefit is to be supplied.
11. Where a medical practitioner makes an application under sub-paragraph 10 (d) and the Secretary approves the application, the Secretary shall record the approval on a numbered authority and—
- (a) where, in the approval, the Secretary requires the medical practitioner to vary the prescription for the supply of the pharmaceutical benefit—return the approval to the medical practitioner; or
 - (b) in any other case—return the approval to the medical practitioner or, if the medical practitioner so requests, forward the approval to the person to whom the pharmaceutical benefit is to be supplied.
12. The name of the manufacturer or the names of manufacturers denoted in accordance with the following table by letters appearing in the column headed 'Brand' in the First and Third Schedules to this Determination in relation to a drug or medicinal preparation the name of which is specified in those Schedules is the brand or brands under which the drug or medicinal preparation may be supplied under Part VII of the *National Health Act 1953* as a pharmaceutical benefit:

Letters Manufacturer's Name

AB Abbott Australasia Pty Ltd
AD Amrad Pharmaceuticals Pty Ltd
AF Alphapharm Pty Ltd
AG Allergan Pharmaceuticals Pty Ltd
AM Ames Company, Division of Miles Laboratories Australia Pty Ltd
AP Astra Pharmaceuticals Pty Ltd
AQ Alcon Laboratories (Australia) Pty Ltd
AY Ayerst Laboratories Pty Ltd
BC Bristol Laboratories Pty Ltd
BF Barnes-Hind Pty Limited
BH Biopharm Pty Ltd
BL David Bull Laboratories Proprietary Limited
BN Bayer Pharmaceutical Company
BO Boehringer Mannheim, GmbH, Germany
BR Beecham Research Laboratories
BT The Boots Company (Australia) Pty Ltd
BW Wellcome Australia Limited
BX Baxter Healthcare Pty Ltd
BY Boehringer Ingelheim Pty Ltd
BZ Boucher & Muir Pty Ltd
CG Ciba-Geigy Australia Limited
CL Cilag Pty Limited
CN CSL-Novo Pty Limited
CS Commonwealth Serum Laboratories
DH Drug Houses of Australia Pty Ltd
DL Dista Products (Australia) & Company
DY Denyer Bros Pty Ltd
EG Eagle Pharmaceuticals Pty Ltd
FA F. H. Faulding and Co. Ltd
FC Fisons Pty Ltd
FE Farmitalia Carlo Erba
FM Fawns and McAllan Pty Ltd
FR Charles E. Frosst, Division of Merck Sharp & Dohme (Australia) Pty Ltd
GL Glaxo
GP G.P. Laboratories
HA Hamilton Laboratories Pty Ltd
HO Hollister Incorporated, U.S.A.
HP Hoechst Australia Ltd
IC ICI Australia Operations Pty Ltd
IQ The Iloquin Company
JC Janssen-Cilag Pty Ltd
JP Janssen Pharmaceutica Pty Ltd
KM Kendall McGaw Laboratories, Division of Kendall Australia Pty Ltd
KN Knoll A. G., Germany
KY Key Pharmaceuticals Pty Ltd
LA L.A. Chemicals Pty Ltd
LE Lederle Laboratories Division, Cyanamid Australia Pty Ltd
LH Lipha Pharmaceuticals, London, U.K.

Letters Manufacturer's Name

LY Eli Lilly (Australia) and Company
MB May & Baker Pharmaceuticals
MG J. McGloin Pty Ltd
MJ Mead Johnson
MK Merck Sharp & Dohme (Australia) Pty Ltd
ML Merrell Dow Pharmaceuticals Australia Pty Ltd
NN Nelson Laboratories (Sales) Pty Ltd
NR Nordia, Denmark
NS Nicholas Kiwi Pty Ltd
NT Nestlé Australia Ltd
NW Norwich Eaton Pharmaceuticals Pty Limited
OL Owen Laboratories
OR Organon (Australia) Pty Ltd
PD Parke Davis Pty Ltd
PF Pfizer Pty Ltd
PS Pharmacia (Australia) Pty Ltd
PT CP Protea
QE Queensland Ethicals
RC Reckitts Pty Ltd
RG Rorer Australia Pty Ltd
RK Riker Laboratories Australia Pty Ltd
RL Roussel Pharmaceuticals Pty Ltd
RO Roche Products Pty Ltd
RS A. H. Robins Pty Limited
RT Roche Tompsitt & Co. Ltd
SA Sayco Pty Ltd
SB Scientific Hospital Supplies (Australia) Pty Ltd
SC Schering Pty Ltd, Australian subsidiary of Schering A. G., Berlin
SD Syntex Pharmaceuticals Ltd
SE Servier Laboratories (Aust.) Pty Ltd
SH Essex Laboratories Pty Ltd, Australian subsidiary of Schering Corporation, U.S.A.
SI Sigma Co. Ltd
SJ Sharpe Laboratories Pty Ltd
SK Smith Kline & French Laboratories (Aust.) Ltd
SN Smith & Nephew (Aust.) Pty Ltd
SQ E. R. Squibb & Sons Pty Ltd
SR Searle Laboratories
ST A. E. Stansen & Co. Pty Ltd
SU Sauter Laboratories (Aust.) Pty Ltd
SV Stafford-Miller Limited
SZ Sandoz Australia Pty Ltd
TO R. D. Toppin and Sons Pty Ltd
UP Upjohn Pty Ltd
US USV Pharmaceuticals, a Division of Rorer Australia Pty Ltd
UW United Works of Pharmaceutical & Dietetic Products, Hungary
WH H. W. Woods Pty Ltd
WL Winthrop Laboratories
WW Wm R. Warner & Co. Pty Ltd
WY Wyeth Pharmaceuticals Pty Ltd
ZY Zyma Pharmaceuticals

FIRST SCHEDULE—PART I

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Acetazolamide B.P.	Capsule, 500 mg (sustained release)	Oral	50	3	LE
Acetazolamide Sodium with any determined brand of Water for Injections or other solvent	Injection, 500 mg vial (with required solvent)	Injection	1	..	LE
Acetazolamide Tablets B.P.	250 mg	Oral	100	3	LE
Acetylcysteine B.P.	Solution, 200 mg per mL, 10 mL	Inhalation	5	3	AP
Acrylic Resin	Solution, 125 g aerosol spray pack	Application	1	..	AP
Acyclovir	Eye ointment, 30 mg per g, 4.5 g	Application to the eye	1	..	BW
	Tablet, 200 mg	Oral	50	..	BW
	Tablet, 400 mg	Oral	70	..	BW
Adrenaline B.P.	Eye drops, 5 mg per mL, 7.5 mL	Application to the eye	2	3	BF
	Eye drops, 10 mg per mL, 7.5 mL	Application to the eye	2	3	BF
	Extemporaneously prepared eye drops	Application to the eye	Sch. 2	Sch. 2	
Adrenaline Hydrochloride	Eye drops, 5 mg (base) per mL, 10 mL	Application to the eye	2	3	AG
	Eye drops, 10 mg (base) per mL, 10 mL	Application to the eye	2	3	AG, AQ
	Eye drops, 20 mg (base) per mL, 10 mL	Application to the eye	2	3	AG, AQ
Adrenaline Injection B.P.	Adrenaline, 1 in 1,000, 1 mL	Injection	5	1	AP, SI
"Albumaid XP"	Powder, 200 g	Oral	10	5	SB
"Albumaid XPXT"	Powder, 200 g	Oral	10	5	SB
"Alfaré"	Powder, 400 g	Oral	2	20	NT
Allopurinol B.P.	Capsule, 100 mg	Oral	200	2	FM
	Capsule, 300 mg	Oral	60	2	FM
Allopurinol Tablets B.P.	100 mg	Oral	200	2	BW, DH, PT
	300 mg	Oral	60	2	BW, DH, PT
Alprenolol Tablets B.P.	100 mg	Oral	100	5	AP, BR
Aluminium Hydroxide and Magnesium Carbonate Co-dried Gel	Tablet, 375 mg	Oral	200	5	GL, WY
Aluminium Hydroxide, Dried B.P.	Tablet, 300 mg	Oral	200	5	WY
Aluminium Hydroxide, Dried B.P. with Magnesium Hydroxide B.P.	Tablet, 200 mg-200 mg	Oral	200	5	PD, WW
	Tablet, dispersible, 230 mg-230 mg	Oral	200	5	BW
Aluminium Hydroxide, Dried B.P. with Magnesium Trisilicate B.P. and Magnesium Hydroxide B.P.	Suspension, 250 mg-120 mg-120 mg per 5 mL, 500 mL	Oral	2	5	FM
	Tablet, 250 mg-120 mg-120 mg	Oral	200	5	FM
Aluminium Hydroxide Mixture B.P.	Suspension, 320 mg per 5 mL, 500 mL	Oral	2	5	DH, WY
Aluminium Hydroxide Mixture B.P. with Light Kaolin B.P. or Light Kaolin (Natural) B.P.	Suspension, 137 mg-1 g per 5 mL, 500 mL	Oral	1	2	WY
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P.	Suspension, 200 mg-200 mg per 5 mL, 500 mL	Oral	2	5	DH, PD, SC, WW
	Suspension, 215 mg-80 mg per 5 mL, 500 mL	Oral	2	5	WY
	Suspension, 300 mg-100 mg per 5 mL, 500 mL	Oral	2	5	AY
Aluminium Hydroxide Mixture B.P. with Magnesium Hydroxide B.P. and Oxethazaine	Suspension, 306 mg-97.5 mg-10 mg per 5 mL, 500 mL	Oral	2	5	AY
Amantadine Hydrochloride	Capsule, 100 mg	Oral	100	5	BT, CG
Ambenonium Chloride	Tablet, 10 mg	Oral	100	2	WL
Amiloride Hydrochloride Tablets B.P.	5 mg	Oral	100	1	AF, MK

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Aminacrine Hydrochloride B.P. 1968	Eye drops, 3 mg in 15 mL	Application to the eye	1	2	SI
Aminogluthethimide	Tablet, 250 mg	Oral	100	5	CG
"Aminogran Food Supplement"	Powder, 500 g	Oral	1	5	GL
"Aminogran Mineral Mixture"	Powder, 250 g	Oral	1	5	GL
Aminophylline B.P.	Mixture, 105 mg per 5 mL, 500 mL	Oral	1	5	FC
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Aminophylline Injection B.P.	Ampoule, 250 mg in 10 mL	I.V. injection	5	..	BT, SI
Aminophylline Tablets B.P.	100 mg	Oral	100	5	HA
Amiodarone Hydrochloride	Tablet, 100 mg	Oral	30	5	RC
	Tablet, 200 mg	Oral	30	5	RC
Amitriptyline Tablets B.P.	10 mg	Oral	50	2	AF, MK, PT, RO
	25 mg	Oral	50	2	AF, MK, NS, PT, RO
	50 mg	Oral	50	2	AF
Ammonium Chloride B.P.	Tablet, 500 mg	Oral	100	3	FM
Amoxycillin Capsules B.P.	250 mg (base)	Oral	20	1	AF, BR, CS, PT, SI
	500 mg (base)	Oral	20	1	AF, BR, CS, PT, SI
Amoxycillin Sodium	Injection, 250 mg (base) vial with 3 mL solvent	Injection	5	1	PT
	Injection, 500 mg (base) vial with 3 mL solvent	Injection	5	1	PT
	Injection, 1 g (base) vial with 4 mL solvent	Injection	5	1	PT
Amoxycillin Trihydrate B.P.	Tablet, chewable, 250 mg (base)	Oral	20	1	BR, CS
	Tablet, dispersible, 3 g (base)	Oral	1	..	BR, CS
Amoxycillin Trihydrate B.P. with Potassium Clavulanate	Tablet, 250 mg (base)-125 mg (acid)	Oral	15	1	BR
	Tablet, 500 mg (base)-125 mg (acid)	Oral	15	1	BR
Amoxycillin Trihydrate B.P. with Potassium Clavulanate and Puri- fied Water B.P.	Powder for syrup, 125 mg (base)-31.25 mg (acid) per 5 mL, 75 mL	Oral	1	1	BR
	Powder for syrup, 250 mg (base)-62.5 mg (acid) per 5 mL, 75 mL	Oral	1	..	BR
Amoxycillin Trihydrate B.P. with Purified Water B.P.	Powder for paediatric drops, 100 mg (base) per mL, 20 mL	Oral	1	1	BR
	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	BR, CS, PT, SI
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS, PT, SI
Amphotericin B.P.	Cream, 30 mg per g, 15 g	Application	1	1	SQ
	Ointment, 30 mg per g, 15 g	Application	1	1	SQ
Amphotericin B.P. with any deter- mined brand of Water for Injec- tions or other solvent	Injection, 50 mg vial (with required solvent)	Injection	1	..	SQ
Amphotericin Lozenges B.P.	10 mg	Oral	20	1	SQ
Ampicillin Capsules B.P.	250 mg	Oral	24	1	BR, PT
	500 mg	Oral	24	..	BR, PT
Ampicillin Sodium B.P. with any deter- mined brand of Water for In- jections or other solvent	Injection, 250 mg (base) vial (with required solvent)	Injection	5	1	CS, PT
	Injection, 500 mg (base) vial (with required solvent)	Injection	5	1	BR, CS, PT
	Injection, 1 g (base) vial (with required solvent)	Injection	5	1	CS, PT

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Ampicillin Trihydrate B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	BR
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR
Amylobarbitone Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 500 mg amp. (with required solvent)	Injection	2	..	LY
Antazoline Phosphate with Naphazoline Hydrochloride	Eye drops, 5 mg-500 micrograms per mL, 15 mL	Application to the eye	1	2	AG
Antazoline Sulphate with Naphazoline Nitrate B.P.	Eye drops, 5 mg-250 micrograms per mL, 10 mL	Application to the eye	1	2	ZY
Aspirin B.P.	Tablet, 325 mg (buffered)	Oral	100	1	AP
	Tablet, 650 mg (enteric coated)	Oral	100	2	SK
	Tablet, 650 mg (sustained release)	Oral	100	2	BT
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Aspirin Tablets B.P.	300 mg	Oral	100	1	SI
Aspirin Tablets, Dispersible B.P.	300 mg	Oral	100	1	RC
Atenolol	Tablet, 50 mg	Oral	30	5	AF, IC
Atropine Eye Ointment B.P.	10 mg per g, 4 g	Application to the eye	1	..	PD
Atropine Sulphate B.P.	Eye drops, 5 mg per mL, 15 mL	Application to the eye	1	2	SI
	Eye drops, 10 mg per mL, 15 mL	Application to the eye	1	2	SI
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Atropine Sulphate Injection B.P.	Ampoule, 600 micrograms in 1 mL	Injection	5	1	AP, BT
	Ampoule, 1.2 mg in 1 mL	Injection	5	1	AP, BT
Atropine Sulphate Tablets B.P.	600 micrograms	Oral	100	2	FM
Auranofin	Tablet, 3 mg	Oral	60	5	SK
Aurothioglucose	Injection, 50 mg per mL, 10 mL	Injection	1	..	SH
Azathioprine Tablets B.P.	50 mg	Oral	100	2	AF, BW
Baclofen Tablets B.P.	10 mg	Oral	100	5	CG
	25 mg	Oral	100	5	CG
"Banish"	Liquid, 15 mL		1	..	DY
Beclomethasone Dipropionate B.P.	Capsule, 100 micrograms	Inhalation by mouth	100	5	GL
	Spray, metered aerosol, 50 micrograms per dose, 200 doses, 20.4 g	Inhalation by mouth	1	5	GL, SH
	Spray, metered aerosol, 100 micrograms per dose, 200 doses, 20.4 g	Inhalation by mouth	1	5	GL
	Spray, metered aerosol, 250 micrograms per dose, 200 doses, 20.4 g	Inhalation by mouth	1	5	GL
Bendrofluazide Tablets B.P.	2.5 mg	Oral	100	1	BT
	5 mg	Oral	100	1	BT, PT
Benzathine Penicillin B.P.	Injection, 1.8 g in 4 mL disposable syringe	Injection	1	..	WY
Benzathine Penicillin B.P. with Procaine Penicillin B.P., Benzylpenicillin Potassium B.P. and Water for Injections	Injection, 450 mg-300 mg-187 mg vial with 2 mL water for injections	Injection	1	..	WY
Benzhexol Tablets B.P.	2 mg	Oral	200	2	LE, PT
	5 mg	Oral	200	1	LE, PT
Benzoin Tincture, Compound B.P.	Spray, aerosol, 3.5 mL per 10 mL, 167 mL	Application	1	..	EG
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Benztropine Injection B.P.	Ampoule, 2 mg in 2 mL	Injection	5	..	MK
Benztropine Tablets B.P.	2 mg	Oral	60	2	MK

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Benzyl Benzoate Application B.P.	50 g in 200 mL	Application	1	2	MG
Benzyl Benzoate B.P.	Application, 50 g in 200 mL	Application	1	2	MB
Benzylpenicillin Potassium B.P. with any determined brand of Water for Injections or other solvent	Injection, 300 mg vial (with required solvent)	Injection	5	1	CS
	Injection, 600 mg vial (with required solvent)	Injection	5	1	CS
	Injection, 3 g vial (with re- quired solvent)	Injection	10	..	CS
	Injection, 6 g vial (with re- quired solvent)	Injection	10	..	CS
	Injection, 3 mg-3.9 mg in 1 mL amp.	Injection	5	..	SH
Betamethasone Acetate with Beta- methasone Sodium Phosphate B.P.	Injection, 3 mg-3.9 mg in 1 mL amp.	Injection	5	..	SH
Betamethasone Dipropionate	Cream, 500 micrograms (base) per g, 15 g	Application	1	1	SH
	Ointment, 500 micrograms (base) per g, 15 g	Application	1	1	SH
	Scalp lotion, 500 micrograms (base) per mL, 30 mL	Application to the scalp	1	1	SH
Betamethasone Tablets B.P.	500 micrograms	Oral	30	4	SH
Betamethasone Valerate B.P.	Gel, 500 micrograms (base) per g, 15 g	Application	1	1	GL
Betamethasone Valerate Cream B.P.	200 micrograms (base) per g, 100 g	Application	2	..	GL, SH
	500 micrograms (base) per g, 15 g	Application	1	1	GL, SH
Betamethasone Valerate Ointment B.P.	200 micrograms (base) per g, 100 g	Application	2	..	SH
	500 micrograms (base) per g, 15 g	Application	1	1	GL, SH
Bethanechol Chloride	Injection, 5 mg in 1 mL amp.	Injection	2	..	MK
	Tablet, 10 mg	Oral	100	2	HA, MK
Biperiden Hydrochloride	Tablet, 2 mg	Oral	200	2	KN
Bisacodyl B.P.	Enema, 10 mg in 5 mL, 25	Enema	1	2	PT
Bisacodyl Suppositories B.P.	10 mg, 10		1	..	BY
Bisacodyl Tablets B.P.	5 mg	Oral	200	1	PT
Bismuth Subcitrate	Tablet, 107.7 mg (as Bi)	Oral	112	2	PD
Bleomycin Sulphate with any deter- mined brand of Water for Injec- tions or other solvent	Injections, 15 mg (base) (with required solvent), 10	Injection	1	..	BC
Bromocriptine Mesylate Capsules B.P.	5 mg (base)	Oral	60	5	SZ
	10 mg (base)	Oral	100	5	SZ
	2.5 mg (base)	Oral	30	..	SZ
Bumetanide	Tablet, 1 mg	Oral	100	1	AP
Busulphan Tablets B.P.	2 mg	Oral	100	..	BW
Butyl Monoester Polymer with Ethanol B.P.	Paste, 60 g	Application	1	..	SQ
Butyl Monoester Polymer with Iso- propyl Alcohol B.P.	Protective dressing aerosol, 120 g	Application	1	..	DY
	Protective dressing solution, 59 mL	Application	1	..	DY
	Protective dressing wipes, 50		1	..	DY, SA
Calciferol Tablets, High-Strength B.P.	250 micrograms	Oral	100	5	GL
Calcitonin (Human)—Synthetic	Injections, 0.5 mg with 2 mL amp. solvent, 5	Injection	3	5	CG
Calcitonin (Pork) B.P.	Injections, 160 I.U. vial with 2 mL vial gelatin solvent, 10	Injection	2	5	RG
Calcitriol	Capsule, 0.25 micrograms	Oral	100	5	RO
Calcium Carbonate B.P.	Tablet, 1.5 g (equivalent to 600 mg calcium)	Oral	120	1	LE

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
	Tablet (chewable), 1.25 g (equivalent to 500 mg calcium)	Oral	120	1	RK
Calcium Carbonate B.P. with Cal- cium Lactate-Gluconate	Tablet, compound efferves- cent, equivalent to 1 g calcium	Oral	60	1	SZ
Calcium Folate	Injection, 3 mg in 1 mL amp.	Injection	5	..	BL
	Tablet, 15 mg	Oral	10	..	LE
Calcium Glubionate	Injection, 1.375 g in 10 mL amp.	Injection	5	1	SZ
Captopril	Tablet, 12.5 mg	Oral	90	5	SQ
	Tablet, 25 mg	Oral	90	5	SQ
	Tablet, 50 mg	Oral	90	5	SQ
Carbachol B.P. 1973	Eye drops, 15 mg per mL, 15 mL	Application to the eye	2	3	AQ
	Eye drops, 30 mg per mL, 15 mL	Application to the eye	2	3	AQ
Carbamazepine B.P.	Syrup, 100 mg per 5 mL, 300 mL	Oral	1	5	CG
Carbamazepine Tablets B.P.	100 mg	Oral	200	2	CG
	200 mg	Oral	200	2	AF, CG
Carbimazole Tablets B.P.	5 mg	Oral	200	2	NS
Carboplatin	Solution for I.V. injection, 50 mg in 5 mL vial	Injection	2	..	BL
	Solution for I.V. injection, 150 mg in 15 mL vial	Injection	6	..	BL
	Solution for I.V. injection, 450 mg in 45 mL vial	Injection	2	..	BL
Carmellose Sodium B.P. with Pectin and Gelatin B.P.	Paste, 167 mg-167 mg-167 mg per g, 15 g	Application	1	..	SQ
	Powder, 333 mg-333 mg-333 mg per g, 15 g	Application	1	..	SQ
Cefotaxime Sodium with any deter- mined brand of Water for Injec- tions or other solvent	Injection, 1 g (base) (with required solvent)	Injection	5	..	RL
	Injection, 2 g (base) (with required solvent)	Injection	5	..	RL
Ceftriaxone Sodium with any deter- mined brand of Water for Injec- tions or other solvent	Injection, 250 mg (base) (with required solvent)	Injection	2	..	RO
	Injection, 500 mg (base) (with required solvent)	Injection	2	..	RO
	Injection, 1 g (base) (with required solvent)	Injection	2	..	RO
	Injection, 2 g (base) (with required solvent)	Injection	2	..	RO
Cephalexin B.P. with Purified Water B.P.	Granules for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	GL, LY
	Granules for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	GL, LY
Cephalexin Capsules B.P.	250 mg	Oral	20	1	GL, LY
	500 mg	Oral	20	1	GL, LY
Cephalothin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 1 g (base) (with required solvent)	Injection	5	..	GL, LY
	Injection, 2 g (base) (with required solvent)	Injection	1	..	LY
	Injection, 4 g (base) (with required solvent)	Injection	1	..	LY
Cephazolin Sodium with any deter- mined brand of Water for Injec- tions or other solvent	Injection, 500 mg (base) (with required solvent)	Injection	5	..	LY
	Injection, 1 g (base) (with required solvent)	Injection	5	..	LY
Charcoal, Activated B.P.	Tablet, 300 mg	Oral	500	1	EG, QE, TO
Chloral Hydrate B.P.	Capsule, 500 mg	Oral	25	..	SQ
	Mixture, 250 mg per 5 mL, 200 mL	Oral	1	..	DH

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Chlorambucil Tablets B.P.	2 mg	Oral	100	2	BW
	5 mg	Oral	100	2	BW
Chloramphenicol B.P.	Ear drops (aqueous), 5 mg per mL, 5 mL	Application to the ear	1	2	PD
Chloramphenicol B.P. with Poly- myxin B Sulphate B.P.	Eye drops, 5 mg-5,000 units per mL, 10 mL	Application to the eye	1	2	PD
	Eye ointment, 10 mg-5,000 units per g, 4 g	Application to the eye	1	..	PD
Chloramphenicol Capsules B.P.	250 mg	Oral	16	..	PD
Chloramphenicol Eye Drops B.P.	5 mg per mL, 10 mL	Application to the eye	1	2	AG, PD, SI
Chloramphenicol Eye Ointment B.P.	10 mg per g, 4 g	Application to the eye	1	..	PD, SI
Chloramphenicol Palmitate Mixture B.P.	125 mg per 5 mL, 100 mL	Oral	1	..	PD
Chloramphenicol Sodium Succinate B.P. with any determined brand of Water for Injections or other solvent	Injection, 1 g vial (with re- quired solvent)	Injection	3	..	PD
Chlorhexidine Gluconate	Solution, 50 mg per mL, 200 mL		1	1	IC
Chlormethiazole Capsules B.P.	192 mg	Oral	50	..	AP
Chlormethiazole Edisylate B.P.	Injection, 8 mg per mL, 500 mL	Injection	1	..	AP
Chloroquine Phosphate Tablets B.P.	250 mg	Oral	100	..	PT
Chloroquine Sulphate B.P.	Tablet, 200 mg	Oral	100	..	MB
Chlorothiazide Tablets B.P.	500 mg	Oral	100	1	FM, FR
Chlorpromazine Elixir B.P.	25 mg per 5 mL, 100 mL	Oral	2	2	MB
Chlorpromazine Injection B.P.	Ampoule, 50 mg in 2 mL	Injection	10	..	MB
Chlorpromazine Suppositories B.P.	100 mg, 5		1	2	MB
Chlorpromazine Tablets B.P.	10 mg	Oral	200	..	MB, PT
	25 mg	Oral	200	..	MB, PT
	50 mg	Oral	200	..	MB, PT
	100 mg	Oral	100	1	MB, PT
Chlorpropamide Tablets B.P.	250 mg	Oral	100	5	PF
Chlorthalidone Tablets B.P.	25 mg	Oral	100	1	CG
Cholestyramine	Sachets, containing 9 g pow- der (equivalent to 4 g cho- lestyramine), 50	Oral	2	5	AP
Choline Theophyllinate B.P.	Elixir, 50 mg per 5 mL, 500 mL	Oral	1	5	PD
	Syrup, 50 mg per 5 mL, 500 mL	Oral	1	5	WW
	Tablet, 100 mg	Oral	100	5	WW
	Tablet, 200 mg	Oral	100	5	PD, WW
Chorionic Gonadotrophin B.P.	Injection set containing 3 ampoules powder for injec- tion 500 units and 3 am- poules solvent 1 mL	Injection	1	5	CS
	Injection set containing 3 ampoules powder for injec- tion 1,000 units and 3 am- poules solvent 1 mL	Injection	1	5	CS
	Injection set containing 3 ampoules powder for injec- tion 2,000 units and 3 am- poules solvent 1 mL	Injection	1	5	CS
	Injection set containing 1 ampoule powder for injec- tion 5,000 units and 1 am- poule solvent 1 mL	Injection	2	..	CS
Cimetidine	Tablet, 200 mg	Oral	120	2	CS, SK
	Tablet, 400 mg	Oral	60	2	CS, SK
	Tablet, 800 mg	Oral	30	1	CS, SK
Ciprofloxacin Hydrochloride	Tablet, 250 mg (base)	Oral	14	..	BN
	Tablet, 500 mg (base)	Oral	14	..	BN

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Clindamycin Capsules B.P.	Tablet, 750 mg (base)	Oral	14	..	BN
	75 mg	Oral	25	..	UP
	150 mg	Oral	25	..	UP
Clindamycin Palmitate Hydrochloride with Purified Water B.P.	Granules for syrup, 75 mg (base) per 5 mL, 100 mL	Oral	1	..	UP
Clioquinol B.P.	Cream, 10 mg per g, 30 g Forms specified in Sch. 2	Application	1 Sch. 2	.. Sch. 2	CG
Clofibrate Capsules B.P.	500 mg	Oral	100	5	IC, PT
Clomiphene Tablets B.P.	50 mg, 5	Oral	2	5	ML
Clomipramine Hydrochloride B.P.	Tablet, 25 mg	Oral	50	1	CG
Clonazepam	Injection, 1 mg in 2 mL (set containing solution 1 mg in 1 mL and 1 mL diluent)	Injection	5	..	RO
	Paediatric drops, 2.5 mg per mL, 10 mL	Oral	2	..	RO
	Tablet, 500 micrograms	Oral	200	2	RO
	Tablet, 2 mg	Oral	200	2	RO
Clonidine Hydrochloride Tablets B.P.	100 micrograms	Oral	100	5	BY
	150 micrograms	Oral	100	5	BY
Clopidamide	Tablet, 5 mg	Oral	100	1	SZ
Clotrimazole B.P.	Cream, 10 mg per g, 20 g	Application	1	1	BN, SH
	Lotion, 10 mg per mL, 20 mL	Application	1	1	BN, SH
	Pessaries, 100 mg, 6		1	..	BN, SH
	Pessary, 500 mg		1	..	BN
	Vaginal cream, 50 mg per 5 g, 35 g		1	..	BN, SH
	Vaginal cream, 100 mg per 5 g, 20 g		1	..	BN
Cloxacillin Capsules B.P.	250 mg (base)	Oral	24	..	AF, BR
	500 mg (base)	Oral	24	..	AF, BR
Cloxacillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) (with required solvent)	Injection	5	..	BR, CS
	Injection, 500 mg (base) (with required solvent)	Injection	5	..	BR, CS
	Injection, 1 g (base) (with required solvent)	Injection	5	..	BR, CS
Codeine Phosphate B.P. with Aspirin B.P.	Tablet, 30 mg-325 mg Forms specified in Sch. 2	Oral	20 Sch. 2	.. Sch. 2	BW
	Tablet, 30 mg-500 mg	Oral	20	..	WL
Codeine Phosphate B.P. with Paracetamol B.P.					
Codeine Phosphate Tablets B.P.	30 mg	Oral	20	..	DH, FA, FM, US
Colchicine Tablets B.P.	500 micrograms	Oral	100	2	DH, PT, RT
Colectipol Hydrochloride	Sachets, 5 g, 120	Oral	1	5	UP
Colistin Sulphate B.P. with Neomycin Sulphate B.P.	Ear drops, 3 mg (base)-3.3 mg (base) per mL, 10 mL	Application to the ear	1	2	WW
Colistin Sulphomethate Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 150 mg (with required solvent)	Injection	5	..	WW
Copper Sulphate B.P.C. 1973	Tablets, diagnostic compound, 36		2	3	AM
Cortisone Tablets B.P.	5 mg	Oral	50	4	PT
	25 mg	Oral	60	4	PT
Co-trimoxazole Mixture, Paediatric B.P.	40 mg-200 mg per 5 mL, 100 mL	Oral	1	1	AF, BW, PT, RO
Co-trimoxazole Tablets B.P.	80 mg-400 mg	Oral	10	..	AF, BW, PT, RO
	160 mg-800 mg	Oral	10	..	AF, BW, PT, RO
Cyclopenthiazide Tablets B.P.	500 micrograms	Oral	100	1	CG

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Cyclophosphamide B.P. with any de- termined brand of Water for In- jections or other solvent	Injection, 100 mg vial (with required solvent)	Injection	6	..	FE
	Injection, 200 mg vial (with required solvent)	Injection	6	..	FE
	Injection, 500 mg vial (with required solvent)	Injection	2	..	FE
	Injection, 1 g vial (with re- quired solvent)	Injection	1	..	FE
Cyclophosphamide Tablets B.P.	50 mg	Oral	50	2	FE
Cyproheptadine Tablets B.P.	4 mg	Oral	100	2	FR
Cytarabine B.P.	Injection, 40 mg in 2 mL amp.	Injection	10	1	BT
	Injection, 100 mg in 5 mL amp.	Injection	10	1	BT
	Injection, 500 mg in 25 mL amp.	Injection	2	1	BT
	Injection set containing 100 mg and 5 mL solvent	Injection	10	1	UP
Danazol	Capsule, 100 mg	Oral	100	5	WL
	Capsule, 200 mg	Oral	100	5	WL
Dantrolene Sodium	Capsule, 25 mg	Oral	100	2	NW
	Capsule, 50 mg	Oral	100	2	NW
Debrisoquine Tablets B.P.	10 mg (base)	Oral	100	5	RO
	20 mg (base)	Oral	100	5	RO
"De-Lact Infant"	Powder, 500 g	Oral	2	..	SJ
Demeclocycline Capsules B.P.	150 mg	Oral	100	3	LE
Desipramine Tablets B.P.	25 mg	Oral	50	2	CG
Desmopressin	Nasal solution, 100 micro- grams per mL, 2.5 mL dropper bottle	Nasal	5	2	FC
Dexamethasone B.P.	Eye drops, 1 mg per mL, 5 mL	Application to the eye	1	2	AQ
Dexamethasone B.P. with Framyce- tin Sulphate B.P. and Gramicidin	Ear ointment, 500 micro- grams-5 mg-50 micrograms per g, 5 g	Application to the ear	1	2	RL
Dexamethasone Sodium Metasul- phobenzoate with Framycetin Sul- phate B.P. and Gramicidin	Ear drops, 500 micrograms (base)-5 mg-50 micrograms per mL, 8 mL	Application to the ear	1	2	RL
Dexamethasone Sodium Phosphate B.P.	Injection, 1 mL amp. con- taining equivalent of 4 mg Dexamethasone Phosphate	Injection	5	..	MK
	Injection, 1 mL vial contain- ing equivalent of 5 mg Dexamethasone Phosphate	Injection	5	..	OR
	Injection, 2 mL vial contain- ing equivalent of 8 mg Dexamethasone Phosphate	Injection	5	..	MK
	Injection, 5 mL vial contain- ing equivalent of 120 mg Dexamethasone Phosphate	Injection	1	..	MK
Dexamethasone Tablets B.P.	500 micrograms	Oral	30	4	OR, PT
	4 mg	Oral	30	4	PT
Dexamphetamine Tablets B.P.	5 mg	Oral	100	5	SI
Dextran 40 Intravenous Infusion B.P. with Glucose B.P.	100 mg per mL-139 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 40 Intravenous Infusion B.P. with Sodium Chloride B.P.	100 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 70 Intravenous Infusion B.P. with Glucose B.P.	60 mg per mL-139 mmol per 500 mL, 500 mL	Injection	3	..	PS
Dextran 70 Intravenous Infusion B.P. with Sodium Chloride B.P.	60 mg per mL-77 mmol per 500 mL, 500 mL	Injection	3	..	PS
Diazepam B.P.	Syrup, 2 mg per 5 mL, 100 mL	Oral	1	..	RO
Diazepam Injection B.P.	10 mg in 2 mL	Injection	5	..	BL, RO

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Diazepam Tablets B.P.	2 mg	Oral	50	..	AF, PT, RO, SU
	5 mg	Oral	50	..	AF, PT, RO, SU
Diazoxide Injection B.P.	300 mg in 20 mL	Injection	1	..	BL, SH
Dichlorphenamide Tablets B.P.	50 mg	Oral	50	6	MK
Diclofenac Sodium	Tablet, 25 mg (enteric coated)	Oral	50	3	CG
	Tablet, 50 mg (enteric coated)	Oral	50	3	CG
Dienoestrol B.P.	Cream, 500 micrograms per 5 g, 85 g		1	1	JC
Difenoxin Hydrochloride with Atropine Sulphate B.P.	Tablet, 500 micrograms-25 micrograms	Oral	20	..	PT
Diffunisal Tablets B.P.	250 mg	Oral	50	3	MK
"Digestelact"	Powder, 500 g	Oral	2	20	SJ
Digoxin Elixir, Paediatric B.P.	50 micrograms per mL, 100 mL	Oral	1	3	BW
Digoxin Injection B.P.	Ampoule, 500 micrograms in 2 mL	Injection	5	1	BW
Digoxin Tablets B.P.	62.5 micrograms	Oral	200	1	BW
	250 micrograms	Oral	100	1	BW
Dihydroergotamine Mesylate B.P.	Injection, 1 mg in 1 mL amp.	Injection	5	..	SZ
Dihydrotachysterol B.P.	Capsule, 125 micrograms	Oral	100	5	WL
Diloxanide Furoate Tablets B.P.	500 mg	Oral	30	..	BT
Diltiazem Hydrochloride	Tablet, 60 mg	Oral	100	5	IC
Dimercaprol Injection B.P.	Ampoule, 100 mg in 2 mL	Injection	12	..	BT
Dimethicones B.P.	Solution, 100 mg per mL, 180 mL aerosol spray pack	Application	1	..	EG
Diphenoxylate Hydrochloride B.P. with Atropine Sulphate B.P.	Tablet, 2.5 mg-25 micrograms	Oral	20	..	SR
Diphtheria and Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	3	..	CS
Diphtheria and Tetanus Vaccine, Adsorbed B.P., Diluted	Injection, 0.5 mL amp. For immunization of adults and children over the age of 8 years	Injection	3	..	CS
Diphtheria Antitoxin B.P.	Injection, 10,000 units amp.	Injection	2	1	CS
Diphtheria, Tetanus and Pertussis Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	3	..	CS, PD
Diphtheria Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	2	1	CS
Diphtheria Vaccine, Adsorbed B.P., Diluted	Injection, 0.5 mL amp. For immunization of adults and children over the age of 8 years	Injection	2	..	CS
Dipivefrine Hydrochloride	Eye drops, 1 mg per mL, 10 mL	Application to the eye	1	6	AG
Disodium Etidronate	Tablet, 200 mg	Oral	60	5	NW
Disopyramide Capsules B.P.	100 mg	Oral	100	5	RL
	150 mg	Oral	100	5	RL
Disopyramide Phosphate Capsules B.P.	100 mg (base)	Oral	100	5	SR
	150 mg (base)	Oral	100	5	SR
Docusate Sodium B.P. with Bisacodyl B.P.	Suppositories, 100 mg-10 mg, 5		2	..	FM
Domperidone	Tablet, 10 mg	Oral	25	..	JC
Dothiepin Capsules B.P.	25 mg	Oral	50	2	BT
Dothiepin Hydrochloride B.P.	Tablet, 75 mg	Oral	30	2	BT
Doxepin Capsules B.P.	10 mg (base)	Oral	50	2	AF, PF
	25 mg (base)	Oral	50	2	AF, PF
Doxepin Hydrochloride B.P.	Tablet, 50 mg (base)	Oral	50	2	AF

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Doxorubicin Hydrochloride	Powder for I.V. injection or intravesical administration, 10 mg vial	Injection or intra- vesical admini- stration	4	..	FE
	Powder for I.V. injection or intravesical administration, 20 mg vial	Injection or intra- vesical admini- stration	4	..	FE
	Powder for I.V. injection or intravesical administration, 50 mg vial	Injection or intra- vesical admini- stration	3	..	FE
Doxycycline Capsules B.P.	100 mg	Oral	7	1	PT
Doxycycline Hydrochloride B.P.	Capsule, 50 mg (base) (con- taining enteric coated pellets)	Oral	25	5	FA
	Capsule, 100 mg (base) (containing enteric coated pellets)	Oral	7	1	FA
	Tablet, 50 mg (base)	Oral	25	5	AF, PF
	Tablet, 100 mg (base)	Oral	7	1	AF, PF
Dydrogesterone Tablets B.P.	10 mg	Oral	50	5	JC
Econazole Nitrate B.P.	Lotion, 10 mg per mL, 20 mL	Application	1	1	SK, SQ
Econazole Nitrate Cream B.P.	10 mg per g, 20 g	Application	1	1	SK, SQ
	75 mg per 5 g, 35 g	Application	1	..	SQ
Econazole Nitrate Pessaries B.P.	150 mg, 3		1	..	SK, SQ
Ecothiopate Iodide B.P.	Eye drops, 300 micrograms per mL (1.5 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
	Eye drops, 600 micrograms per mL (3 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
	Eye drops, 1.25 mg per mL (6.25 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
	Eye drops, 2.5 mg per mL (12.5 mg and 5 mL vial of solvent)	Application to the eye	1	6	AY
Enalapril Maleate	Tablet, 5 mg	Oral	30	5	AD, MK
	Tablet, 10 mg	Oral	30	5	AD, MK
	Tablet, 20 mg	Oral	30	5	AD, MK
Ergometrine and Oxytocin Injection B.P.	Ampoule, 500 micrograms-5 units in 1 mL	Injection	5	..	SZ
Ergometrine Injection B.P.	Ampoule, 250 micrograms in 1 mL	Injection	5	..	BL
Ergometrine Tablets B.P.	200 micrograms	Oral	24	..	LY
Ergotamine Tablets B.P.	1 mg	Oral	50	2	WL
Ergotamine Tartrate B.P. with Caf- feine B.P.	Suppositories, compound, 6 Tablet, 1 mg-100 mg		1	2	SZ
		Oral	50	2	SZ
Erythromycin B.P.	Capsule, 125 mg (containing enteric coated pellets)	Oral	25	1	FA
	Capsule, 175 mg (containing enteric coated pellets)	Oral	25	1	FA
	Capsule, 250 mg (containing enteric coated pellets)	Oral	25	1	FA, LY
Erythromycin Estolate B.P.	Drops, paediatric, 100 mg (base) per mL, 10 mL	Oral	1	1	LY
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	LY
Erythromycin Ethyl Succinate B.P.	Injection, 100 mg (base) in 2 mL	I.M. injection	5	..	AB
	Tablet, chewable, 200 mg (base)	Oral	25	1	AB

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Erythromycin Ethyl Succinate B.P. with Purified Water B.P.	Tablet, 400 mg (base)	Oral	25	1	AB
	Granules for suspension, 200 mg (base) per 5 mL, 100 mL	Oral	1	1	AB
Erythromycin Lactobionate	Infusion, I.V., 300 mg (base)	Injection	5	..	AB
	Infusion, I.V., 1 g (base)	Injection	1	..	AB
Erythromycin Stearate B.P.	Capsule, 250 mg (base)	Oral	25	1	AB
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	1	AB
	Suspension, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
	250 mg (base)	Oral	25	1	AB
Erythromycin Stearate Tablets B.P.	250 mg	Oral	25	1	AB, UP
Ethacrynic Acid Tablets B.P.	50 mg	Oral	50	3	MK
Ethinyloestradiol Tablets B.P.	10 micrograms	Oral	200	1	GL
	20 micrograms	Oral	200	1	GL
	50 micrograms	Oral	200	1	GL
Ethosuximide Capsules B.P.	250 mg	Oral	200	2	PD
Ethosuximide Elixir B.P.	250 mg per 5 mL, 250 mL	Oral	1	4	PD
Ethylloestrenol Tablets B.P.	2 mg	Oral	100	3	OR
Ethinodiol Diacetate B.P. with Ethinyloestradiol B.P.	Pack containing 21 tablets, 500 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SR
	Pack containing 21 tablets, 1 mg-50 micrograms and 7 inert tablets	Oral	4	2	SR
	Tablets, 500 micrograms-50 micrograms, 21	Oral	4	2	SR
	Tablets, 1 mg-50 micrograms, 21	Oral	4	2	SR
Etretnate	Capsule, 10 mg	Oral	100	5	RO
	Capsule, 25 mg	Oral	100	5	RO
Famotidine	Tablet, 20 mg	Oral	60	2	MK
	Tablet, 40 mg	Oral	30	1	MK
Felodipine	Tablet, 5 mg	Oral	60	5	AP, HP
	Tablet, 10 mg	Oral	60	5	AP, HP
Fenoterol Hydrobromide B.P.	Solution, 1 mg per mL, 20 mL	Inhalation	1	5	BY
	Spray, metered aerosol, 200 micrograms per dose, 300 doses, 21 g	Inhalation by mouth	1	5	BY
Ferrous Aminoacetosulphate	Syrup, 100 mL	Oral	1	4	NN
Ferrous Gluconate B.P.	Elixir, 300 mg per 5 mL, 100 mL	Oral	1	4	WL
Ferrous Gluconate Tablets B.P.	300 mg	Oral	100	2	WL
Ferrous Sulphate, Dried B.P.	Capsule, 320 mg, equivalent to 96 mg Ferrous Iron (delayed release)	Oral	30	2	SK
	Tablet, 320 mg, equivalent to 96 mg Ferrous Iron (delayed release)	Oral	30	2	CG
	Tablet, 350 mg, equivalent to 105 mg Ferrous Iron (sustained release)	Oral	30	2	AB, PT
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Ferrous Sulphate, Dried B.P. with Folic Acid B.P.	Capsule, 270 mg, equivalent to 80 mg Ferrous Iron-300 micrograms (delayed release)	Oral	30	2	SK
	Tablet, 270 mg, equivalent to 80 mg Ferrous Iron-300 micrograms (delayed release)	Oral	30	2	PT
	Tablet, 270 mg, equivalent to 80 mg Ferrous Iron-300 micrograms (sustained release)	Oral	30	2	AB
Flecainide Acetate	Tablet, 100 mg	Oral	60	5	RK
Fluclorolone Acetonide B.P.	Cream, 250 micrograms per g, 15 g	Application	1	1	SD

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Flucloxacillin Capsules B.P.	250 mg (base)	Oral	24	..	AF, BR, CS
	500 mg (base)	Oral	24	..	AF, BR, CS
Flucloxacillin Magnesium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS
Flucloxacillin Sodium B.P. with any determined brand of Water for In- jections or other solvent	Injection, 250 mg (base) (with required solvent)	Injection	5	..	CS
	Injection, 500 mg (base) (with required solvent)	Injection	5	..	BR, CS
	Injection, 1 g (base) (with re- quired solvent)	Injection	5	..	BR, CS
Flucytosine Tablets B.P.	500 mg	Oral	100	..	RO
Fludrocortisone Tablets B.P.	100 micrograms	Oral	200	1	SQ
Flumethasone Pivalate with Cli- oquinol B.P.	Ear drops, 200 micrograms-10 mg per mL, 7.5 mL	Application to the ear	1	..	CG
Fluocortolone Pivalate and Fluocor- tolone Hexanoate Cream B.P.	1 mg-1 mg per g, 15 g	Application	1	1	SC
Fluocortolone Pivalate and Fluocor- tolone Hexanoate Ointment B.P.	1 mg-1 mg per g, 15 g	Application	1	1	SC
	Anhydrous base, 1 mg-1 mg per g, 15 g	Application	1	1	SC
Fluorometholone	Eye drops, 1 mg per mL, 5 mL	Application to the eye	1	6	AG, AQ
Fluorouracil Injection B.P.	Ampoule, 250 mg in 10 mL	Injection	10	..	RO
	Ampoule, 500 mg in 10 mL	Injection	5	1	FE
Fluoxymesterone Tablets B.P.	5 mg	Oral	100	3	UP
Fluphenazine Decanoate Injection B.P.	Ampoule, 12.5 mg in 0.5 mL	Injection	5	..	SQ
	Ampoule, 50 mg in 2 mL	Injection	5	..	SQ
	Syringe, disposable, 25 mg in 1 mL	Injection	5	..	SQ
Fluphenazine Tablets B.P.	1 mg	Oral	200	..	SQ
	2.5 mg	Oral	200	..	SQ
	5 mg	Oral	100	1	SQ
Folic Acid B.P.	Injection, 15 mg in 1 mL amp.	Injection	10	..	AB
Folic Acid Tablets B.P.	500 micrograms	Oral	200	..	DH, PT, SI
	5 mg	Oral	200	1	DH, FM, NN, PT, RT, SI, US
Fosfestrol Sodium B.P.	Injection, 250 mg in 5 mL	Injection	10	..	BC
	Tablet, 120 mg	Oral	100	2	BC
Framycetin Sulphate B.P.	Eye/ear drops, 5 mg per mL, 8 mL	Application to the eye/ear	1	2	RL
	Eye ointment, 5 mg per g, 5 g	Application to the eye	1	..	RL
Frusamide B.P.	Solution, 10 mg per mL, 30 mL	Oral	1	3	HP
Frusamide Injection B.P.	Ampoule, 20 mg in 2 mL	Injection	5	..	AF, HP
Frusamide Tablets B.P.	20 mg	Oral	100	1	FM, HP
	40 mg	Oral	100	1	FM, HP, PT
	500 mg	Oral	50	3	FM, HP
Fusidic Acid Mixture B.P.	50 mg per mL, 90 mL	Oral	1	..	SK
Gas-gangrene Antitoxin, Mixed B.P.	Injection, 1 amp. containing 10,000 units Perfringens; 5,000 units Septicum; 10,000 units Novyi	Injection	2	1	CS
Gentamicin Eye Drops B.P.	3 mg (base) per mL, 5 mL	Application to the eye	1	2	AG
Gentamicin Injection B.P.	Ampoule, 40 mg (base) in 1 mL	Injection	5	..	BL, SH
	Ampoule, 60 mg (base) in 1.5 mL	Injection	5	..	BL, SH

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
	Ampoule, 80 mg (base) in 2 mL	Injection	5	..	BL, RL, SH
	Syringe, disposable, 80 mg (base)	Injection	5	..	SH
Glibenclamide Tablets B.P.	5 mg	Oral	100	5	AF, HP, RC
Gliclazide	Tablet, 80 mg	Oral	100	5	SE
Glipizide	Tablet, 5 mg	Oral	100	5	FE
Glucagon Hydrochloride	Injection, 1 I.U. with diluent	Injection	1	1	CN, LY
Glucose and Ketone Indicator—Urine	100 reagent strips		1	2	AM
Glucose, Anhydrous B.P., Sodium Chloride B.P., Potassium Chloride B.P., Citric Acid B.P. and Sodium Citrate B.P.	Powder, 36.354 g-354 mg-903 mg-606 mg-1.781 g per sachet, 6	Oral	1	..	DH
Glucose Indicator—Blood	50 reagent strips (Ames-BG)		2	5	AM
	50 reagent strips (BM-Test-BG)		2	5	BO
	50 reagent strips (BM-Test-Glycemic 20-800)		2	5	BO
	50 reagent strips (Glucostix)		2	5	AM
Glucose Indicator—Urine	4 m dispenser		1	2	LY
	100 reagent strips (Clinistix)		1	2	AM
	100 reagent strips (Diastix)		1	2	AM
Glucose Intravenous Infusion B.P.	278 mmol per L, 1 L	Injection	5	1	AB, BX, KM
	555 mmol per L, 1 L	Injection	5	1	AB, BX
	1,110 mmol per L, 1 L	Injection	2	1	AB
	1,387 mmol per L, 1 L	Injection	2	1	AB, BX
	1,387 mmol per 500 mL, 500 mL	Injection	2	1	AB
	Ampoule, 5 g in 10 mL	Injection	5	..	AP
Glyceryl Trinitrate	Ointment, 20 mg per g, 60 g	Application	1	5	FC
	Transdermal disc, 16 mg	Application	30	2	SR
	Transdermal disc, 32 mg	Application	30	2	SR
	Transdermal pad, 25 mg	Application	30	2	CG
	Transdermal pad, 50 mg	Application	30	2	CG
Glyceryl Trinitrate Tablets B.P.	600 micrograms, 100	Oral	1	5	BW
Griseofulvin Tablets B.P.	125 mg	Oral	100	2	GL, IC
	330 mg	Oral	28	2	SH
	500 mg	Oral	28	2	GL, IC
Haloperidol B.P.	Injection, 5 mg in 1 mL amp.	Injection	10	..	SR
Haloperidol Solution B.P.	2 mg per mL, 15 mL	Oral	1	2	SR
	2 mg per mL, 100 mL	Oral	1	1	SR
Haloperidol Tablets B.P.	1.5 mg	Oral	200	..	SR
	5 mg	Oral	50	1	SR
Heparin Injection B.P. (Calcium Salt)	5,000 I.U. in 0.2 mL	Injection	5	5	BL, CS, FC
	5,000 I.U. in 0.5 mL	Injection	5	5	CS
	12,500 I.U. in 0.5 mL	Injection	2	5	BL, CS
	25,000 I.U. in 1 mL	Injection	2	5	BL, CS
Heparin Injection B.P. (Sodium Salt)	Ampoule, 5,000 units in 0.2 mL	Injection	5	5	BL, CS, FC
	Ampoule, 5,000 units in 1 mL	Injection	5	5	BL, CS, FC
	Ampoule, 20,000 units in 20 mL	Injection	12	5	BL
	Ampoule, 25,000 units in 5 mL	Injection	2	5	CS, FC
	Vial, 35,000 units in 35 mL	Injection	12	5	CS, FC
Hexamine Hippurate	Tablet, 1 g	Oral	100	5	RK
Hexamine Mandelate	Tablet, 250 mg	Oral	200	2	WW
	Tablet, 500 mg	Oral	200	2	WW
	Tablet, 1 g	Oral	100	5	WW

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Homatropine Hydrobromide B.P.	Eye drops, 20 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ
	Eye drops, 50 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ
Hydralazine Hydrochloride Tablets B.P.	25 mg	Oral	200	2	AF, CG, PT
	50 mg	Oral	200	2	AF, CG, PT
Hydrochlorothiazide B.P. with Amloride Hydrochloride B.P.	Tablet, 50 mg-5 mg	Oral	100	1	MK, PT
Hydrochlorothiazide B.P. with Triamterene B.P.	Tablet, 25 mg-50 mg	Oral	100	1	SK
Hydrochlorothiazide Tablets B.P.	25 mg	Oral	100	1	CG, MK
	50 mg	Oral	100	1	CG, MK
Hydrocortisone B.P.	Tablet, 4 mg	Oral	50	4	PT
	Tablet, 20 mg	Oral	60	4	PT
Hydrocortisone Acetate B.P.	Eye drops, 5 mg per mL, 10 mL	Application to the eye	1	2	SI
	Eye drops, 10 mg per mL, 10 mL	Application to the eye	1	2	SI
	Eye drops, 25 mg per mL, 5 mL	Application to the eye	1	2	SI
	Eye drops, 25 mg per mL, 10 mL	Application to the eye	1	2	SI
	Eye ointment, 5 mg per g, 4 g	Application to the eye	1	..	UP
	Eye ointment, 5 mg per g, 5 g	Application to the eye	1	..	SI
	Eye ointment, 10 mg per g, 5 g	Application to the eye	1	..	SI
	Rectal foam, 100 mg per g, aerosol, 25 g		2	3	SV
Hydrocortisone Acetate B.P. with Neomycin Sulphate B.P.	Ear drops, 15 mg-3.5 mg (base) per mL, 5 mL	Application to the ear	1	..	UP
	Ear ointment, 15 mg-3.5 mg (base) per g, 4 g	Application to the ear	1	2	UP
Hydrocortisone Acetate Cream B.P.	10 mg per g, 30 g	Application	1	1	NN, PD, SI, SQ, UP, US
	10 mg per g, 50 g	Application	1	1	NN, PD, SI, SQ, UP
Hydrocortisone Acetate Injection B.P.	Ampoule, 25 mg in 1 mL	Intra-articular injection	5	..	PT
Hydrocortisone Acetate Ointment B.P.	10 mg per g, 30 g	Application	1	1	NN, PD, SI, SQ, UP
	10 mg per g, 50 g	Application	1	1	NN, PD, SI, SQ, UP
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 100 mg Hydrocortisone and 2 mL solvent	Injection	2	..	NR, UP
	Injection set containing equivalent of 250 mg Hydrocortisone and 2 mL solvent	Injection	1	..	UP
	Injection set containing equivalent of 500 mg Hydrocortisone and 4 mL solvent	Injection	2	..	UP
Hydroxocobalamin Injection B.P.	1 mg in 1 mL amp.	Injection	3	..	GL
Hydroxychloroquine Tablets B.P.	200 mg	Oral	100	1	WL
Hydroxyurea Capsules B.P.	500 mg	Oral	100	..	SQ

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Hyoscyamine Hydrobromide with Atropine Sulphate B.P. and Hyos- cine Hydrobromide B.P.	Tablet, 101.1 micrograms- 14.8 micrograms-10.7 micrograms	Oral	100	2	FM
	Tablet, 151.6 micrograms- 22.2 micrograms-16.0 micrograms	Oral	100	2	FM
Hyoscyamine Sulphate B.P. with Atropine Sulphate B.P. and Hyos- cine Hydrobromide B.P.	Tablet, 103.7 micrograms- 19.4 micrograms-6.5 micrograms	Oral	100	2	RS
Hypromellose 4500 B.P.	Eye drops, 5 mg per mL, 15 mL	Application to the eye	2	3	AG, AQ, SI
	Eye drops, 10 mg per mL, 15 mL	Application to the eye	2	3	SI
Hypromellose 4500 B.P. with Dex- tran 70	Eye drops, 3 mg-1 mg per mL, 15 mL	Application to the eye	2	3	AQ
Ibuprofen Tablets B.P.	200 mg	Oral	50	3	AF, BT, PT
	400 mg	Oral	50	3	BT, PT
Idoxuridine B.P.	Eye ointment, 5 mg per g, 5 g	Application to the eye	1	..	SK
	Ointment, 5 mg per g, 5 g	Topical application	1	..	SK
Idoxuridine Eye Drops B.P.	1 mg per mL, 15 mL	Application to the eye	1	2	AG, SK
Imipramine Hydrochloride B.P.	Injection, 25 mg in 2 mL amp.	Injection	10	..	CG
Imipramine Tablets B.P.	10 mg	Oral	50	2	CG, PT
	25 mg	Oral	50	2	CG, PT, UW
Indapamide	Tablet, 2.5 mg	Oral	60	1	SE
Indomethacin Capsules B.P.	25 mg	Oral	50	3	AF, MK, PT
Indomethacin Suppositories B.P.	100 mg		40	3	MK
Influenza Vaccine (Split Virion), In- activated B.P.	Injection containing antigens representative of the following types: A/Singapore/6/86 (H1N1)- like strain 15 micrograms haemagglutinin; A/Leningrad/360/86 (H3N2)-like strain 15 mi- crograms haemagglutinin; B/Victoria/2/87-like strain 15 micrograms haemagglu- tinin; 0.5 mL pre-filled syringe	Injection	1	..	CS, MB
Insect Allergen Extract—Honey Bee Venom	Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials di- luent 1.8 mL	Injection	1	..	BN
Insect Allergen Extract—Paper Wasp Venom	Injection set containing 550 micrograms vial with 9 mL vial solvent and 3 vials di- luent 1.8 mL	Injection	1	..	BN
Insulin Injection, Acid B.P.	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	CN
	Vial, (bovine) 300 units per mL, 5 mL	Injection	10	2	CN
Insulin Injection, Biphasic B.P.	Vial, (mixed porcine/bovine) 100 units per mL, 10 mL	Injection	5	2	CN
Insulin Injection, Isophane B.P.	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	CN, FC
	Vial, (porcine) 100 units per mL, 10 mL	Injection	5	2	BW, CN
Insulin Injection, Isophane B.P. and Insulin Injection, Neutral B.P.	Vial, (porcine) 50 units-50 units per mL, 10 mL	Injection	5	2	BW
	Vial, (porcine) 70 units-30 units per mL, 10 mL	Injection	5	2	BW, CN

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Insulin Injection, Neutral B.P.	Cartridges, (porcine) 100 units per mL, 1.5 mL, 5	Injection	7	2	CN
	Cartridges, (porcine) 100 units per mL, 2 mL, 5	Injection	5	2	BW
	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	FC
	Vial, (porcine) 100 units per mL, 10 mL	Injection	5	2	BW, CN
Insulin Injection, Protamine Zinc B.P.	Vial, (bovine) 100 units per mL, 10 mL	Injection	5	2	CN
Insulin Isophane, Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	BW, CN, LY
	Injection, cartridges, 100 units per mL, 1.5 mL, 5	Injection	7	2	CN
	Injection, cartridges, 100 units per mL, 2.5 mL, 5	Injection	4	2	BW
Insulin Isophane, Human (Synthetic) and Insulin Neutral, Human (Synthetic)	Injection, 50 units-50 units per mL, 10 mL vial	Injection	5	2	BW
	Injection, 70 units-30 units per mL, 10 mL vial	Injection	5	2	BW, CN
	Injection, cartridges, 70 units-30 units per mL, 1.5 mL, 5	Injection	7	2	CN
	Injection, cartridges, 70 units-30 units per mL, 2.5 mL, 5	Injection	4	2	BW
Insulin Neutral, Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	BW, CN, LY
	Injection, cartridges, 100 units per mL, 1.5 mL, 5	Injection	7	2	CN
	Injection, cartridges, 100 units per mL, 2.5 mL, 5	Injection	4	2	BW
Insulin Zinc Suspension B.P.	Injection, (bovine) 100 units per mL, 10 mL vial	Injection	5	2	CN
	Injection, (porcine) 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension (Amorphous) B.P.	Injection, (porcine) 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension (Crystalline) B.P.	Injection, (bovine) 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension (Crystalline), Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	CN
Insulin Zinc Suspension, Human (Synthetic)	Injection, 100 units per mL, 10 mL vial	Injection	5	2	CN
Intraperitoneal Dialysis Solutions B.P.C. 1973	1 L (Glucose 76 mmol per L), 12	Injection	2	1	BX
	2 L (Glucose 76 mmol per L), 6	Injection	2	1	BX
	1 L (Glucose 126 mmol per L), 12	Injection	2	1	BX
	2 L (Glucose 126 mmol per L), 6	Injection	2	1	BX
	1 L (Glucose 214 mmol per L), 10	Injection	2	1	BX
	2 L (Glucose 214 mmol per L), 6	Injection	2	1	BX
Ipratropium Bromide	Nebuliser solution, 250 micrograms per mL, 20 mL	Inhalation	2	2	BY
	Spray, metered aerosol, 20 micrograms per dose, 200 doses, 10 mL	Inhalation by mouth	1	5	BY
Iron Dextran Injection B.P.	Ampoule, 2 mL	Injection	5	..	FC
Iron Polymaltose Complex	Injection, 100 mg (Iron) in 2 mL amp.	Injection	5	..	SI
	Tablet, 40 mg (Iron)	Oral	100	2	SI
Isoconazole Nitrate	Cream, 10 mg per g, 20 g	Application	1	1	SC
	Lotion, 10 mg per mL, 20 mL	Application	1	1	SC

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Isoniazid Tablets B.P.	Pessaries, 300 mg, 2		1	..	SC
Isopropyl Monoester Polymer with Isopropyl Alcohol B.P.	100 mg	Oral	100	2	FM
Isosorbide Dinitrate Tablets B.P.	Gel, adhesive protective, 28.35 g	Application	1	..	HO
	5 mg (sublingual)	Oral	200	2	AY, PD
	10 mg	Oral	200	2	AY, PD
Isotretinoin	Capsule, 10 mg	Oral	60	3	RO
	Capsule, 20 mg	Oral	60	3	RO
Kaolin, Light B.P. or Light Kaolin (Natural) B.P. with Pectin	Suspension, 5.91 g-132 mg per 30 mL, 375 mL	Oral	1	2	UP
Ketoconazole	Tablet, 200 mg	Oral	30	5	JC
Ketoprofen B.P.	Capsule, 100 mg (sustained release)	Oral	50	3	MB
	Suppository, 100 mg		40	3	MB
Ketoprofen Capsules B.P.	50 mg	Oral	50	3	MB
	100 mg	Oral	50	3	MB
Labetalol Hydrochloride Tablets B.P.	100 mg	Oral	100	5	AF, GL
	200 mg	Oral	100	5	AF, GL
Lactulose Solution B.P.	3.34 g per 5 mL, 500 mL	Oral	1	5	JC
Lauramine Oxide with Octoxinol	Cleansing solution, compound, 80 mg-10 mg per g, 240 mL		1	..	DY
Leuporelin Acetate	Injection, 5 mg per mL, 2.8 mL vial	Injection	2	2	AB
Levodopa and Carbidopa Tablets B.P.	100 mg-10 mg	Oral	100	5	MK
	100 mg-25 mg	Oral	100	5	MK
	250 mg-25 mg	Oral	100	5	MK
Levodopa B.P. with Benserazide	Capsule, 50 mg-12.5 mg	Oral	100	5	RO
	Capsule, 100 mg-25 mg	Oral	100	5	RO
	Capsule, 200 mg-50 mg	Oral	100	5	RO
	Tablet, 200 mg-50 mg	Oral	100	5	RO
Levodopa Tablets B.P.	100 mg	Oral	50	5	RO
	250 mg	Oral	100	5	RO
	500 mg	Oral	250	5	RO
Levonorgestrel B.P.	Tablets, 30 micrograms, 28	Oral	4	2	SC, WY
Levonorgestrel B.P. with Ethinylloestradiol B.P.	Pack containing 21 tablets, 125 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 21 tablets, 150 micrograms-30 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 21 tablets, 250 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	WY
	Pack containing 11 tablets, 50 micrograms-50 micrograms and 10 tablets, 125 micrograms-50 micrograms	Oral	4	2	WY
	Pack containing 11 tablets, 50 micrograms-50 micrograms, 10 tablets, 125 micrograms-50 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Pack containing 6 tablets, 50 micrograms-30 micrograms, 5 tablets, 75 micrograms-40 micrograms and 10 tablets, 125 micrograms-30 micrograms	Oral	4	2	SC, WY
	Pack containing 6 tablets, 50 micrograms-30 micrograms, 5 tablets, 75 micrograms-40 micrograms, 10 tablets, 125 micrograms-30 micrograms and 7 inert tablets	Oral	4	2	SC, WY
	Tablets, 125 micrograms-50 micrograms, 21	Oral	4	2	SC

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Manner of adminis- tration	Maxi- mum quantity	Number of repeats	Brand
	Tablets, 150 micrograms-30 micrograms, 21	Oral	4	2	SC, WY
	Tablets, 250 micrograms-50 micrograms, 21	Oral	4	2	WY
Lignocaine Hydrochloride B.P.	Injection, 100 mg in 5 mL Forms specified in Sch. 2	Injection	2 Sch. 2	.. Sch. 2	AP
Lignocaine Hydrochloride Injection B.P.	Syringe, disposable, 300 mg in 3 mL	I.M. injection	1	..	AP
	500 mg in 5 mL	Infusion	5	..	AP
Lincomycin Injection B.P.	Ampoule, 300 mg (base) in 1 mL	Injection	5	..	UP
	Ampoule, 600 mg (base) in 2 mL	Injection	5	..	UP
Lindane B.P.	Head lotion, 2 mg per mL, 200 mL	Application	1	..	IC
	Lotion concentrate, 10 mg per mL, 200 mL	Application	1	..	IC
Lindane Cream B.P.	10 mg per g, 200 g	Application	1	2	IC
Liothyronine Tablets B.P.	20 micrograms	Oral	100	2	GL
Lithium Carbonate B.P.	Tablet, 400 mg (delayed release)	Oral	200	1	PT
Lithium Carbonate Tablets B.P.	250 mg	Oral	200	2	DH, PT
"Locasol New Formula"	Powder, 450 g	Oral	2	20	KY
"Lofenalac"	Powder, 1 lb	Oral	5	5	MJ
Loperamide Hydrochloride	Capsule, 2 mg	Oral	12	..	JC
Lypressin	Spray, nasal, 50 units per mL, 5 mL	Nasal spray	10	2	SZ
"Maxamaid RVHB"	Powder, 200 g	Oral	5	5	SB
"Maxamaid XP"	Powder, 200 g	Oral	5	5	SB
"Maxamum XP"	Powder, 200 g	Oral	5	5	SB
Medroxyprogesterone Acetate B.P.	Injection, 50 mg in 1 mL vial	Injection	1	..	UP
	Injection, 150 mg in 1 mL vial	Injection	1	..	UP
	Injection, 500 mg in 2.5 mL vial	Injection	1	..	FE
	Oral suspension, 100 mg per mL, 100 mL	Oral	1	2	UP
	Tablet, 10 mg	Oral	30	5	UP
	Tablet, 100 mg	Oral	100	2	FE, UP
	Tablet, 200 mg	Oral	60	2	FE, UP
	Tablet, 250 mg	Oral	60	2	UP
	Tablet, 500 mg	Oral	30	2	FE, UP
Medrysone	Eye drops, 10 mg per mL, 5 mL	Application to the eye	1	6	AG
Mefenamic Acid Capsules B.P.	250 mg	Oral	50	2	AF, PD
Mefruside	Tablet, 25 mg	Oral	100	1	BN
Megestrol Acetate B.P.	Tablet, 40 mg	Oral	100	2	BC
Melphalan Tablets B.P.	2 mg	Oral	100	..	BW
	5 mg	Oral	100	..	BW
Menopausal Gonadotrophin, Human	Injection set containing 10 ampoules powder for injection providing 75 units follicle stimulating hormone and 75 units luteinizing hormone and 10 ampoules solvent 1 mL	Injection	1	5	CS, OR
Mercaptopurine Tablets B.P.	50 mg	Oral	100	2	BW
Metformin Tablets B.P.	500 mg	Oral	100	5	AF, FC, LH
Methacycline Hydrochloride B.P. 1973	Capsule, 150 mg	Oral	21	1	WW
	Capsule, 300 mg	Oral	10	1	WW
Methadone Injection B.P.	Ampoule, 10 mg in 1 mL	Injection	5	..	BW
Methadone Tablets B.P.	5 mg	Oral	20	..	BW
	10 mg	Oral	20	..	BW

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Methdilazine Hydrochloride	Tablet, 4 mg Tablet, 8 mg	Oral Oral	100 100	2 2	GL GL
Methenolone Acetate	Tablet, 5 mg	Oral	100	3	SC
Methotrexate B.P. with any deter- mined brand of Water for Injec- tions or other solvent	Injection, 50 mg vial (with required solvent)	Injection	5	..	LE
Methotrexate Injection B.P.	Vial, 5 mg in 2 mL Vial, 50 mg in 2 mL	Injection Injection	5 5		FE, LE BL, FE, LE
Methotrexate Tablets B.P.	2.5 mg 10 mg	Oral Oral	100 100	2 2	FE, LE FE
Methsuximide	Capsule, 300 mg	Oral	200	2	PD
Methyclothiazide	Tablet, 2.5 mg Tablet, 5 mg	Oral Oral	100 100	1 1	AB AB
Methyldopa Tablets B.P.	125 mg 250 mg	Oral Oral	100 100	5 5	MK AF, MK, US
Methylphenobarbitone B.P.	Tablet, 60 mg Tablet, 200 mg	Oral Oral	200 200	2 2	WL WL
Methylprednisolone Acetate Injec- tion B.P.	Vial, 40 mg in 1 mL	Injection	5	..	UP
Methylprednisolone Sodium Succinate	Injection, 40 mg (base) in 1 mL amp.	Injection	5	..	UP
Methyl Salicylate Liniment A.P.F.	100 mL	Application	1	1	DH, MG, NN, QE, SI, TO
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Methyltestosterone Tablets B.P.	5 mg 25 mg 50 mg	Oral Oral Oral	100 100 100	2 2 2	PT PT PT
Methysergide Tablets B.P.	1 mg (base)	Oral	100	2	SZ
Metoclopramide Hydrochloride B.P.	Syrup, 5 mg per 5 mL, 100 mL	Oral	1	..	BR
Metoclopramide Injection B.P.	Ampoule, 10 mg in 2 mL	Injection	10	..	BR
Metoclopramide Tablets B.P.	10 mg	Oral	25	..	AF, BR, PT
Metolazone	Tablet, 2.5 mg	Oral	100	1	SR
Metoprolol Tartrate	Tablet, 50 mg Tablet, 100 mg	Oral Oral	100 60	5 5	AP, CG AP, CG
Metronidazole Benzoate	Suspension, 320 mg per 5 mL, 100 mL	Oral	1	..	MB
Metronidazole B.P.	Intravenous infusion, 500 mg in 100 mL	Injection	1	..	BL, MB
Metronidazole Suppositories B.P.	500 mg, 10 1 g, 10		1 1		MB, PT MB
Metronidazole Tablets B.P.	200 mg 250 mg 400 mg 500 mg	Oral Oral Oral Oral	21 21 5 4	1 1 1 1	AF, MB, PT, SR JC AF, MB JC
Mexiletine Hydrochloride Capsules B.P.	50 mg 200 mg	Oral Oral	100 100	5 5	BY BY
Mianserin Hydrochloride Tablets B.P.	10 mg 20 mg	Oral Oral	50 50	5 5	OR OR
Miconazole	Oral gel, 20 mg per mL, 20 g Tincture, 20 mg per mL, 20 mL	Oral Application	1 1	1 1	JC JC
Miconazole Nitrate B.P.	Lotion, 20 mg per g, 20 g Pessaries, 100 mg, 7 Pessaries, 200 mg, 3	Application Application Application	1 1 1 1	1 1	JC CL, JP JC CL, JP CL, JP
Miconazole Nitrate Cream B.P.	20 mg per g, 20 g 20 mg per g, 40 g	Application Application	1 1	1 ..	CL, JP CL, JP
Minocycline Hydrochloride	Capsule, 100 mg	Oral	11	..	LE
Minoxidil	Tablet, 10 mg Tablet, 25 mg	Oral Oral	100 100	5 5	UP UP
Misoprostol	Tablet, 200 micrograms	Oral	120	1	SR

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Mithramycin	Injection, 2.5 mg (with re- quired solvent)	Injection	5	..	PF
Mitozantrone Hydrochloride	Injection, 20 mg (base) in 10 mL vial	Injection	1	..	LE
	Injection, 25 mg (base) in 12.5 mL vial	Injection	1	..	LE
	Injection, 30 mg (base) in 15 mL vial	Injection	1	..	LE
Morphine Sulphate B.P. with Tac- rine Hydrochloride	Tablet, 30 mg-15 mg	Oral	20	..	WH
Morphine Sulphate Injection B.P.	Ampoule, 10 mg in 1 mL	Injection	5	..	BL, BT, SI
	Ampoule, 15 mg in 1 mL	Injection	5	..	BL, BT, SI
	Ampoule, 30 mg in 1 mL	Injection	5	..	BL
Morphine Sulphate Tablets B.P.	30 mg	Oral	20	..	FM
"M.S.U.D. AID"	Powder, 200 g	Oral	5	5	SB
Mustine Hydrochloride B.P. with any determined brand of Water for Injections or other solvent	Injection, 10 mg amp. (with required solvent)	Injection	4	..	BT
Nalidixic Acid Tablets B.P.	500 mg	Oral	56	2	WL
Naloxone Hydrochloride	Injection, 40 micrograms in 2 mL amp.	Injection	5	..	BT
	Injection, 400 micrograms in 1 mL disposable injection set	Injection	1	..	CS
	Injection, 800 micrograms in 2 mL disposable injection set	Injection	1	..	CS
	Injection, 2 mg in 5 mL disposable injection set	Injection	1	..	CS
Nandrolone Decanoate Injection B.P.	Disposable syringe, 50 mg in 1 mL	Injection	1	3	OR
Nandrolone Phenylpropionate Injec- tion B.P.	Ampoule, 25 mg in 1 mL	Injection	3	3	OR
Naphazoline Hydrochloride	Eye drops, 1 mg per mL, 15 mL	Application to the eye	1	2	AG
Naproxen B.P.	Suppository, 500 mg		40	3	SD
Naproxen Tablets B.P.	250 mg	Oral	50	3	AF, SD
	500 mg	Oral	50	3	SD
Neomycin Sulphate Eye Drops B.P.	5 mg per mL, 10 mL	Application to the eye	1	2	SI
Neomycin Tablets B.P.	500 mg	Oral	25	1	PT
Neomycin Undecenoate with Baci- tracin Zinc B.P.	Ear ointment, 12 mg (3.5 mg base)-400 units per g, 10 g	Application to the ear	1	..	HA
Neostigmine Injection B.P.	Ampoule, 500 micrograms in 1 mL	Injection	5	3	RO
	Ampoule, 2.5 mg in 1 mL	Injection	5	3	RO
Neostigmine Tablets B.P.	15 mg	Oral	200	1	RO
Niclosamide Tablets B.P.	500 mg	Oral	4	..	BN
Nicotinic Acid Tablets B.P.	25 mg	Oral	100	2	DH, US
	50 mg	Oral	100	2	DH, RT, SI, US
	100 mg	Oral	100	2	DH, US
Nifedipine	250 mg	Oral	100	2	DH
	Capsule, 5 mg	Oral	100	5	BN
	Capsule, 10 mg	Oral	100	5	AF, BN
	Tablet, 20 mg	Oral	60	5	BN
Nitrazepam Tablets B.P.	5 mg	Oral	25	..	AF, RO
Nitrofurantoin B.P.	Capsule, 50 mg	Oral	30	1	NW
	Capsule, 100 mg	Oral	30	1	NW
Nitrofurantoin Mixture B.P.	25 mg per 5 mL, 200 mL	Oral	1	..	NW
Nitrofurantoin Tablets B.P.	50 mg	Oral	25	1	NW
	100 mg	Oral	25	1	NW

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Norethisterone Acetate B.P.	Tablet, 10 mg	Oral	100	2	SC
Norethisterone B.P. with Ethinyloestradiol B.P.	Pack containing 21 tablets, 500 micrograms-35 micrograms and 7 inert tablets	Oral	4	2	SD
	Pack containing 21 tablets, 1 mg-35 micrograms and 7 inert tablets	Oral	4	2	SD
	Pack containing 12 tablets, 500 micrograms-35 micrograms and 9 tablets, 1 mg-35 micrograms	Oral	4	2	SD
	Pack containing 12 tablets, 500 micrograms-35 micrograms, 9 tablets, 1 mg-35 micrograms and 7 inert tablets	Oral	4	2	SD
	Tablets, 500 micrograms-35 micrograms, 21	Oral	4	2	JC, SD
	Tablets, 1 mg-35 micrograms, 21	Oral	4	2	SD
Norethisterone B.P. with Mestranol B.P.	Pack containing 21 tablets, 1 mg-50 micrograms and 7 inert tablets	Oral	4	2	SD
	Tablets, 1 mg-50 micrograms, 21	Oral	4	2	JC, SD
Norethisterone Tablets B.P.	350 micrograms, 28	Oral	4	2	JC, SD
	5 mg	Oral	30	5	SC
Norflaxacin	Tablet, 400 mg	Oral	14	1	MK
Nortriptyline Hydrochloride B.P.	Elixir, 10 mg per 5 mL, 100 mL	Oral	1	4	DL
Nortriptyline Tablets B.P.	10 mg	Oral	50	2	DL, SQ
	25 mg	Oral	50	2	DL, SQ
"Nutramigen"	Powder, 1 kg	Oral	1	20	MJ
Nystatin B.P.	Capsule, 500,000 units	Oral	50	..	LE, SQ
	Cream, 100,000 units per g, 15 g	Application	1	1	LE, SQ
	Gel, 100,000 units per g, 15 g	Application	1	1	SQ
	Lozenge, 100,000 units	Oral	20	1	LE
	Tablet, 500,000 units	Oral	50	..	LE
	Vaginal cream, 100,000 units per 4 g, 75 g		1	1	SQ
	Vaginal cream, 100,000 units per 5 g, 75 g		1	1	LE
Nystatin Mixture B.P.	100,000 units per mL, 24 mL	Oral	1	1	LE, SQ
Nystatin Ointment B.P.	100,000 units per g, 15 g	Application	1	1	LE, SQ
Nystatin Pessaries B.P.	100,000 units, 15		1	1	LE, SQ
	100,000 units (cream base), 15		1	1	LE
Nystatin Tablets B.P.	500,000 units	Oral	50	..	SQ
"Odorgon"	Liquid, 15 mL		1	..	LA
Oestradiol Valerate	Injection, 10 mg in 1 mL amp.	Injection	3	..	SC
	Tablets, 1 mg, 28	Oral	2	2	SC
	Tablets, 2 mg, 28	Oral	2	2	SC
Oestrogens—Conjugated	Tablets, 300 micrograms, 28	Oral	2	2	AY
	Tablets, 625 micrograms, 28	Oral	2	2	AY
Oestrone B.P.C. 1954	Pessaries, 100 micrograms, 12		1	1	OR
	Pessaries, 1 mg, 12		1	1	OR
Olsalazine Sodium	Capsule, 250 mg	Oral	100	5	PS
Orphenadrine Hydrochloride Tablets B.P.	50 mg	Oral	200	2	RK
Oxazepam Tablets B.P.	15 mg	Oral	25	..	AF, AY, WY
	30 mg	Oral	25	..	AF, AY, WY

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Oxprenolol Hydrochloride B.P. with any determined brand of Water for Injections or other solvent	Injection, 2 mg (with required solvent)	Injection	5	..	CG
Oxprenolol Tablets B.P.	20 mg	Oral	100	5	AF, CG
	40 mg	Oral	100	5	AF, CG
Oxycodone Hydrochloride	Tablet, 5 mg	Oral	20	..	BT
Oxycodone Pectinate	Suppositories, 30 mg (base), 12		1	..	BT
Oxymetholone Tablets B.P.	50 mg	Oral	100	5	SD
	100 mg	Oral	100	5	PD
Oxytocin Injection B.P.	Ampoule, 2 units in 2 mL	Injection	5	..	SZ
	Ampoule, 5 units in 1 mL	Injection	5	..	SZ
	Ampoule, 10 units in 1 mL	Injection	5	..	SZ
Pancreatin B.P.	Capsule, providing not less than 6,500 B.P. units of lipase activity	Oral	500	10	RS
	Tablet, providing not less than 6,500 B.P. units of lipase activity	Oral	500	10	RS
Pancrelipase	Capsule, providing not less than 5,000 B.P. units of lipase activity	Oral	500	10	JC
	Capsule, providing not less than 10,000 B.P. units of lipase activity	Oral	500	10	OR
Papaveretum B.P.C. 1973	Injection, 20 mg in 1 mL amp.	Injection	5	..	RO
Papaveretum B.P.C. 1973 with Hyoscine Hydrobromide B.P.	Injection, 20 mg-400 micrograms in 1 mL amp.	Injection	5	..	RO
Paracetamol B.P.	Mixture, 120 mg per 5 mL, 100 mL	Oral	1	2	BW, WL
Paracetamol Tablets B.P.	500 mg	Oral	100	1	BW, DH, FM, WL
Paraffin, Soft White B.P.	Cream, compound, 85 g	Application	1	..	DY
	Ointment, compound, 70 g	Application	1	..	DY
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Paraffin, Soft White B.P. with Liquid Paraffin B.P.	Eye ointment, compound, 3.5 g	Application to the eye	2	3	AQ
	Eye ointment, compound, 7 g	Application to the eye	2	3	AG
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Penicillamine Tablets B.P.	125 mg	Oral	100	1	DL
	250 mg	Oral	100	1	DL
Perhexiline Maleate	Tablet, 100 mg	Oral	100	5	ML
Pericyazine	Tablet, 2.5 mg	Oral	200	..	MB
	Tablet, 10 mg	Oral	100	1	MB
Pethidine Injection B.P.	Ampoule, 50 mg in 1 mL	Injection	5	..	BL, BT, SI
	Ampoule, 100 mg in 2 mL	Injection	5	..	BL, BT, SI
Pethidine Tablets B.P.	50 mg	Oral	20	..	SI
Phenelzine Tablets B.P.	15 mg	Oral	50	2	WW
Phenethicillin Capsules B.P.	250 mg	Oral	25	1	SI
	500 mg	Oral	25	1	SI
Phenethicillin Potassium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	1	SI
	Powder for syrup, 250 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	..	SI
Phenethicillin Tablets B.P.	250 mg	Oral	25	1	SI
Phenindione Tablets B.P.	10 mg	Oral	100	2	GL
	50 mg	Oral	100	2	GL
Phenobarbitone Injection B.P.	Ampoule, 200 mg in 1 mL	Injection	5	..	FM

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Phenobarbitone Tablets B.P.	30 mg	Oral	200	4	DH, FM, SI
Phenoxybenzamine Capsules B.P.	10 mg	Oral	100	5	SK
Phenoxymethylpenicillin (Benzathine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	1	CS, SI
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	1	CS, SI
Phenoxymethylpenicillin (Hydrabamine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	1	AB
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	1	AB
	Tablet, 125 mg	Oral	25	1	AB
	Tablet, 250 mg	Oral	25	1	AB, CS, LY, SI
Phenoxymethylpenicillin Potassium Capsules B.P.	250 mg	Oral	25	1	CS, SI
	500 mg	Oral	25	1	CS, SI
Phenoxymethylpenicillin Potassium Tablets B.P.	250 mg	Oral	25	1	AB, CS, LY, SI
	500 mg	Oral	25	1	AB, CS, FM, LY
Phensuximide B.P.C. 1973	Capsule, 500 mg	Oral	200	2	PD
Phenylephrine Hydrochloride B.P.	Eye drops, 1.2 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ
	Ointment, compound, 60 g		1	1	RL
	Suppositories, compound, 12		1	1	RL
Phenytoin B.P.	Tablet, 50 mg	Oral	200	2	PD
Phenytoin Capsules B.P.	30 mg	Oral	200	2	PD
	100 mg	Oral	200	2	PD
Phenytoin Mixture B.P.	30 mg per 5 mL, 500 mL	Oral	1	3	PD
Phytomenadione Injection B.P.	Ampoule, 1 mg	Injection	5	..	RO
	Ampoule, 10 mg	Injection	5	..	RO
Pilocarpine	Eye disc, 5 mg (releasing 20 micrograms per hour)	Application to the eye	8	5	PT
	Eye disc, 11 mg (releasing 40 micrograms per hour)	Application to the eye	8	5	PT
	Eye disc, 11 mg (releasing 40 micrograms per hour)	Application to the eye	8	5	PT
Pilocarpine Hydrochloride B.P.	Eye drops, 5 mg per mL, 15 mL	Application to the eye	2	3	AG, AQ, IQ, SI
	Eye drops, 10 mg per mL, 15 mL	Application to the eye	2	3	AG, AQ, IQ, SI
	Eye drops, 20 mg per mL, 15 mL	Application to the eye	2	3	AG, AQ, IQ, SI
	Eye drops, 30 mg per mL, 15 mL	Application to the eye	2	3	AG, AQ, IQ, SI
	Eye drops, 40 mg per mL, 15 mL	Application to the eye	2	3	AG, AQ, IQ, SI
	Eye drops, 60 mg per mL, 15 mL	Application to the eye	2	3	AG, AQ, SI
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Pindolol B.P.	Injection, 400 micrograms in 2 mL amp.	Injection	5	..	SZ
Pindolol Tablets B.P.	5 mg	Oral	100	5	AF, SZ
	15 mg	Oral	50	5	AF, SZ
Piperazine Oestrone Sulphate	Tablets, 730 micrograms, 28	Oral	2	2	AB
	Tablets, 1.46 mg, 28	Oral	2	2	AB
Piroxicam	Capsule, 10 mg	Oral	50	3	PF
Pizotifen Malate	Capsule, 20 mg	Oral	25	3	PF
	Tablet, 500 micrograms (base)	Oral	100	2	SZ
"PK AID I"	Powder, 250 g	Oral	2	5	SB
"PK AID II"	Powder, 250 g	Oral	2	5	SB
Pneumococcal Vaccine, Polyvalent	Injection, 0.5 mL in disposable syringe (17 valent)	Injection	1	..	SK
	Injection, 0.5 mL vial (23 valent)	Injection	1	..	CS

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Manner of adminis- tration	Maxi- mum quantity	Number of repeats	Brand
Polygeline	Intravenous infusion, 17.5 g per 500 mL with Na ⁺ 145 mmol per L, K ⁺ 5.1 mmol per L, Ca ²⁺ 6.25 mmol per L and Cl ⁻ 145 mmol per L; 500 mL	Injection	3	..	HP
Polyisobutylene	Wafers, compound adhesive, pack of 5	Topical	1	5	DY, HO
	Wafers, compound adhesive with discs, pack of 5	Topical	1	5	BH, SQ
Polymyxin B Sulphate B.P. with Bacitracin B.P. 1968 and Neomycin Sulphate B.P.	Eye ointment, 5,000 units-400 units-5 mg per g, 4 g	Application to the eye	1	..	UP
Polymyxin B Sulphate B.P. with Bacitracin Zinc B.P. and Neomycin Sulphate B.P.	Ear drops, 10,000 units-500 units-3.5 mg (base) per mL, 15 mL	Application to the ear	1	..	JC
	Eye ointment, 5,000 units-400 units-5 mg per g, 4 g	Application to the eye	1	..	BW
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Gramicidin	Eye drops, 5,000 units-2.5 mg-25 micrograms per mL, 10 mL	Application to the eye	1	2	BW
Polymyxin B Sulphate B.P. with Neomycin Sulphate B.P. and Hydrocortisone B.P.	Ear drops, 10,000 units-5 mg-10 mg per mL, 7 mL	Application to the ear	1	2	BW
Polyvinyl Alcohol	Eye drops, 14 mg per mL, 15 mL	Application to the eye	2	3	AG
	Eye drops, 30 mg per mL, 15 mL	Application to the eye	2	3	AG
Polyvinyl Alcohol with Povidone B.P.	Eye drops, 14 mg-6 mg per mL, 15 mL	Application to the eye	2	3	AG
Polyvinylpyrrolidone and Vinyl Acetate Copolymer	Spray, aerosol, 60 mg per mL, 121 mL	Application	1	..	EG
"Portagen"	Powder, 450 g	Oral	2	20	MJ
Potassium Chloride B.P.	Elixir, 1.5 g per 15 mL, 500 mL	Oral	2	1	SC
	Tablet, 600 mg (sustained release)	Oral	200	1	AF, CG, PT
Potassium Chloride B.P. with Potassium Bicarbonate Effervescent Tablets	14 mmol K ⁺ and 8 mmol Cl ⁻	Oral	60	1	PT
Pralidoxime Iodide	Injection, 500 mg	Injection	5	..	AB
Prazosin Hydrochloride	Tablet, 1 mg (base)	Oral	100	5	PF
	Tablet, 2 mg (base)	Oral	100	5	PF
	Tablet, 5 mg (base)	Oral	100	5	PF
Prednisolone Acetate	Eye drops, 5 mg per mL, 5 mL	Application to the eye	1	6	AQ
	Injection, 10 mg in 1 mL amp.	Intra-articular injection	5	..	SC
Prednisolone Acetate with Phenylephrine Hydrochloride B.P.	Eye drops, 10 mg-1.2 mg per mL, 10 mL	Application to the eye	1	2	AG
Prednisolone Sodium Phosphate B.P.	Enema, retention, 20 mg in 100 mL	Enema	28	3	GL
	Eye/ear drops, 5 mg per mL, 5 mL	Application to the eye/ear	1	6	GL
	Suppositories, 5 mg (base), 10		3	3	GL
Prednisolone Stearoylglycolate	Tablet, 6.65 mg	Oral	60	1	FE
Prednisolone Tablets B.P.	1 mg	Oral	100	4	PT
	5 mg	Oral	60	4	FM, NN, PT, UP, US
	25 mg	Oral	30	4	FM, PT
Prednisone Tablets B.P.	1 mg	Oral	100	4	PT
	5 mg	Oral	60	4	DH, FM, NN, PT, US

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
	25 mg	Oral	30	4	FM, PT
"Pregestimil"	Powder, 454 g	Oral	2	20	MJ
Primaquine Tablets B.P.	Tablet, equivalent to 7.5 mg Primaquine base	Oral	42	..	IC
Primidone Tablets B.P.	250 mg	Oral	200	2	IC
Probenecid Tablets B.P.	500 mg	Oral	100	5	FR
Probucol	Tablet, 250 mg	Oral	112	5	ML
Procainamide Hydrochloride B.P.	Capsule, 250 mg	Oral	200	1	SQ
	Capsule, 375 mg	Oral	100	2	SQ
Procainamide Injection B.P.	Vial, 100 mg per mL, 10 mL	Injection	2	..	SQ
Procaine Penicillin Injection B.P.	Syringe, disposable, 1 g	Injection	5	..	SI
	Syringe, disposable, 1.5 g	Injection	5	..	SI
Procarbazine Hydrochloride	Capsule, 50 mg	Oral	100	2	RO
Prochlorperazine	Suppositories, 3 mg, equiva- lent to 5 mg Prochlorpera- zine Maleate, 5		1	2	MB
	Suppositories, 15 mg, equiva- lent to 25 mg Prochlorper- azine Maleate, 5		1	2	MB
Prochlorperazine Edisylate	Injection, 12.5 mg in 1 mL	Injection	10	..	SK
Prochlorperazine Injection B.P.	Ampoule, 12.5 mg in 1 mL	Injection	10	..	MB
Prochlorperazine Tablets B.P.	5 mg	Oral	25	..	MB, PT, SK
Procyclidine Tablets B.P.	5 mg	Oral	200	2	BW
Promethazine Hydrochloride Injec- tion B.P.	Ampoule, 50 mg in 2 mL	Injection	10	..	BL
Promethazine Theoclate Tablets B.P.	25 mg	Oral	30	1	MB
Propantheline Tablets B.P.	15 mg	Oral	200	2	PT
Propranolol Injection B.P.	1 mg in 1 mL	Injection	5	..	IC
Propranolol Tablets B.P.	10 mg	Oral	100	5	AF, IC
	40 mg	Oral	100	5	AF, IC, PT
	160 mg	Oral	50	5	AF, IC, PT
Propylthiouracil Tablets B.P.	50 mg	Oral	200	2	JC
Protamine Sulphate Injection B.P.	Ampoule, 10 mg per mL, 10 mL	Injection	6	..	BT
Pyrantel Embonate	Tablet, 125 mg (base)	Oral	6	..	AF
	Tablet, 250 mg (base)	Oral	6	..	AF
Pyridostigmine Tablets B.P.	10 mg	Oral	100	2	RO
	60 mg	Oral	100	2	RO
	180 mg (sustained release)	Oral	100	1	RO
Pyridoxine Hydrochloride B.P.	Injection, 50 mg in 1 mL amp.	Injection	5	1	FM
Pyridoxine Hydrochloride Tablets B.P.	25 mg	Oral	100	..	DH, FM, PT
Pyrimethamine Tablets B.P.	25 mg	Oral	50	..	BW
Quinethazone	Tablet, 50 mg	Oral	100	1	LE
Quinidine Bisulphate B.P.	Tablet, 250 mg (sustained release)	Oral	100	5	AP
Quinidine Sulphate B.P.	Tablet, 300 mg (sustained release)	Oral	100	5	RS
Quinidine Sulphate Tablets B.P.	200 mg	Oral	100	5	BW, DH, NN, PT, QE
Quinine Bisulphate Tablets B.P.	300 mg	Oral	50	2	AF, DH, FM, NN, PT, SI, US
Quinine Sulphate Tablets B.P.	300 mg	Oral	50	2	AF, DH, FM, NN, PT, SI, US
Ranitidine Hydrochloride	Tablet, 150 mg (base)	Oral	60	2	GL
	Tablet, 300 mg (base)	Oral	30	1	GL
Red-back Spider Antivenom	Injection, 500 units amp.	Injection	2	..	CS
Rifampicin B.P.	Capsule, 150 mg	Oral	10	..	AF
	Capsule, 300 mg	Oral	10	..	AF

Name of Pharmaceutical Benefit	Form (strength, type, size, etc.)	Manner of adminis- tration	Maxi- mum quantity	Number of repeats	Brand
Rolitetraacycline	Injection, 275 mg amp. and 10 mL solvent	I.V. injection	5	..	HP
	Injection, 350 mg amp. and 2 mL solvent	I.M. injection	5	..	HP
Salbutamol B.P.	Spray, metered aerosol, 100 micrograms per dose, 200 doses, 17 g	Inhalation by mouth	2	5	GL
Salbutamol Sulphate B.P.	Capsule, 200 micrograms (base)	Inhalation by mouth	100	5	GL
	Solution, 2.5 mg (base) in 2.5 mL ampoules, 30	Inhalation	1	5	GL
	Solution, 5 mg (base) in 2.5 mL ampoules, 30	Inhalation	1	5	GL
	Solution, 5 mg (base) per mL, 30 mL	Inhalation	2	2	GL, RK
	Spray, metered aerosol, 100 micrograms (base) per dose, 200 doses, 13.5 g	Inhalation by mouth	2	5	RK
	Spray, metered aerosol, 100 micrograms (base) per dose, 400 doses, 13.5 g	Inhalation by mouth	1	5	RK
	Syrup, 2 mg (base) per 5 mL, 300 mL	Oral	1	5	GL
Salbutamol Tablets B.P.	4 mg	Oral	100	5	GL
Salcatonin Injection B.P.	50 I.U. in 1 mL amp., 5	Injection	6	5	SZ
	80 I.U. in 0.8 mL amp., 5	Injection	3	5	SZ
	100 I.U. in 1 mL amp., 5	Injection	3	5	RG, SZ
	400 I.U. in 2 mL vial	Injection	4	5	RG
Semisodium Valproate	Tablet, 135 mg (enteric coated)	Oral	200	2	AB
	Tablet, 269 mg (enteric coated)	Oral	200	2	AB
	Tablet, 538 mg (enteric coated)	Oral	200	2	AB
Silver Sulphadiazine with Chlorhexidine Gluconate	Cream, 10 mg-2 mg per g, 50 g	Application	1	..	SN
	Cream, 10 mg-2 mg per g, 100 g	Application	1	..	SN
	Cream, 10 mg-2 mg per g, 500 g	Application	1	..	SN
Sodium Acid Citrate B.P.	Mixture, 5.5 g per 20 mL, 500 mL	Oral	1	4	PD
Sodium Acid Phosphate B.P.	Tablet, compound effervescent, equivalent to 500 mg phosphorus	Oral	100	5	SZ
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Sodium Aurothiomalate Injection B.P.	Ampoule, 10 mg	Injection	5	..	MB
	Ampoule, 20 mg	Injection	10	1	MB
	Ampoule, 50 mg	Injection	10	1	MB
Sodium Bicarbonate Intravenous Infusion B.P.	100 mmol in 100 mL	Injection	5	..	AB
Sodium Chloride and Glucose Intravenous Infusion B.P.	31 mmol-222 mmol per L, 1 L	Injection	5	1	AB, BX, KM
	19 mmol-104 mmol per 500 mL, 500 mL	Injection	5	1	AB, BX
	39 mmol-69 mmol per 500 mL, 500 mL	Injection	5	1	AB, BX
	154 mmol-278 mmol per L, 1 L	Injection	2	1	AB, BX
Sodium Chloride B.P. with Potassium Chloride B.P. and Calcium Chloride B.P. in Water for Injections	Sodium Chloride Compound Injection—1 L	Injection	4	1	AB, BX
Sodium Chloride B.P. with Sodium Acetate B.P., Sodium Gluconate, Potassium Chloride B.P. and Magnesium Chloride B.P.	Electrolyte Replacement Solution, 5.26 g-3.68 g-5.02 g-370 mg-300 mg per L, 1 L	Injection	2	1	AB, BX

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Sodium Chloride Intravenous Infusion B.P.	Ampoule, 9 mg per mL, 2 mL	Injection	5	1	AP, BT
	Ampoule, 9 mg per mL, 5 mL	Injection	5	1	AP, BT
	Ampoule, 9 mg per mL, 10 mL	Injection	5	1	AP, BT
	154 mmol per L, 1 L	Injection	5	1	AB, BX, KM
Sodium Citro-Tartrate	513 mmol per L, 1 L	Injection	2	1	BX
	Granules, effervescent, 100 g	Oral	1	4	AB, PT
Sodium Cromoglycate B.P.	Eye drops, 20 mg per mL, 10 mL	Application to the eye	1	5	FC
	Nebuliser solution, 20 mg per 2 mL, ampoule	Inhalation	120	3	FC
	Spray, metered aerosol, 1 mg per dose, 200 doses, 13.87 g	Inhalation by mouth	1	5	FC
	Capsule, 20 mg	Inhalation by mouth	100	5	FC
Sodium Cromoglycate Insufflation B.P.					
Sodium Fusidate B.P.	Tablet, 250 mg (enteric coated)	Oral	36	..	SK
Sodium Lactate Compound Intravenous Infusion B.P.	1 L	Injection	5	1	AB, BX, KM
Sodium Lactate Compound Intravenous Infusion B.P. with Anhydrous Glucose B.P.	278 mmol per L, 1 L	Injection	2	1	AB, BX
Sodium Nitroprusside B.P.	Infusion, 50 mg	Injection	10	..	RO
Sodium Valproate B.P.	Oral liquid, 200 mg per 5 mL, 200 mL	Oral	3	2	RC
	Tablet, 200 mg (enteric coated)	Oral	200	2	RC
	Tablet, 500 mg (enteric coated)	Oral	200	2	RC
	Tablet, crushable, 100 mg	Oral	200	2	RC
	200 mg per 5 mL, 200 mL	Oral	3	2	RC
Sodium Valproate Elixir B.P.					
Sotalol Hydrochloride	Tablet, 160 mg	Oral	60	5	AP
Spectinomycin Hydrochloride B.P.	Injection, 2 g (base) with 3.2 mL diluent	Injection	1	..	UP
	Injection, 4 g (base) with 6.5 mL diluent	Injection	1	..	UP
Spironolactone Tablets B.P.	25 mg	Oral	100	5	SR
Staphylococcus Toxoid B.P. 1968	Injection, 5 mL (diluted 1 in 10)	Injection	1	..	CS
	Injection, 5 mL (undiluted)	Injection	1	..	CS
Sterculia B.P.	Discs, 12		1	5	BH
	Discs, compound, 10		1	5	DY
	Paste, 127.6 g		1	..	HO
	Powder, 71 g		1	..	DY
	Squares, 6		1	5	BH
Sterculia B.P. with Frangula Bark B.P.	Granules, 473 mg-83 mg per g, 250 g	Oral	2	1	SC
Streptokinase B.P. with any determined brand of Water for Injections or other solvent	Injection, 100,000 I.U. (with required solvent)	Injection	2	..	PS
	Injection, 250,000 I.U. (with required solvent)	Injection	2	..	HP, PS
	Injection, 600,000 I.U. (with required solvent)	Injection	5	..	PS
	Injection, 750,000 I.U. (with required solvent)	Injection	5	..	HP
Sucralfate	Tablet, 1 g	Oral	120	2	BT
Sulindac Tablets B.P.	100 mg	Oral	50	3	FR
Sulphacetamide Sodium B.P.	Eye drops, 100 mg per mL, 15 mL	Application to the eye	1	2	AG, SI
	Eye drops, 200 mg per mL, 15 mL	Application to the eye	1	2	SI
Sulphadimidine Tablets B.P.	500 mg	Oral	40	2	PT

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Sulphafurazole B.P.	Eye drops, 40 mg per mL, 10 mL	Application to the eye	1	2	RO
Sulphamethizole Tablets B.P.	500 mg	Oral	40	2	WW
	1 g	Oral	20	2	WW
Sulphasalazine	Tablet, 500 mg	Oral	200	5	AF, PS
	Tablet, 500 mg (enteric coated)	Oral	200	5	PS
Sulphinpyrazone Tablets B.P.	100 mg	Oral	100	5	CG
Sulthiame Tablets B.P.	50 mg	Oral	200	2	BN
	200 mg	Oral	200	2	BN
"Super Banish"	Liquid, 7.5 mL		1	..	DY
Surgical Cement	Skin Bond Adhesive, 118 mL	Application	1	2	DY
Surgical Cement Solvent	227 mL	Application	1	2	DY
	240 mL	Application	1	2	EG
	250 mL	Application	1	2	EG
Tamoxifen Citrate Tablets B.P.	10 mg (base)	Oral	60	5	IC
	20 mg (base)	Oral	60	5	IC
Temazepam	Capsule, 10 mg	Oral	25	..	AF, SI, WY
Terbutaline Sulphate B.P.	Elixir, 300 micrograms per mL, 300 mL	Oral	1	5	AP
	Injection, 100 micrograms in 1 mL amp.	Injection	5	..	AP
	Injection, 500 micrograms in 1 mL amp.	Injection	5	..	AP
	Nebuliser solution, 10 mg per mL, 50 mL	Inhalation	1	5	AP
	Spray, metered aerosol, 250 micrograms per dose, 400 doses, 14 g	Inhalation by mouth	1	5	AP
Terbutaline Sulphate Tablets B.P.	5 mg	Oral	100	5	AP
Testosterone Enanthate B.P.	Injection, 250 mg in 1 mL amp.	Injection	3	3	SC
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P. and Testosterone Isocaproate B.P.	Injection, 20 mg-40 mg-40 mg amp.	Injection	3	3	OR
Testosterone Propionate B.P. with Testosterone Phenylpropionate B.P., Testosterone Isocaproate B.P. and Testosterone Decanoate B.P.	Injection, 30 mg-60 mg-60 mg-100 mg amp.	Injection	3	3	OR
Testosterone Propionate Injection B.P.	Ampoule, 50 mg in 1 mL	Injection	9	..	SC
Tetanus Vaccine, Adsorbed B.P.	Injection, 0.5 mL amp.	Injection	3	..	CS
Tetrabenazine	Tablet, 25 mg	Oral	100	2	RO
Tetracosactrin Zinc Injection B.P.	Ampoule, 500 micrograms in 1 mL	Injection	5	5	CG
	Ampoule, 1 mg in 1 mL	Injection	5	5	CG
Tetracycline B.P. with a buffering agent	Capsule, 250 mg	Oral	25	1	AP, CS, FM, HP, LE, SQ
Tetracycline B.P. with a buffering agent and Nystatin B.P.	Capsule, 250 mg-250,000 units	Oral	25	1	SQ
Tetracycline Capsules B.P.	250 mg	Oral	25	1	BZ, LE, UP
Tetracycline Hydrochloride B.P.	Eye ointment, 10 mg per g, 5 g	Application to the eye	1	..	BZ
Tetracycline Hydrochloride B.P. with Nystatin B.P.	Capsule, 250 mg-250,000 units	Oral	25	1	AP, LE
Theophylline B.P.	Capsule, 50 mg (containing sustained release beads)	Oral	100	5	RG, RK
	Capsule, 100 mg (containing sustained release beads)	Oral	100	5	RG, RK
	Capsule, 100 mg (controlled release)	Oral	100	5	FC

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
	Capsule, 250 mg (controlled release)	Oral	100	5	FC
	Elixir, 80 mg per 15 mL, 500 mL	Oral	1	5	SC
	Syrup, 80 mg per 15 mL, 500 mL	Oral	1	5	RK
	Tablet, 50 mg	Oral	100	5	RK
	Tablet, 125 mg	Oral	100	5	RK
	Tablet, 200 mg	Oral	100	5	RK
	Tablet, 200 mg (sustained release)	Oral	100	5	AP
	Tablet, 250 mg (sustained release)	Oral	100	5	RK
	Tablet, 300 mg (sustained release)	Oral	100	5	AP
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Thiabendazole Tablets B.P.	500 mg	Oral	16	..	MK
Thiamine Hydrochloride Injection B.P.	Ampoule, 100 mg in 1 mL	Injection	5	1	FM
Thiamine Hydrochloride Tablets B.P.	100 mg	Oral	100	2	FM, NN, US
Thiethylperazine Malate	Injection, 6.5 mg (base) in 1 mL amp.	Injection	10	..	SZ
Thiethylperazine Maleate	Tablet, 6.5 mg (base)	Oral	50	..	SZ
	Suppositories, 6.5 mg (base), 6		1	2	SZ
Thioguanine Tablets B.P.	40 mg	Oral	25	1	BW
Thiopropazate Hydrochloride Tablets B.P.	5 mg	Oral	200	..	SR
Thioridazine Hydrochloride B.P.	Solution, 30 mg per mL, 30 mL	Oral	2	2	SZ
Thioridazine Tablets B.P.	10 mg	Oral	200	..	AF, SZ
	25 mg	Oral	200	..	AF, SZ
	50 mg	Oral	200	..	AF, SZ
	100 mg	Oral	100	1	AF, SZ
Thiotepa B.P. with any determined brand of Water for Injections or other solvent	Eye drops, set, 15 mg with required solvent	Application to the eye	1	5	LE
	Injection, 15 mg (solvent required)	Injection	2	1	LE
Thyroxine Tablets B.P.	50 micrograms	Oral	200	1	BW
	100 micrograms	Oral	200	1	BW
	200 micrograms	Oral	200	1	BW
Ticarcillin Sodium with any determined brand of Water for Injections or other solvent	Injection, vial containing equivalent 1 g Ticarcillin (with required solvent)	Injection	10	..	BR, CS
	Injection, vial containing equivalent 3 g Ticarcillin (with required solvent)	Injection	10	..	BR, CS
Timolol Maleate Eye Drops B.P.	2.5 mg per mL, 5 mL	Application to the eye	1	6	FR, SI
	5 mg per mL, 5 mL	Application to the eye	1	6	FR, SI
Timolol Maleate Tablets B.P.	5 mg	Oral	100	5	FR
Tinidazole	Tablet, 500 mg	Oral	4	..	PF
Tobramycin B.P.	Eye drops, 3 mg per mL, 5 mL	Application to the eye	1	2	AQ
	Eye ointment, 3 mg per g, 3.5 g	Application to the eye	1	..	AQ
Tobramycin Injection B.P.	40 mg	Injection	5	..	LY
	80 mg	Injection	5	..	LY
Tolazamide Tablets B.P.	250 mg	Oral	100	5	UP
Tolbutamide Tablets B.P.	500 mg	Oral	200	2	HP
	1 g	Oral	100	5	HP
Tranexamic Acid Tablets B.P.	500 mg	Oral	100	2	PS
Tranylcypromine Tablets B.P.	10 mg	Oral	50	2	SK

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Triamcinolone Acetonide B.P.	Injection, 10 mg in 1 mL amp.	Injection	5	..	SQ
Triamcinolone Acetonide B.P. with Neomycin Sulphate B.P., Gramicidin and Nystatin B.P.	Ear cream, 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g, 5 g	Application to the ear	1	2	SQ
	Ear drops, 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g, 7.5 mL	Application to the ear	1	2	SQ
	Ear ointment, 1 mg-2.5 mg (base)-250 micrograms-100,000 units per g, 5 g	Application to the ear	1	2	SQ
Triamcinolone Acetonide Cream B.P.	200 micrograms per g, 45 g	Application	1	..	SQ
	200 micrograms per g, 100 g	Application	2	..	LE, SQ
	500 micrograms per g, 15 g	Application	1	1	LE, SQ
Triamcinolone Acetonide Ointment B.P.	200 micrograms per g, 45 g	Application	1	..	SQ
	200 micrograms per g, 100 g	Application	2	..	LE, SQ
	500 micrograms per g, 15 g	Application	1	1	LE, SQ
Triamterene B.P.	Tablet, 100 mg	Oral	100	1	SK
Trifluoperazine Hydrochloride B.P.	Injection, 1 mg (base) in 1 mL amp.	Injection	10	..	SK
Trifluoperazine Hydrochloride Tablets B.P.	1 mg	Oral	200	..	PT, SK
	2 mg	Oral	200	..	PT, SK
	5 mg	Oral	100	1	PT, SK
Triglycerides Oil, Medium Chain	1 L	Oral	1	5	KY
Trimethoprim Tablets B.P.	300 mg	Oral	7	1	AF, BW
Trimipramine	Capsule, 50 mg	Oral	50	2	MB
Trimipramine Tablets B.P.	25 mg (base)	Oral	50	2	MB
Trioxysalen	Tablet, 5 mg	Oral	100	2	PT
Urea Cream B.P.	100 mg per g, 100 g	Application	1	2	AG, HA, NW, OL, PS
Vancomycin Hydrochloride B.P.	Capsule, 125 mg (125,000 I.U.) vancomycin activity	Oral	40	..	LY
	Capsule, 250 mg (250,000 I.U.) vancomycin activity	Oral	40	..	LY
Vancomycin Hydrochloride B.P. with any determined brand of Water for Injections or other solvent	Injection, 500 mg (500,000 I.U.) vancomycin activity (with required solvent)	Injection	5	..	LY
Vasopressin Tannate	Injection, (oily) 5 units in 1 mL amp.	Injection	10	1	PD
Verapamil Hydrochloride B.P.	Tablet, 40 mg	Oral	100	5	KN, SC
	Tablet, 80 mg	Oral	100	5	KN, SC
Verapamil Hydrochloride Injection B.P.	Ampoule, 5 mg in 2 mL	Injection	5	..	KN, SC
Verapamil Hydrochloride Tablets B.P.	40 mg	Oral	100	5	AF, PT, US
	80 mg	Oral	100	5	AF, PT, US
	120 mg	Oral	100	5	KN, PT, SC, US
	160 mg	Oral	60	5	KN, SC
Vidarabine	Eye ointment, 30 mg per g, 3.5 g	Application to the eye	1	..	PD
Vinblastine Sulphate B.P.	Injection, 10 mg and 10 mL solvent	Injection	2	..	BL
Vinblastine Sulphate B.P. with any determined brand of Water for Injections or other solvent	Injection, 10 mg (with required solvent)	Injection	2	..	LY
Vincristine Sulphate B.P.	Injection, 1 mg and 10 mL solvent	Injection	5	..	BL, LY
	Injection, 5 mg and 10 mL solvent	Injection	1	..	BL
Warfarin Tablets B.P.	1 mg	Oral	50	2	BT, GL
	2 mg	Oral	50	2	BT

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
	2.5 mg	Oral	50	2	BT
	3 mg	Oral	50	2	GL
	5 mg	Oral	50	2	BT, GL
	7.5 mg	Oral	50	2	BT
	10 mg	Oral	50	2	BT
Water for Injections B.P.	Ampoule, 2 mL	Injection	5	3	AP, BT, BZ, SI
	Ampoule, 5 mL	Injection	5	3	AP, BT, BZ, SI
	Ampoule, 10 mL	Injection	5	3	AP, BT, BZ, SI
Wool Alcohols Ointment B.P.	100 g		1	1	SN
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Zinc Oxide B.P.	Ointment, compound, 50 g		1	1	WW
	Suppositories, compound, 12		1	1	WW
	Forms specified in Sch. 2		Sch. 2	Sch. 2	
Zinc Sulphate B.P. with Phenylephrine Hydrochloride B.P.	Eye drops, 2.5 mg-1.2 mg per mL, 15 mL	Application to the eye	1	2	AG, AQ

FIRST SCHEDULE—PART 2

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Purposes</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Acyclovir	Tablets, 200 mg, 90	In compliance with authority procedures set out in sub-paragraph 10 (d): Moderate to severe recurrent (more than ten attacks per year) genital herpes, confirmed by appropriate microbiological technique Suppression of genital herpes in severely immunocompromised patients	Oral	1	2	BW
Bromocriptine Mesylate Tablets B.P.	2.5 mg (base)	In compliance with authority procedures set out in sub-paragraph 10 (d): Acromegaly, prior to surgery or radiotherapy or where surgery or radiotherapy is inappropriate Parkinson's disease Pathological hyperprolactinaemia where appropriate surgery or radiotherapy is not indicated or has already been used with incomplete resolution	Oral	60	5	SZ
Codeine Phosphate B.P. with Aspirin B.P.	Tablet, 30 mg- 325 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain not responding to non-narcotic analgesics	Oral	40	..	BW
Codeine Phosphate B.P. with Paracetamol B.P.	Tablet, 30 mg- 500 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain not responding to non-narcotic analgesics	Oral	40	..	WL
Diazepam B.P.	Syrup, 2 mg per 5 mL, 100 mL	In compliance with authority procedures set out in sub-paragraph 10 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Oral	2	..	RO
Diazepam Injection B.P.	10 mg in 2 mL	In compliance with authority procedures set out in sub-paragraph 10 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal Malignant neoplasia (late stage)	Injection	10	..	BL, RO

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Purposes</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Diazepam Tablets B.P.	2 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	Oral	100	..	AF, PT, RO, SU
	5 mg	Malignant neoplasia (late stage) In compliance with authority procedures set out in sub-paragraph 10 (d): Disabling spasticity For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	Oral	100	..	AF, PT, RO, SU
Doxycycline Capsules B.P.	100 mg	Urethritis	Oral	21	..	PT
Doxycycline Hydrochloride B.P.	Capsule, 100 mg (base) (containing enteric coated pellets)	Urethritis	Oral	21	..	FA
	Tablet, 100 mg (base)	Urethritis	Oral	21	..	AF, PF
Hydrocortisone Sodium Succinate B.P.	Injection set containing equivalent of 100 mg Hydrocortisone and 2 mL solvent	For use in a hospital	Injection	6	..	NR, UP
	Injection set containing equivalent of 250 mg Hydrocortisone and 2 mL solvent	For use in a hospital	Injection	6	..	UP
Medroxyprogesterone Acetate B.P.	Tablet, 10 mg	Endometriosis	Oral	100	2	UP
Methadone Injection B.P.	Ampoule, 10 mg in 1 mL	In compliance with authority procedures set out in sub-paragraph 10 (d):	Injection	10	..	BW

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Purposes</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Methadone Tablets B.P.	5 mg	Severe disabling pain associated with proven malignant neoplasia	Oral	40	..	BW
		Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)				
	10 mg	In compliance with authority procedures set out in sub-paragraph 10 (d):	Oral	40	..	BW
		Severe disabling pain associated with proven malignant neoplasia				
Metronidazole Tablets B.P.	400 mg	Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	21	1	AF, MB
		Treatment of anaerobic infections				
Morphine Sulphate Tablets B.P.	30 mg	In compliance with authority procedures set out in sub-paragraph 10 (d):	Oral	40	..	FM
		Severe disabling pain associated with proven malignant neoplasia				
Niclosamide Tablets B.P.	500 mg	Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	16	..	BN
		Hymenolepiasis nana				
Nitrazepam Tablets B.P.	5 mg	In compliance with authority procedures set out in sub-paragraph 10 (d):	Oral	50	5	AF, RO
		For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal				
Oxazepam Tablets B.P.	15 mg	Myoclonic epilepsy	Oral	50	5	AF, AY, WY
		In compliance with authority procedures set out in sub-paragraph 10 (d):				
	30 mg	For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	Oral	50	5	AF, AY, WY
		In compliance with authority procedures set out in sub-paragraph 10 (d):				

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Purposes</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
		For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal				
Oxycodone Hydrochloride	Tablet, 5 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)	Oral	40	..	BT
Oxycodone Pectinate	Suppositories, 30 mg (base), 12	In compliance with authority procedures set out in sub-paragraph 10 (d): Severe disabling pain associated with proven malignant neoplasia Severe disabling pain where treatment is initiated in a hospital (in-patient or out-patient)		2	..	BT
Pethidine Injection B.P.	Ampoule, 50 mg in 1 mL	In compliance with authority procedures set out in sub-paragraph 10 (d): Late stage malignant neoplasia	Injection	10	..	BL, BT, SI
	Ampoule, 100 mg in 2 mL	In compliance with authority procedures set out in sub-paragraph 10 (d): Late stage malignant neoplasia	Injection	10	..	BL, BT, SI
Phenethicillin Capsules B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	SI
Phenethicillin Tablets B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	SI
Phenoxymethylpenicillin (Hydrabamine Salt)	Tablet, 125 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB
Phenoxymethylpenicillin Potassium Capsules B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB, CS, LY, SI
Phenoxymethylpenicillin Potassium Tablets B.P.	250 mg	Prophylaxis of recurrent streptococcal infections (including rheumatic fever)	Oral	50	5	AB, CS, LY, SI
Prochlorperazine Tablets B.P.	5 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Emesis associated with malignant disease Rotational vertigo	Oral	100	5	MB, PT, SK
Rifampicin B.P.	Capsule, 150 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Leprosy in adults	Oral	100	..	AF
	Capsule, 300 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): Leprosy in adults	Oral	100	..	AF

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Purposes</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Temazepam	Capsule, 10 mg	In compliance with authority procedures set out in sub-paragraph 10 (d): For use by patients receiving long-term nursing care in hospitals and nursing homes who have been demonstrated, within the past six months, to be benzodiazepine dependent by an unsuccessful attempt at gradual withdrawal	Oral	50	5	AF, SI, WY
Tetracycline B.P with a buffering agent	Capsule, 250 mg	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	AP, CS, FM, HP, LE, SQ
Tetracycline B.P with a buffering agent and Nystatin B.P.	Capsule, 250 mg-250,000 units	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	SQ
Tetracycline Capsules B.P.	250 mg	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	BZ, LE, UP
Tetracycline Hydrochloride B.P. with Nystatin B.P.	Capsule, 250 mg-250,000 units	Bronchiectasis in patients over the age of 8 years Chronic bronchitis in patients over the age of 8 years Severe acne	Oral	50	5	AP, LE

SECOND SCHEDULE

<i>Form of Pharmaceutical Benefit</i>	<i>Maximum quantity</i>	<i>Number of repeats</i>
Creams	100 g	1
Ear Drops	15 mL	2
Elixirs	100 mL	4
Eye Drops		
Cocaine	15 mL	..
Pilocarpine	15 mL	6
Others	15 mL	6
Eye Lotions	200 mL	1
Gargles	200 mL	4
Glycerins	100 mL	1
Inhalations	50 mL	1
Inhalations, Solid	4 g	1
Linctuses	100 mL	2
Liniments	100 mL	1
Lotions	200 mL	2
Mixtures	200 mL	4
Mixtures for Children	100 mL	4
Mouth Washes	200 mL	1
Nasal Instillations	15 mL	2
Ointments and Waxes	100 g	1
Paints	25 mL	1
Pastes		
Cocaine	25 g	..
Others	100 g	1
Powders, Dusting	100 g	1
Powders for Internal Use	100 g	2
Powders, Irrigation	100 g	1
Soaps	200 mL	1
Solutions	200 mL	2
Syrups	100 mL	4
Tinctures	25 mL	1

THIRD SCHEDULE

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Amoxycillin Capsules B.P.	250 mg (base)	Oral	20	..	AF, BR, CS, PT, SI
	500 mg (base)	Oral	20	..	AF, BR, CS, PT, SI
Amoxycillin Trihydrate B.P.	Tablet, chewable, 250 mg (base)	Oral	20	..	BR, CS
	Tablet, dispersible, 3 g (base)	Oral	1	..	BR, CS
Amoxycillin Trihydrate B.P. with Purified Water B.P.	Powder for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS, PT, SI
	Powder for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	BR, CS, PT, SI
Amphotericin B.P.	Lozenge, 10 mg	Oral	20	..	SQ
	Ointment, 30 mg per g, 15 g	Application	1	..	SQ
Ampicillin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 250 mg (base) vial (with required solvent)	Injection	5	..	CS, PT
	Injection, 500 mg (base) vial (with required solvent)	Injection	5	..	BR, CS, PT
	Injection, 1 g (base) vial (with required solvent)	Injection	5	..	CS, PT
Aspirin Mixture A.P.F. 13 with Codeine Phosphate B.P.	Mixture, 500 mg-30 mg per 10 mL	Oral	200 mL	..	
Benzylpenicillin Potassium B.P. with any determined brand of Water for Injections or other solvent	Injection, 300 mg vial (with required solvent)	Injection	5	..	CS
	Injection, 600 mg vial (with required solvent)	Injection	5	..	CS
	Injection, 3 g vial (with required solvent)	Injection	5	..	CS
Cephalexin B.P. with Purified Water B.P.	Granules for syrup, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	GL, LY
	Granules for syrup, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	GL, LY
Cephalexin Capsules B.P.	250 mg	Oral	20	..	GL, LY
	500 mg	Oral	20	..	GL, LY
Cephalothin Sodium B.P. with any determined brand of Water for Injections or other solvent	Injection, 1 g (base) (with required solvent)	Injection	5	..	GL, LY
	Injection, 2 g (base) (with required solvent)	Injection	1	..	LY
	Injection, 4 g (base) (with required solvent)	Injection	1	..	LY
Codeine Phosphate B.P. with Aspirin B.P.	Tablet, 30 mg-325 mg	Oral	20	..	BW
Codeine Phosphate B.P. with Paracetamol B.P.	Tablet, 30 mg-500 mg	Oral	20	..	WL
Co-trimoxazole Mixture, Paediatric B.P.	40 mg-200 mg per 5 mL, 100 mL	Oral	1	..	AF, BW, PT, RO
Co-trimoxazole Tablets B.P.	80 mg-400 mg	Oral	10	..	AF, BW, PT, RO
	160 mg-800 mg	Oral	10	..	AF, BW, PT, RO
Doxycycline Capsules B.P.	100 mg	Oral	7	..	PT
Doxycycline Hydrochloride B.P.	Capsule, 100 mg (base) (containing enteric coated pellets)	Oral	7	..	FA
Erythromycin B.P.	Tablet, 100 mg (base)	Oral	7	..	AF, PF
	Capsule, 125 mg (containing enteric coated pellets)	Oral	25	..	FA
	Capsule, 250 mg (containing enteric coated pellets)	Oral	25	..	FA, LY
Erythromycin Estolate B.P.	Drops, paediatric, 100 mg (base) per mL, 10 mL	Oral	1	..	LY
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	LY
Erythromycin Ethyl Succinate B.P.	Tablet, chewable, 200 mg (base)	Oral	25	..	AB
	Tablet, 400 mg (base)	Oral	25	..	AB
Erythromycin Ethyl Succinate B.P. with Purified Water B.P.	Granules for suspension, 200 mg (base) per 5 mL, 100 mL	Oral	1	..	AB

<i>Name of Pharmaceutical Benefit</i>	<i>Form (strength, type, size, etc.)</i>	<i>Manner of adminis- tration</i>	<i>Maxi- mum quantity</i>	<i>Number of repeats</i>	<i>Brand</i>
Erythromycin Stearate B.P.	Capsule, 250 mg (base)	Oral	25	..	AB
	Suspension, 125 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
	Suspension, 250 mg (base) per 5 mL, 100 mL	Oral	1	..	AB
Erythromycin Stearate Tablets B.P.	250 mg (base)	Oral	25	..	AB
Erythromycin Tablets B.P.	250 mg	Oral	25	..	AB, UP
Metronidazole Tablets B.P.	200 mg	Oral	21	..	AF, MB, PT, SR
Nystatin B.P.	250 mg	Oral	21	..	JC
	Lozenge, 100,000 units	Oral	20	..	LE
	Tablet, 500,000 units	Oral	25	..	LE
Nystatin Mixture B.P.	100,000 units per mL, 24 mL	Oral	1	..	LE, SQ
Nystatin Tablets B.P.	500,000 units	Oral	25	..	SQ
Paracetamol B.P.	Mixture, 120 mg per 5 mL, 100 mL	Oral	1	..	BW, US, WL
Phenethicillin Capsules B.P.	250 mg	Oral	25	..	SI
	500 mg	Oral	25	..	SI
Phenethicillin Potassium B.P. with Purified Water B.P.	Powder for syrup, 125 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	..	SI
	Powder for syrup, 250 mg (Phenethicillin) per 5 mL, 100 mL	Oral	1	..	SI
Phenethicillin Tablets B.P.	250 mg	Oral	25	..	SI
Phenoxymethylpenicillin (Benzathine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	..	CS, SI
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	..	CS, SI
Phenoxymethylpenicillin (Hydraba- mine Salt)	Suspension, 125 mg per 5 mL, 100 mL	Oral	1	..	AB
	Suspension, 250 mg per 5 mL, 100 mL	Oral	1	..	AB
	Tablet, 125 mg	Oral	25	..	AB
Phenoxymethylpenicillin Potassium Capsules B.P.	250 mg	Oral	25	..	AB, CS, LY, SI
	500 mg	Oral	25	..	CS, SI
Phenoxymethylpenicillin Potassium Tablets B.P.	250 mg	Oral	25	..	AB, CS, LY, SI
	500 mg	Oral	25	..	AB, CS, FM, LY
Procaine Penicillin Injection B.P.	Syringe, disposable, 1 g	Injection	5	..	SI
	Syringe, disposable, 1.5 g	Injection	5	..	SI
Sulphadimidine Tablets B.P.	500 mg	Oral	40	..	PT
Tetracycline B.P. with a buffering agent	Capsule, 250 mg	Oral	25	..	AP, CS, FM, HP, LE, SQ
Tetracycline Capsules B.P.	250 mg	Oral	25	..	BZ, LE, UP
Water for Injections B.P.	Ampoule, 2 mL	Injection	5	..	AP, BT, BZ, SI
	Ampoule, 5 mL	Injection	5	..	AP, BT, BZ, SI
	Ampoule, 10 mL	Injection	5	..	AP, BT, BZ, SI

Dated this 16th day of November 1988.

JOHN DEEBLE

Acting First Assistant Secretary
Health Benefits Division

Delegate of the Minister of State for Community Services and Health

N.N.—8852513

Industrial Relations

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

NOTICE OF APPLICATION DECLARE THE ACTORS (THEATRICAL) AWARD 1981 AS VARIED TO DATE, A COMMON RULE IN THE NORTHERN TERRITORY

(C No. 22679 of 1988)

Notice is hereby given that at 2.15 p.m. on 5 December 1988 at CML Building, University Ave, Canberra, ACT the Australian Conciliation and Arbitration Commission will hear an application by Actors Equity of Australia to declare the award known as the Actors (Theatrical) Award 1981 as varied to date, a Common Rule of the industry covered by the said award namely actors in the live entertainment industry in the Northern Territory.

A copy of the said award as varied to date may be inspected free of charge at the Office of the Industrial Registrar, 80 Collins St, Melbourne Vic.; the Office of the Deputy Industrial Registrar, 50 Grenfell St, Adelaide, South Australia; the Office of the Deputy Industrial Registrar, University Ave, Canberra, Australian Capital Territory; the Office of the Deputy Industrial Registrar, 1 Briggs St Darwin.

Compliance with Regulation 35 is not required.

Persons and organisations not appearing or represented will be bound by any order or declaration made by the Commission in the matter.

Dated this sixteenth day of November 1988.

L. J. SOETENS
Deputy Industrial Registrar

N.N.—8878095

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

NOTICE OF APPLICATION DECLARE THE ACTORS ETC. (TELEVISION) AWARD 1979 AS VARIED TO DATE, A COMMON RULE IN THE NORTHERN TERRITORY

(C No. 22680 of 1988)

Notice is hereby given that at 2.15 p.m. on 5 December 1988 at CML Building, University Ave, Canberra, ACT the Australian Conciliation and Arbitration Commission will hear an application by Actors Equity of Australia to declare the award known as the Actors Etc. (Television) Award 1979 as varied to date, a Common Rule of the industry covered by the said award namely actors in the live entertainment industry in the Northern Territory.

A copy of the said award as varied to date may be inspected free of charge at the Office of the Industrial Registrar, 80 Collins St, Melbourne Vic.; the Office of the Deputy Industrial Registrar, 50 Grenfell St, Adelaide, South Australia; the Office of the Deputy Industrial Registrar, University Ave, Canberra, Australian Capital Territory; the Office of the Deputy Industrial Registrar, 1 Briggs St Darwin.

Compliance with Regulation 35 is not required.

Persons and organisations not appearing or represented will be bound by any order or declaration made by the Commission in the matter.

Dated this sixteenth day of November 1988.

L. J. SOETENS
Deputy Industrial Registrar

N.N.—8878096

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

NOTICE UNDER SUB-SECTION 49A (3) IN RELATION TO VARIATION OF A COMMON RULE In the matter of the LIQUOR TRADES HOTELS (AUSTRALIAN CAPITAL TERRITORY) CONSOLIDATED AWARD 1977

C No. 32885 of 1988

And in the matter of the variation of the award dated 25 July 1977 in the above matter.

Notice is hereby given:

- that on 3 November 1988 the Commission varied the terms of the above mentioned award referred to in the Schedule as set out in the Schedule;
- that the variation will be a common rule in the Australian Capital Territory in the industry in respect of which the dispute arose with effect from the first pay period to commence on or after 12 September 1988 and 12 March 1989; and
- that any person or organisation having an objection to the variation binding that person or organisation and desiring to be heard in relation to that objection is invited to lodge with the Commission a notice of that objection is invited to lodge with the Commission a notice of that objection within 28 days after the date specified in paragraph (a).

A copy of the award may be inspected at the office of the Registrar. Objections should be lodged with the Registrar at 4th Floor, CML Building, University Ave, Canberra, by 4.30 p.m. on 1 December 1988.

SCHEDULE TERMS VARIED

Clause No.	Subject	Substance of variation
	PRINT NO. H4660	
6	Minimum Wage	National Wage Case August 1988
7	Wages	National Wage Case August 1988
7A	No Extra Claims	National Wage Case August 1988
10	Overtime and Penalty Rates	National Wage Case August 1988
11	Casual Employees	National Wage Case August 1988
15	Board and Residence	National Wage Case August 1988

Dated 16 November 1988.

CHRISTOPHER BRENDON
Deputy Industrial Registrar

N.N.—8878097

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

NOTICE UNDER SUB-SECTION 49A (3) IN RELATION TO VARIATION OF A COMMON RULE In the matter of the AUSTRALIAN WORKERS' UNION CONSTRUCTION-ON-SITE AND CIVIL ENGINEERING (ACT) AWARD 1981

C No. 90220 of 1988

And in the matter of the variation of the award dated 13 October 1982 in the above matter.

Notice is hereby given:

- (a) that on 3 November 1988 the Commission varied the terms of the above mentioned award referred to in the Schedule as set out in the Schedule;
- (b) that the variation will be a common rule in the Australian Capital Territory in the industry in respect of which the dispute arose with effect from the first pay period to commence on or after 1 September 1988; and
- (c) that any person or organisation having an objection to the variation binding that person or organisation and desiring to be heard in relation to that objection is invited to lodge with the Commission a notice of that objection within twenty-eight days after the date specified in paragraph (a).

A copy of the award may be inspected at the office of the Registrar. Objections should be lodged with the Registrar at 4th Floor, CML Building, University Ave, Canberra, by 4.30 p.m. on 1 December 1988.

SCHEDULE TERMS VARIED

Clause No.	Subject	Substance of variation
PRINT NO. H4665		
7	Classifications and Wage Rates	National Wage Case August 1988
8	Leading hands	National Wage Case August 1988
9	Industry Allowance	National Wage Case August 1988
10	Extra Rates	National Wage Case August 1988
16	Meal Breaks and Meal Allowance	National Wage Case August 1988
17	Compensation for Travel Patterns etc	National Wage Case August 1988
27	First Aid Ambulance Chest	National Wage Case August 1988
33	Fares and Travelling Expenses	National Wage Case August 1988

Dated 16 November 1988

CHRISTOPHER BRENDON
Deputy Industrial Registrar

N.N.—8878098

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

NOTICE UNDER SUB-SECTION 49A (3) IN RELATION TO VARIATION OF A COMMON RULE

In the matter of the PARKING STATIONS ETC. EMPLOYEES (ACT) AWARD 1983

C No. 21171 of 1988

And in the matter of the variation of the award dated 10 October 1983 in the above matter.

Notice is hereby given:

- (a) that on 7 November 1988 the Commission varied the terms of the above mentioned award referred to in the Schedule as set out in the Schedule;
- (b) that the variation will be a common rule in the Australian Capital Territory in the industry in respect of which the dispute arose with effect from the first pay period to commence on or after 27 September 1988; and

- (c) that any person or organisation having an objection to the variation binding that person or organisation and desiring to be heard in relation to that objection is invited to lodge with the Commission a notice of that objection within twenty-eight days after the date specified in paragraph (a).

A copy of the award may be inspected at the office of the Registrar. Objections should be lodged with the Registrar at 4th Floor, CML Building, University Ave, Canberra, by 4.30 p.m. on 5 December 1988.

SCHEDULE TERMS VARIED

Clause No.	Subject	Substance of variation
PRINT NO. H5020		
4	Wages	Second Tier Increase
19	Uniforms	Second Tier Increase
21	Wages etc. Time and payment of	Second Tier Increase
22	Terms of engagement	Second Tier Increase
27	Holidays	Second Tier Increase
28	Sick Leave	Second Tier Increase

Dated 16 November 1988

CHRISTOPHER BRENDON
Deputy Industrial Registrar

N.N.—8878099

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

COMMON RULE

1. Application has been made that the following Award shall be declared common rule in the Australian Capital Territory in the industry in connection with which the dispute arose which led to the making of the Award. The said industry is described in the said Award.

2. That Award is: Actors etc. (Television) Award 1979

3. A copy of the Award may be inspected free of charge at the office of the Registrar at the address shown in item 4.

4. The application will be heard at 2.15 p.m. Monday, 5 December 1988 at 4th Floor, CML Building, University Ave, Canberra ACT.

5. All persons and organisations interested and desiring to be heard may appear or be represented before the Commission and shall be heard.

6. Persons and organisations not so appearing or represented will be bound by any declaration made by the Commission in the matter which is applicable to them.

7. Compliance with Regulation 35 is not required.

Dated 15 November 1988

CHRISTOPHER BRENDON
Registrar

N.N.—8878100

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

COMMON RULE

1. Application has been made that the following Award shall be declared common rule in the Australian Capital Territory in the industry in connection with which the

dispute arose which led to the making of the Award. The said industry is described in the said Award.

2. That Award is: Actors (Theatrical) Award 1981

3. A copy of the Award may be inspected free of charge at the office of the Registrar at the address shown in item 4.

4. The application will be heard at 2.15 p.m. Monday, 5 December 1988 at 4th Floor, CML Building, University Ave, Canberra ACT.

5. All persons and organisations interested and desiring to be heard may appear or be represented before the Commission and shall be heard.

6. Persons and organisations not so appearing or represented will be bound by any declaration made by the Commission in the matter which is applicable to them.

7. Compliance with Regulation 35 is not required.

Dated 15 November 1988.

CHRISTOPHER BRENDON
Registrar

N.N.—8878101

IN THE AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

In the matter of an application by the Federated Miscellaneous Workers Union of Australia for the CHILD CARE INDUSTRY (AUSTRALIAN CAPITAL TERRITORY) AWARD 1985 to be declared a common rule in the Australian Capital Territory
(C No. 21686 of 1988)

Mr Commissioner Laing Canberra, 9 November 1988

DECLARATION

1. That the whole of the terms of the Child Care Industry (Australian Capital Territory) Award including variations thereto, be a common rule of the relevant industry in the Australian Capital Territory and shall be binding on all employers in the said industry in respect of the employment by them of employees in the classifications for which provision is made in the said award and shall be binding on all such employees.

2. That this declaration shall not apply to the ACT Health Authority in respect of employees under the *Capital Territory Health Commission Ordinance 1975* (as amended) and Calvary Hospital ACT Incorporated.

3. That the foregoing declaration shall operate from 9 November 1988.

By the Commission,

COMMISSIONER

Appearances:

D. Cseti for the Federated Miscellaneous Workers Union of Australia.

B. G. Cooke for Confederation of ACT Industry on behalf of respondents.

Date and place of hearing: 1988; Canberra;

(1) Print G0220

N.N.—8878102

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

NOTICE UNDER SUB-SECTION 49A (3) IN RELATION TO VARIATION OF A COMMON RULE

In the matter of the NURSES PRIVATE
EMPLOYMENT (ACT) AWARD 1972

C No. 90275 of 1988

And in the matter of the variation of the award dated 16 August 1972 in the above matter.

Notice is hereby given:

(a) that on 8 November 1988 the Commission varied the terms of the above mentioned award referred to in the Schedule as set out in the Schedule;

(b) that the variation will be a common rule in the Australian Capital Territory in the industry in respect of which the dispute arose with effect on and from 13 October 1988; and

(c) that any person or organisation having an objection to the variation binding that person or organisation and desiring to be heard in relation to that objection is invited to lodge with the Commission a notice of that objection within twenty-eight days after the date specified in paragraph (a).

A copy of the award may be inspected at the office of the Registrar. Objections should be lodged with the Registrar at 4th Floor, CML Building, University Ave, Canberra, by 4.30 p.m. on 6 December 1988.

SCHEDULE TERMS VARIED

Clause No.	Subject	Substance of variation
	PRINT NO. H5276	
4	Wages	National Wage Case August 1988
4A	No Extra Claims	National Wage Case August 1988
5 (a) (b) (c) (d) (i) (ii) (iii)	Special Allowance	National Wage Case August 1988

Dated 11 November 1988.

DAVID SINCLAIR
Deputy Industrial Registrar

N.N.—8878103

AUSTRALIAN CONCILIATION AND ARBITRATION COMMISSION

Conciliation and Arbitration Act 1904

NOTICE UNDER SUB-SECTION 49A (3) IN RELATION TO VARIATION OF A COMMON RULE

In the matter of the NURSES PRIVATE
EMPLOYMENT (ACT) AWARD 1972

C No. 90278 of 1988

And in the matter of the variation of the award dated 16 August 1972 in the above matter.

Notice is hereby given:

(a) that on 4 November 1988 the Commission varied the terms of the abovementioned award referred to in the Schedule as set out in the Schedule;

(b) that the variation will be a common rule in the Australian Capital Territory in the industry in respect of which the dispute arose with effect on and from 23 August 1988; and

(c) that any person or organisation having an objection to the variation binding that person or organisation and desiring to be heard in relation to that objection is invited to lodge with the Commission a notice of that objection within twenty-eight days after the date specified in paragraph (a).

A copy of the award may be inspected at the office of the Registrar. Objections should be lodged with the Registrar at 4th Floor, CML Building, University Ave, Canberra, by 4.30 p.m. on 1 December 1988.

**SCHEDULE
TERMS VARIED**

Clause No.	Subject	Substance of variation
PRINT NO. H5275		
4	Wages	Second Tier Increase
5 (d)	Special Allowance	Second Tier Increase

Dated 11 November 1988.

DAVID SINCLAIR
Deputy Industrial Registrar

CA031048 CRACTOIRS N.N.—8878104

COMMONWEALTH OF AUSTRALIA

Commonwealth Teaching Service Act 1972

DECLARATION UNDER SUBSECTION 50A (1)

WHEREAS on 13 October 1988, Allan Clyde Holding, Minister of State for the Arts and Territories, certified in accordance with subsection 50A (1) of the *Commonwealth Teaching Service Act 1972* ('the Act') that the performance of teaching and associated duties, being a function that has been performed by persons appointed or engaged as Commonwealth Teaching Service staff under the Act in the Canberra School of Art and the Canberra School of Music is to be performed by the Canberra Institute of the Arts, a Commonwealth authority within the meaning of subsection 4 (1) of the Act:

Now, therefore I, RAE MARTIN TAYLOR, Secretary to the Department of Industrial Relations, declare, pursuant to subsection 50A (1) of the Act that the officers and employees specified in the Schedule attached to this instrument are in the employment of the Canberra Institute of the Arts and that 16 November 1988 is the specified date for the purposes of subsection 50A (2).

Dated 16 November 1988.

R. M. TAYLOR
Secretary
Department of Industrial Relations

SCHEDULE

Permanent Officers

Boynes, Robert John
Dabros, Ante
Hansen, Finn Ragnar
Harry, Patricia Joyce
Herel, Peter
Hill, Vernon Kingsley
Huff-Johnston, William
Langridge, Anne Balcome
Kleinert, Ingo Dietmar
Mann-Hay, Gillian
Martin, Amanda Laura De Rose
Meadham, Christopher William
Reid, John Colin
Schmeisser, Jorg Giseler
Swen, Hiroe

Temporary Fixed-Term Employees

Butler, Michael Anthony
Crisp, Deborah Gay
Crisp, Leanne Christine
Croft, Christopher (LWOP)
De Borah, Anna
Bommett, Leonard Bertram
Douglas, Anne
Eaton, Janenne Pearl
Ewington, Julie Mary
Gadd, Charmian Jane
Geier, Helen Maria
Greenwood, Garry

Grey-Smith, Mark Fancis
Hawkey, William
Haynes, Peter John
Ingham, George Richard
Johnson, Donald Duane
Kain, Timothy Patrick
Kean, Roselyn Annette
Kleinert, Sylvia Joyce
Legrand, Michael Martin
Leibbrandt, Ingrid Olga
Lewis, Barbara Dianne
Luxton, John Fraser
Maconaghie, Ronald Dereck
McClure, Elizabeth
McDonald, Hector Harcourt
McElhinny, Christopher Michael
Mulcahy, Michael
Noone, Michael John
Nuttall, David Christopher
Palmqvist, Bengt-Olov
Plunkett, Paul
Pratt, Daryl Loring
Robertson-Swann, Ronald Charles
Taylor, Virginia
Teakel, Wendy Evelyn
Tremblay, Theodore Paul
Trew, Dennis Michael
Van Hove, Marie Celeste
Vivian, Alan Edward
Watt, Alan Hugh Douglas
West, Susan Dawn
Worrall, David Robert

N.N.—8878112

**Industry, Technology and
Commerce**

COMMONWEALTH OF AUSTRALIA

**DECLARATION BY THE MINISTER FOR
INDUSTRY, TECHNOLOGY AND COMMERCE,
PURSUANT TO SUB-SECTION 6 (7) OF THE
BOUNTY (METAL WORKING MACHINES AND
ROBOTS) ACT 1985**

I, JOHN NORMAN BUTTON, the Minister of State for Industry, Technology and Commerce, pursuant to subsection 6 (7) of the *Bounty (Metal Working Machines and Robots) Act 1985*, hereby declare that this Act is to have effect as if there were substituted for the definition of 'modification' in subsection 4 (1) the definition set out below:

'modification', in relation to bountiable equipment B, means:

- a conversion of the equipment that, in the opinion of the Minister, will substantially improve the designed capability of the equipment; or
- the conversion of the equipment from equipment that is not designed to form part of a flexible manufacturing cell or system into equipment intended to form part of such a cell or system,

but does not include:

- the conversion of the equipment in the course of the normal manufacturing of the equipment; or
- retrofit manufacture of, or involving, the equipment.

This declaration shall take effect on and from the first day of July 1985.

Dated this 28th day of October 1988.

JOHN NORMAN BUTTON
Minister of State
for Industry, Technology and Commerce

N.N.—8878105

Bounty (Computers) Act 1984

NOTICE OF DECLARATION OF EQUIPMENT

I, BARRY OWEN JONES, Minister for Science Customs and Small Business hereby declare, pursuant to subsection 5 (1) of the *Bounty (Computers) Act 1984*, that each class of computer equipment appearing in Column 1 of the Schedule hereunder shall, as from the date specified opposite it in Column 2 of the said Schedule, be a class of computer equipment to which paragraph (e) to the definition of 'bountiable equipment' in subsection 3 (1) of the *Bounty (Computers) Act 1984* applies.

Dated this 11th day of November 1988.

BARRY O. JONES

Minister for
Science, Customs and Small Business

Reference in the Schedule hereunder to the word 'subheading' followed by a set of numerals shall be a reference to the relevant subheading, as indicated by those numerals, in Schedule 3 to the *Customs Tariff Act 1987* as in force on the date of this Notice and as amended from time to time thereafter.

SCHEDULE

<i>Column 1</i> <i>Class of computer equipment</i>	<i>Column 2</i> <i>Date of effect</i>
Automatic Monitoring and Control Systems for in-motion weighing machines to which if imported, subheading 9032.89.90 of Schedule 3 of the Customs Tariff Act 1987 would apply.	6 July 1984

N.N.—8878106

Social Security

COMMONWEALTH OF AUSTRALIA

Social Security Act 1947

APPOINTMENT OF SENIOR MEMBER

I, SIR NINIAN MARTIN STEPHEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, pursuant to subsection 218 (1) of the *Social Security Act 1947*, hereby appoint Anne Coghlan as National Convener, Social Security Appeals Tribunal for five years.

Dated 8 November 1988.

N. M. STEPHEN
Governor-General

By His Excellency's Command,

BRIAN HOWE

Minister of State
for Social Security
(Ex. Min. No. 12)

N.N.—8878107

Transport and Communications

COMMONWEALTH OF AUSTRALIA

Telecommunications Act 1975

**APPOINTMENT OF PART-TIME COMMISSIONER
OF THE AUSTRALIAN TELECOMMUNICATIONS
COMMISSION**

I, SIR NINIAN MARTIN STEPHEN, Governor-General of the Commonwealth of Australia acting with the advice of the Federal Executive Council pursuant to subsection 22 (2) of the *Telecommunications Act 1975*, hereby appoint Graham Charles Evans to be a part-time Commissioner of the Australian Telecommunications Commission referred to in paragraph 22 (1) (b) of that Act.

Dated 27 October 1988.

N. M. STEPHEN
Governor-General

By His Excellency's Command,

RALPH WILLIS

Minister of State
for Transport and Communications

N.N.—8878108

COMMONWEALTH OF AUSTRALIATELECOMMUNICATIONS ACT 1975DETERMINATION OF RENTAL AND CHARGES

I, Mario Dominic Zilko, the General Manager, Operator Assisted Services of the Australian Telecommunications Commission, being a person to whom the Commission has, by instrument in writing under Section 33 of the Telecommunications Act 1975, delegated its powers and functions under the Act in pursuance of Section 11 of the Act, hereby make the following determination.

1. The determination of rentals and charges made by the Commission on 21 August 1975*, as varied to date 0, is further varied by including at the end of Item 1L of Schedule 1 the following item:

"ITEM 1M CHARGES FOR TELEPHONE ANSWERING SERVICE

The fee payable by a subscriber to a personalised telephone answering service (TAS) provided by the Commission, not being a service as described in Item 1F of this Schedule shall be in accordance with the following:

- | | \$ |
|---|--------|
| (a) An annual fee in respect of a personalised telephone answering service as follows - | |
| (i) For each standard message telephone answering service | 600.00 |
| (ii) For each premium message telephone answering service | 720.00 |
| with a minimum charge equal to one-twelfth of the annual rate prescribed in paragraph (a) | |
| (b) a fee in respect of each printed report of messages processed by a telephone answering service requested by the subscriber of | 10.00" |
2. This determination will take effect on and from 1 November 1988.

DATED this thirty-first day of October 1988.

M.D. Zilko
Delegate of the Australian
Telecommunications Commission

* Notified in Gazette No. S170 of 29.8.75.

0 For previous amendments see footnote 0 appearing on Pages 2223 - 2229 of Gazette No. GN36 of 28.9.88.

**AUSTRALIAN BROADCASTING TRIBUNAL
BROADCASTS BY MR RON CASEY AND MR LES
THOMPSON ON 2KY—NOTICE OF INQUIRY**

IP/88/196

November 1988

PUBLIC SUBMISSIONS INVITED

Following a Federal Court decision, the Australian Broadcasting Tribunal is commencing a new inquiry into certain broadcasts by Mr Ron Casey and Mr Les Thompson on radio station 2KY ('2KY'). The inquiry is also being held in consequence of an application dated 23 March 1988 to the Tribunal by the Anti-Discrimination Board, the Ethnic Affairs Commission of New South Wales, the Human Rights and Equal Opportunity Commission, the Ethnic Communities Council of New South Wales and the Federation of Ethnic Communities Councils of Australia ('the joint applicants') requesting the exercise by the Tribunal of its powers under sections 85, 99, 101 and 119 of the *Broadcasting Act 1942* ('the Act') in respect of a broadcast by Mr Ron Casey on 2KY at 10.50 a.m. on 18 February 1988. The joint applicants alleged this broadcast was in breach of Radio Program Standard 3 ('RPS3'). Further particulars of the application may be found in Appendix A to the Tribunal's information paper relating to the inquiry.

The Tribunal is interested in your views on whether any of the broadcasts (listed at Issue 1, below) breached RPS3 and the Act. It would also like to know what action, if any, you believe the Tribunal should take in accordance with sections 85, 99, 101 and 119 of the Act if it is found that any of these broadcasts breached RPS3 and the Act.

The inquiry is to be conducted in accordance with section 17C of the Act and the issues to be considered in the inquiry are:

1. Whether any of the programs respectively presented on radio station 2KY ('2KY') by Ron Casey on 23 April 1987, 24 April 1987, 19 October 1987 and 18 February 1988 and by Les Thompson on 22 October 1987 failed to comply with Radio Program Standard 3 ('RPS3').

If any of the programs did fail to comply with RPS3:

2. Whether the licensee of 2KY contravened subsection 99 (1A) of the *Broadcasting and Television Act 1942* by failing to supervise the broadcasting of the programs in such a manner as to ensure that RPS3 was complied with.
3. Whether the Tribunal should give any direction to the licensee of 2KY pursuant to subsection 99 (2) of the Act for the purpose of ensuring that program standards are complied with in relation to the broadcasting of programs by 2KY and in relation to programs to be broadcast by 2KY and, if so, the form of any such direction.
4. Whether the Tribunal should impose further conditions in respect of the licence held by the licensee of 2KY pursuant to subsection 85 (1) of the Act requiring the licensee to adopt management procedures relating to talk-back radio programs broadcast by 2KY for the purpose of preventing breaches of program standards and the Act.
5. Whether the Tribunal should issue a written reprimand or admonishment to the licensee of 2KY pursuant to subsection 101 (1) of the Act and, if so, the form of any such reprimand or admonishment.

6. Whether the Tribunal should also direct the licensee of 2KY pursuant to subsection 101 (2) of the Act to publish the reprimand or admonishment and, if so, in what form and manner.
7. (a) Whether the Tribunal should give a direction pursuant to subsection 119 (1) of the Act:
 - (i) prohibiting Ron Casey and/or Les Thompson from presenting programs in live broadcasts;
 - (ii) imposing restrictions on the presenting by Ron Casey and/or Les Thompson of programs in live broadcasts;
 - (iii) prohibiting any person who passed or selected for broadcasting the whole or a part of the programs from passing or selecting programs for broadcasting;
 - (iv) imposing restrictions on the passing or selecting by that person of programs for broadcasting.
7. (b) If the Tribunal decides to give any such direction, whether the direction should have effect indefinitely, or for a specified period.

You are invited to make submissions in relation to the inquiry. Your submissions should reach the Tribunal's office at Tandem House, 76 Berry St, North Sydney 2060 or be sent to the General Manager, Australian Broadcasting Tribunal, PO Box 1308, North Sydney 2059, before 5.00 p.m. on 20 January 1989. Each submission will become a public document and will be attached to the inquiry file unless access is restricted by the Tribunal for the whole or part of it. The inquiry files which contain copies of the application for the inquiry and other relevant information can be inspected at the Tribunal's North Sydney office.

A guide and information package is available by contacting the Tribunal on (02) 959 7941 or 959 7946.

N.N.—8878109

Treasurer

Insurance Act 1973

**NOTIFICATION OF GRANT OF AUTHORITY IN
ACCORDANCE WITH SECTION 28**

In pursuance of section 28 of the *Insurance Act 1973*, I, RICHARD MATTHEW BEETHAM, Insurance and Superannuation Commissioner, hereby give notice that I did on 9th day of November 1988, pursuant to section 23 of the *Insurance Act 1973*, grant to Continental Pacific Insurance Company (Australia) Limited, the Registered Office of which is situated at Level 32, 100 Miller St, North Sydney, an authority to carry on insurance business.

In accordance with section 122 of the *Insurance Act 1973*, copies of grants of authority are contained in the Register of Authorised Insurers which can be inspected at my Office.

Dated this 9th day of November 1988.

RICHARD M. BEETHAM
Commissioner

N.N.—8878110

Australian Banking Statistics

Savings Banks

STATEMENTS PREPARED FROM RETURNS DELIVERED TO THE STATISTICIAN UNDER SECTION 53 OF THE BANKING ACT 1959 OR UNDER SPECIAL ARRANGEMENTS WITH BANKS NOT SUBJECT TO THAT ACT
LIABILITIES AND ASSETS WITHIN AUSTRALIA OF EACH SAVINGS BANK AT THE END OF SEPTEMBER 1988(a)
(\$'000)

	Liabilities			Assets															
	Depositors' balances	Balances due to other banks, bills payable and all other liabilities (c)	Total	Coin, bullion and Australian notes	Deposits with Reserve Bank	Deposits in Australia with Trading Banks	Australian public securities			Local and semi-governmental authorities	Other securities	Loans to authorised dealers in the short-term money market	Cheques and bills of other banks and balances with and due from other banks (d)	Loans (other than loans to authorised dealers in the short-term money market), advances and bills discounted		Bank premises, furniture and sites	Bills receivable and all other assets	Total	
							Treasury Bills	Treasury Notes	Other					Housing	Other				
Savings Banks (b)																			
Commonwealth	15 227 007	705 650	15 932 657	131 859	..	19 441	..	130 000	1 708 925	2 653 440	208 653	17 800	104 605	9 501 844	1 428 948	846 622	126 936	16 879 073	
State Banks (e)—																			
S.B. of Vic.	10 322 956	4 004 571	14 327 527	68 197	725	398	..	498 112	996 648	394 561	103 859	..	125 269	5 479 488	3 199 542	405 093	3 683 075	14 954 967	
S.B. of S.A.	1 596 110	970 831	2 566 941	..	..	..	..	..	543 642	..	..	..	..	2 023 299	..	..	..	2 566 941	
R. & I. of W.A.	1 303 113	..	1 303 113	596	..	..	..	19 525	153 295	40 020	..	..	..	933 843	..	..	222	1 147 501	
Tasmania Bank	690 531	17 275	707 806	5 807	51	31 282	..	13 625	62 079	106 811	13	16 800	2 499	216 813	255 661	23 009	13 126	747 576	
Total, State	13 912 710	4 992 677	18 905 387	74 600	776	31 680	..	531 262	1 755 664	541 392	103 872	16 800	127 768	8 653 443	3 455 203	428 102	3 696 423	19 416 985	
Trustee Banks—																			
S.B. of Tas.	411 772	29 705	441 477	3 128	104	10 011	..	3 000	35 000	95 619	37	8 900	22 072	116 061	152 306	7 985	10 557	464 780	
Private Banks—																			
A.N.Z. S.B.	5 968 138	375 012	6 343 150	197	..	59 011	..	590 000	335 555	240 485	47 610	..	500	4 370 841	875 036	..	..	6 519 235	
National Aust. S.B.	7 885 404	526 778	8 412 182	..	..	..	..	341 500	733 493	992 280	500	..	500	4 710 441	1 762 453	..	2 343	8 543 510	
Westpac S.B.	10 698 554	117 738	10 816 292	..	..	69 485	..	1 428 050	382 322	1 170 070	195	..	..	7 082 282	814 300	131 464	335 006	11 413 174	
Advance	3 827 316	384 052	4 211 368	13 928	327	64 219	..	27 287	526 951	108 040	98 119	46 800	225 295	2 132 515	910 813	205 209	176 443	4 535 946	
B.N.Z. S.B.	78 346	6 038	84 384	..	..	..	..	..	11 617	16 632	..	..	..	251	59 271	16	..	88 254	
Challenge	2 051 391	434 015	2 485 406	3 929	..	28 325	..	136 724	155 723	67 440	49 910	43 550	63 641	1 741 857	329 565	19 626	-1 294	2 638 996	
Citibank	1 320 149	34 942	1 355 091	..	..	..	..	72 000	109 000	..	..	..	..	27	1 067 253	168 061	..	6 728	1 423 069
Civic Advance	500 518	28 999	529 517	1 460	7	..	..	..	51 416	3 980	..	25 145	53 550	297 020	105 750	13 313	11 423	563 064	
Metway	1 129 265	43 126	1 172 391	4 638	7	30 351	..	19 844	133 531	9 872	90	12 030	1 257	925 591	86 379	17 834	7 456	1 248 880	
Nat. Mutual	2 021 583	151 287	2 172 870	13 517	..	1 000	..	4 979	266 452	46 020	16 697	..	61 358	1 467 237	441 696	27 996	307	2 347 259	
Qld S.B.	262 234	21 554	283 788	..	..	660	..	..	35 808	..	..	..	..	262 880	4 273	..	167	303 788	
Total, Private	35 742 898	2 123 541	37 866 439	37 669	341	253 051	..	2 620 384	2 741 868	2 654 819	213 121	127 525	406 379	24 117 188	5 498 342	415 442	539 046	39 625 175	
Total, All Banks	65 294 387	7 851 573	73 145 960	247 256	1 221	314 183	..	3 284 646	6 241 457	5 945 270	525 683	171 025	660 824	42 388 536	10 534 799	1 698 151	4 372 962	76 386 013	

(a) Particulars for The State Bank of Victoria, The Rural and Industries Bank of Western Australia (Savings Bank Division) and The Hobart Savings Bank relate to the end of the month, those for Tasmania Bank to the last Monday in the month, and those for the other Savings Banks to the last Wednesday in the month. Excludes capital and reserves and inter-branch accounts. (b) For legend on abbreviations of Bank names see footnote on page 2633. (c) Includes provisions for contingencies. (d) Includes deposits with and loans to specified banks other than Trading Banks. (e) The information for the State Savings Banks is supplied and published under a special arrangement with the banks and not under the Banking Act.
Note: Any discrepancies between totals and sums of components are due to rounding.

DEPOSITORS' BALANCES IN EACH STATE AND THE TERRITORIES FOR EACH SAVINGS BANK AT THE END OF SEPTEMBER 1988

(Excludes inter-branch accounts)

(\$'000)

Savings Banks †	New South Wales	Victoria	Queensland	South Australia	Western Australia	Tasmania	Northern Territory	Australian Capital Territory	Other Territories
Commonwealth.	6 702 585	3 170 314	2 743 849	913 898	1 106 567	245 524	79 864	254 321	10 085
State Banks (e)—									
S.B. of Vic.	..	10 322 956	..	..	..	..	..	..	..
S.B. of S.A.	..	..	236	1 586 471	..	..	9 403	..	..
R. & I. of W.A.	5 677	..	..	..	1 297 436	..	..	..	..
Tasmania Bank	..	..	..	..	..	690 531	..	..	..
Total, State	5 677	10 322 956	236	1 586 471	1 297 436	690 531	9 403	..	..
Trustee Banks—									
S.B. of Tas.	..	..	..	..	..	411 772	..	..	..
Private Banks—									
A.N.Z.S.B.	1 339 251	2 454 058	958 334	567 373	400 872	134 957	60 695	52 598	..
National Aust. S.B.	2 512 646	3 138 819	1 349 321	336 254	407 501	34 783	27 882	78 198	..
Westpac S.B.	4 519 238	2 294 226	2 072 554	465 668	943 306	185 292	84 213	126 890	7 167
Advance	3 459 841	270 648	96 679	148	..	..	..	..	..
B.N.Z. S.B.	59 693	5 160	11 362	838	1 293	..	..	..	..
Challenge	90 430	432 484	83 044	1 776	1 443 657	..	..	..	..
Citibank	935 840	117 553	181 992	46 263	16 586	6 082	..	15 833	..
Civic Advance	15 138	..	..	..	..	..	..	485 380	..
Metway	..	..	1 129 265	..	..	..	..	..	..
Nat. Mutual	1 626 342	380 658	4 971	6 081	2 448	..	..	1 083	..
Qld S.B.	..	..	262 234	..	..	..	..	..	..
Total, Private	14 558 419	9 093 606	6 149 756	1 424 401	3 215 663	361 114	172 790	759 982	7 167
Total, All Banks	21 266 681	22 586 876	8 893 841	3 924 770	5 619 666	1 708 941	262 057	1 014 303	17 252

† Commonwealth—Commonwealth Savings Bank of Australia.

S.B. of Vic.—The State Bank of Victoria.

S.B. of S.A.—The State Bank of South Australia.

R. & I. of W.A.—The Rural and Industries Bank of Western Australia (Savings Bank Division).

Tasmania Bank—Tasmania Bank.

S.B. of Tas.—The Hobart Savings Bank (trading as The Savings Bank of Tasmania).

A.N.Z.S.B.—Australia and New Zealand Savings Bank Limited.

National Aust. S.B.—National Australia Savings Bank Limited.

Westpac S.B.—Westpac Savings Bank Limited.

Advance—Advance Bank Australia Limited.

B.N.Z.S.B.—Bank of New Zealand Savings Bank Limited.

Challenge—Challenge Bank Limited.

Citibank—Citibank Savings Limited.

Civic Advance—Civic Advance Bank Limited.

Metway—Metway Bank Limited.

Nat. Mutual—National Mutual Royal Savings Bank Limited.

Qld S.B.—Bank of Queensland Savings Bank Limited.

N.N.—

Australian Banking Statistics

Trading Banks

STATEMENTS PREPARED FROM RETURNS DELIVERED TO THE STATISTICIAN UNDER SECTION 52 OF THE BANKING ACT 1959 OR UNDER SPECIAL ARRANGEMENTS WITH BANKS NOT SUBJECT TO THAT ACT

LIABILITIES

AVERAGES OF THE LIABILITIES WITHIN AUSTRALIA OF EACH BANK AT THE CLOSE OF BUSINESS ON WEDNESDAYS, 7, 14, 21 AND 28 SEPTEMBER 1988 (a)
(\$'000)

Bank (b)	Deposits repayable in Australia												Balances due to other banks	Bills payable and all other liabilities to the public (excluding share-holders' funds) (c)			
	Fixed				Current									Total current deposits	Total deposits	Total liabilities (c)	
	Common-wealth and State Govern-ments	Other banks	Other	Total fixed deposits	Bearing interest				Not bearing interest								
					Common-wealth and State Govern-ments	Other banks	Other	Total	Common-wealth and State Govern-ments	Other banks	Other	Total					
Major Banks—																	
A.N.Z.	19 709	15	8 805 399	8 825 122	4 861	165	730 123	735 149	4 558	437 504	3 094 812	3 536 873	4 272 022	13 097 144	630 505	16 160 965	29 888 614
Commonwealth	14 725	1 969	7 123 328	7 140 022	29 600	11 876	527 463	568 939	13 676	63 299	2 993 641	3 070 615	3 639 554	10 779 576	74 875	10 403 874	21 258 325
National	119 363	5 981	8 021 060	8 146 403	14 088	1 329	1 327 686	1 343 103	2 588	274 958	2 910 194	3 187 739	4 530 842	12 677 245	931 629	13 251 387	26 860 261
Westpac	3 321		5 591 310	5 594 630	25 796	39 565	2 174 329	2 239 689	52 534	441 091	4 271 415	4 765 039	7 004 728	12 599 359	558 806	12 390 121	25 548 285
Total, Major	157 117	7 964	29 541 096	29 706 177	74 345	52 936	4 759 600	4 886 880	73 355	1 216 851	13 270 061	14 560 267	19 447 147	49 153 324	2 195 814	52 206 347	103 555 484
Other Banks—																	
America			91 312	91 312							5 419	5 419	5 419	96 732	33 156	318 746	448 633
Aust. Bank			3 351	3 351			73 400	73 400			5 380	5 380	78 781	82 131	126 328	84 874	293 334
Bankers Trust			67 107	67 107							2 437	2 437	69 544	82 131	198 494	893 124	1 161 161
Barclays			212 389	212 389			52 832	52 832			7 674	7 674	60 505	272 895	162 668	1 008 400	1 443 963
Chase A.M.P.	43	49 378	328 340	377 761		7 340	264 471	271 811			6 846	6 846	278 657	656 418	90 985	943 677	1 691 079
China			8 574	8 574			5 615	5 615					5 615	14 189	20 358	4 642	39 188
Citicbank		29 550	49 205	78 755			21 432	21 432			21 248	21 248	42 680	121 435	24 231	1 512 213	1 657 878
Deutsche	3 534	3 000	91 109	97 643							3 311	3 311	3 311	100 953	16 557	265 062	382 572
Hong Kong			44 967	44 967			117 567	117 567			8	8	117 575	162 542	47 667	1 253 422	1 463 631
I.B.J.			78 130	78 130			6 005	6 005			289	289	6 295	84 424	22 750	326 955	434 129
Lloyds N.Z.A.	363	188	47 975	48 525			21 192	21 192			7 597	7 597	28 790	77 315	262 864	365 187	705 366
Macquarie			101 574	101 574			106 257	106 257			44 977	44 977	151 233	252 807	126 225	287 473	666 504
Mitsubishi			60 662	60 662			4 473	4 473			99	99	4 572	65 233	30 462	194 863	290 557
Nat. Mutual			82 476	82 476			74 161	74 161					74 161	156 636	164 531	1 089 928	1 411 095
NatWest			330 046	330 046			8 600	8 600			14 012	14 012	22 612	352 658	134 871	955 571	1 443 099
New Zealand			217 103	217 103			296 756	296 756			72 834	72 834	369 590	586 693	159 920	1 062 478	1 809 091
Paris		2 220	204 206	206 426			6 133	6 133		4 916	29 794	34 710	40 843	247 269	148 451	727 446	1 123 167
P.I.B.A.		500	155 845	156 345										156 345	45 668	476 032	678 044
Queensland			72 653	72 653		65	53 738	53 803	119			119	53 922	126 574	10 343	50 116	187 033
Singapore			134 294	134 294			9 985	9 985					9 985	144 279	46 851	249 781	440 911
Standard			162 746	162 746			45 483	45 483			3 966	3 966	49 450	212 196	63 263	674 388	949 846
Tokyo			95 659	95 659			2 486	2 486		73	8 886	8 959	11 445	107 104	39 761	250 078	396 943
State Bank N.S.W. (d)			3 295 613	3 295 613	91 268		301 164	392 432	10 508		549 736	560 245	952 676	4 248 289	168 771	4 055 967	8 473 027
State Bank S.A. (d)			1 608 566	1 608 566			200 833	200 833			73 198	73 198	274 031	1 882 596	68 230	2 942 830	4 893 656
R. & I. of W.A. (d)	45 151		1 942 944	1 988 095	1 470		107 718	109 187	98		301 983	302 081	411 268	2 399 363	88 453	649 265	3 137 081
Total, Other	49 090	84 835	9 486 843	9 620 769	92 738	7 405	1 780 299	1 880 441	10 725	4 989	1 159 694	1 175 408	3 055 849	12 676 617	2 301 855	20 642 513	35 620 985
Total, All Banks	206 207	92 800	39 027 939	39 326 946	167 082	60 340	6 539 899	6 767 321	84 080	1 221 840	14 429 755	15 735 675	22 502 995	61 829 941	4 497 669	72 848 860	139 176 469
A.R.D.B.			283 260	283 260										283 260	29 709	87 516	400 485
C.D.B.	1 100	14 750	1 507 115	1 522 965										1 522 965	127 918	33 608	1 684 491

(a) Excludes shareholders' funds, inter-branch accounts and contingencies. (b) For legend on abbreviations of Bank names see footnote on page 2640. (c) Includes the Australian dollar equivalent of foreign currency balances. (d) The information for these banks is supplied and published under a special arrangement with the banks and not under the Banking Act.

Note: Any discrepancies between totals and sums of components are due to rounding.

ASSETS

AVERAGES OF THE ASSETS WITHIN AUSTRALIA OF EACH BANK AT THE CLOSE OF BUSINESS ON WEDNESDAYS, 7, 14, 21 AND 28 SEPTEMBER 1988 (a)

(\$'000)

Bank(b)	Coin and bullion		Australian notes	Cash with Reserve Bank	Australian Public Securities			Local and semi-governmental authorities	Other securities (c)	Loans to authorised dealers in the short-term money market	Statutory Reserve Deposit account with Reserve Bank	Cheques and bills of other banks and balances with and due from other banks (c)	Loans (other than loans to authorised dealers in the short-term money market), advances and bills discounted (c)	Bank premises, furniture and sites	Bills receivable and all other assets (c)	Total assets (c)
	Gold	Coin			Commonwealth and States											
					Treasury bills	Treasury notes	Other securities									
Major Banks—																
A.N.Z.	9	14 411	155 800	218 428	..	1 309 275	1 876 048	..	2 254 142	41 745	664 918	251 145	12 182 341	304 895	14 051 510	33 324 666
Commonwealth	..	8 973	98 807	184 645	..	461 100	1 766 426	3 773	1 104 587	31 875	564 931	399 281	10 590 076	801 453	7 500 375	23 516 302
National	..	13 863	167 351	280 318	..	1 006 675	1 643 775	137 989	2 510 002	128 161	654 354	289 108	13 236 434	400 269	10 986 246	31 454 543
Westpac	..	20 948	181 395	219 576	..	924 000	1 406 789	5	2 279 876	82 301	665 478	136 600	14 734 523	541 899	7 745 529	28 938 918
Total, Major	9	58 193	603 353	902 967	..	3 701 050	6 693 038	141 767	8 148 608	284 082	2 549 680	1 076 133	50 743 374	2 048 515	40 283 660	117 234 428
Other Banks—																
America	..	..	3	1 053	..	23 414	34 414	25	26 431	13 456	3 084	22 719	258 002	3 590	133 630	519 821
Aust. Bank	..	4	82	1 446	..	41 336	3 116	4 033	16 446	11 250	4 188	9 419	179 436	2 641	84 647	358 043
Bankers Trust	..	..	1	82	..	..	145 883	..	122 335	36 850	4 007	202 041	617 275	..	181 723	1 310 196
Barclays	..	18	490	4 165	..	81 958	7 889	5 442	83 300	105 955	12 305	19 235	674 426	11 612	556 059	1 562 853
Chase A.M.P.	..	62	972	10 970	..	150 600	..	98 111	63 019	14 775	31 713	147 098	808 555	29 208	382 683	1 737 766
China	..	..	188	260	..	6 250	..	..	2 200	8 773	756	495	131 694	4 787	82	155 483
Citibank	..	2	1 089	5 512	..	58 500	133 750	..	217 268	89 970	5 369	136 716	501 796	..	1 136 435	2 286 407
Deutsche	..	..	78	1 850	..	18 750	13 202	..	16 971	37 320	5 644	2 219	512 289	3 805	79 812	691 939
HongKong	..	23	699	2 795	..	137 143	27 215	..	77 425	11 450	7 903	22 737	659 833	9 733	736 803	1 693 758
I.B.J.	..	..	39	1 388	..	..	45 922	11 708	30 796	3 325	3 915	22 906	438 418	2 276	57 427	618 119
Lloyds N.Z.A.	..	..	68	1 548	..	39 000	..	5 458	17 102	36 569	4 531	40 246	615 367	3 789	61 243	824 920
Macquarie	..	500	245	2 831	..	50 230	25 156	35 824	44 111	24 450	8 649	46 421	476 206	6 920	119 434	840 976
Mitsubishi	..	..	123	23	..	20 000	30 300	26 000	..	1 083	5 005	1 026	301 192	1 782	57 326	443 858
Nat. Mutual	..	..	..	2 488	..	3 248	159 239	3 031	147 590	..	6 227	16 481	349 789	..	966 670	1 654 762
NatWest	..	..	135	5 823	..	29 835	21 315	..	149 135	183 534	17 407	32 390	1 171 384	15 294	545 075	2 171 326
New Zealand	..	35	1 141	210	..	63 400	84 374	..	1	118 248	27 334	33 913	883 513	10 029	984 323	2 206 518
Paris	..	20	517	3 517	..	100 683	20 000	..	36 587	31 575	10 192	109 341	521 798	4 832	483 653	1 322 713
P.I.B.A.	..	..	..	2 911	..	9 480	36 525	..	10 002	9 765	8 529	365 246	280 181	559	451	723 648
Queensland	..	340	3 491	1 839	..	3 250	15 100	4 842	40 423	2 730	5 082	10 586	109 447	9 166	45 730	252 024
Singapore	..	4	313	3 048	..	6 131	52 959	6 580	..	1 269	9 506	2 511	315 000	3 571	80 272	481 163
Standard	..	17	529	4 199	..	39 514	55 924	..	85 701	8 625	13 232	2 165	315 081	5 774	563 337	1 094 097
Tokyo	..	3	150	1 586	..	27 818	..	..	11 372	19 263	4 672	17 834	186 042	3 625	159 185	431 548
State Bank N.S.W. (d)	..	2 700	40 242	610	..	437 500	553 688	8 952	488 206	161 556	..	76 984	6 443 934	243 677	2 084 609	10 542 657
State Bank S.A. (d)	..	1 957	26 653	1 330	..	128 241	..	174 850	226 471	28 117	..	820 925	2 949 987	99 087	871 592	5 329 209
R. & I. of W.A. (d)	..	1 544	21 360	862	..	100 163	253 909	80 042	48 898	163 325	..	84 261	2 451 085	191 832	559 957	3 957 236
Total, Other	..	7 228	98 606	62 342	..	1 576 442	1 719 877	464 897	1 961 788	1 123 230	199 248	2 245 912	22 151 727	667 589	10 932 152	43 211 036
Total, All Banks	9	65 422	701 958	965 309	..	5 277 492	8 412 915	606 664	10 110 396	1 407 312	2 748 928	3 322 045	72 895 101	2 716 104	51 215 811	160 445 464
A.R.D.B.	..	..	..	16	..	..	..	..	4 086	..	..	155 069	278 549	191	-3 744	434 166
C.D.B.	..	..	..	..	..	..	88 296	..	775	..	..	7 310	1 845 204	2 485	-43 324	1 900 746

(a) Excludes inter-branch accounts and contingencies. (b) For legend on abbreviations of Bank names see footnote on page 2640. (c) Includes the Australian dollar equivalent of foreign currency balances. (d) The information for these banks is supplied and published under a special arrangement with the banks and not under the Banking Act.

Note: Any discrepancies between totals and sums of components are due to rounding.

DEPOSITS AND ADVANCES

AVERAGES OF DEPOSITS AND ADVANCES IN EACH STATE AND THE TERRITORIES FOR EACH BANK AT THE CLOSE OF BUSINESS ON WEDNESDAYS, 7, 14, 21 and 28 SEPTEMBER 1988
(\$'000)

Deposits repayable in Australia								Loans (other than loans to authorised dealers in the short-term money market), advances and bills discounted (b)
Commonwealth and State Governments			Other than Commonwealth and State Governments			Total Deposits		
Bank(a)	Current		Not Bearing Interest	Current			Not Bearing Interest	
	Fixed	Bearing Interest		Fixed	Bearing Interest			
NEW SOUTH WALES								
Major Banks—								
A.N.Z.	9 989	..	13	3 320 481	176 332	866 016	4 372 831	2 958 719
Commonwealth	5 750	9 492	696	3 466 421	259 844	1 534 848	5 277 050	4 637 308
National	54 900	3 223	1 174	2 628 610	476 248	930 814	4 094 967	3 540 471
Westpac	..	1 610	10 103	2 878 395	937 193	2 308 409	6 135 710	7 730 974
Total, Major	70 639	14 325	11 985	12 293 907	1 849 616	5 640 086	19 880 557	18 867 471
Other Banks—								
America	..	..	..	34 129	..	2 856	36 984	104 067
Aust. Bank	..	..	..	2 983	73 400	5 380	81 763	179 310
Bankers Trust	..	..	..	51 663	..	2 437	54 100	617 275
Barclays	..	..	..	212 389	22 301	7 674	242 364	585 865
Chase A.M.P.	43	..	..	195 195	167 377	6 846	369 461	744 907
China	..	..	..	8 574	5 615	..	14 189	131 694
Citibank	..	..	..	70 100	14 345	1 850	86 295	446 246
Deutsche	..	..	..	44 201	..	2 317	46 517	225 532
HongKong	..	..	..	27 236	54 438	..	81 674	308 978
I.B.J.	..	..	..	57 684	2 261	221	60 166	199 982
Lloyds N.Z.A.	..	..	..	28 302	17 229	7 597	53 128	481 840
Macquarie	..	..	..	38 866	57 442	23 976	120 284	321 035
Mitsubishi	..	..	..	13 156	3 380	99	16 634	233 004
Nat. Mutual	..	..	..	31 796	34 921	..	66 717	123 908
NatWest	..	..	..	155 370	3 175	10 910	169 455	624 857
New Zealand	..	..	..	124 298	123 990	34 200	282 487	565 379
Paris	..	..	..	152 889	4 399	21 254	178 542	271 983
P.I.B.A.	..	..	..	77 070	..	..	77 070	136 548
Singapore	..	..	..	14 135	6 967	..	21 101	183 548
Standard	..	..	..	26 557	20 570	3 003	50 130	136 560
Tokyo	..	..	..	65 765	1 807	7 056	74 627	142 507
State Bank N.S.W.(c)	..	91 268	10 508	3 248 896	298 798	541 190	4 190 660	6 230 147
R. & I. of W.A.(c)	..	..	..	183 992	1 901	344	186 237	165 205
Total, Other.	43	91 268	10 508	4 865 242	914 313	679 208	6 560 583	13 160 375
Total, All Banks	70 682	105 593	22 494	17 159 149	2 763 929	6 319 294	26 441 140	32 027 846
A.R.D.B	..	..	..	125 513	..	..	125 513	104 162
C.D.B.	1 100	..	..	1 521 865	..	..	1 522 965	514 824
VICTORIA								
Major Banks—								
A.N.Z.	1 343	4 861	4 116	3 020 283	290 040	1 589 232	4 909 874	5 490 112
Commonwealth	4 468	5 856	47	1 311 296	94 706	554 842	1 971 215	2 276 911
National	50 689	8 366	1 078	2 547 642	469 768	1 311 888	4 389 430	6 031 371
Westpac	2 828	23 300	41 899	941 733	410 587	919 078	2 339 425	2 502 445
Total, Major	59 328	42 383	47 140	7 820 953	1 265 100	4 375 040	13 609 943	16 300 838
Other Banks—								
America	..	..	..	53 391	..	384	53 775	153 625
Aust. Bank	..	..	..	368	..	..	368	126
Bankers Trust	..	..	..	2 979	..	..	2 979	..
Barclays	..	..	..	..	30 531	..	30 531	17 864
Chase A.M.P.	..	..	..	89 612	46 458	..	136 070	43 535
Citibank	..	..	..	1 949	3 318	19 398	24 664	32 414

(a) For legend on abbreviations of Bank names see footnote on page 2640. (b) See note (c) on Statement of Assets. (c) See note (d) on Statement of Assets.

Note. Any discrepancies between totals and sums of components are due to rounding.

(\$'000)

<i>Deposits repayable in Australia</i>								<i>Loans (other than loans to authorised dealers in the short-term money market), advances and bills discounted (b)</i>
<i>Commonwealth and State Governments</i>				<i>Other than Commonwealth and State Governments</i>				
<i>Bank(a)</i>	<i>Current</i>			<i>Current</i>			<i>Total Deposits</i>	
	<i>Fixed</i>	<i>Bearing Interest</i>	<i>Not Bearing Interest</i>	<i>Fixed</i>	<i>Bearing Interest</i>	<i>Not Bearing Interest</i>		
Deutsche	3 534	..	..	49 909	..	994	54 436	286 757
HongKong	..	..	..	11 613	45 751	8	57 372	241 049
I.B.J.	..	..	..	1 290	755	..	2 045	185 261
Lloyds N.Z.A.	..	..	..	4 505	772	..	5 277	45 708
Macquarie	..	..	..	60 359	43 463	13 673	117 496	122 842
Mitsubishi	..	..	..	47 506	1 093	..	48 599	68 188
Nat. Mutual	..	..	..	28 158	35 165	..	63 323	212 965
NatWest	..	..	..	21 891	4 193	2 004	28 088	265 765
New Zealand	..	..	..	27 870	73 927	7 437	109 233	94 022
Paris	..	..	..	18 478	729	5 914	25 120	170 188
P.I.B.A.	..	..	..	38 855	..	..	38 855	21 619
Singapore	..	..	..	120 159	3 018	..	123 178	124 001
Standard	..	..	..	27 186	2 534	84	29 804	28 178
Tokyo	..	..	..	29 895	679	1 903	32 477	43 536
Total, Other.	3 534	..	..	635 972	292 385	51 798	983 689	2 157 640
Total, All Banks	62 861	42 383	47 140	8 456 925	1 557 485	4 426 838	14 593 632	18 458 478
A.R.D.B	..	..	..	77 379	..	..	77 379	154 027
C.D.B.	..	..	..	..	..	..	..	318 970

QUEENSLAND

Major Banks—								
A.N.Z.	2 650	..	272	1 295 906	103 574	492 372	1 894 775	1 540 785
Commonwealth	1 228	3 343	10 988	1 181 562	89 397	495 677	1 782 196	1 528 441
National	2 327	..	302	1 717 437	205 045	570 329	2 495 440	1 829 853
Westpac	..	..	..	917 782	425 811	798 633	2 142 226	2 242 679
Total, Major	6 205	3 343	11 562	5 112 687	823 828	2 357 012	8 314 636	7 141 757
Other Banks—								
America	..	..	..	1 631	..	1 354	2 985	..
Bankers Trust	..	..	..	3 420	..	..	3 420	..
Barclays	..	..	..	..	..	..	..	48 276
Chase A.M.P.	..	..	..	49 960	30 514	..	80 474	10 029
Citibank	..	..	..	6 707	3 397	..	10 104	12 424
HongKong	..	..	..	1 965	9 356	..	11 321	41 785
Lloyds N.Z.A.	350	..	..	13 046	3 191	..	16 586	83 719
Macquarie	..	..	..	2 349	5 352	7 327	15 027	32 329
Nat. Mutual	..	..	..	12 624	2 126	..	14 750	8 348
NatWest	..	..	..	66 012	..	..	66 012	62 147
New Zealand	..	..	..	24 037	54 235	15 558	93 830	120 970
Paris	..	..	..	17 462	566	2 755	20 782	29 410
P.I.B.A.	..	..	..	12 135	..	..	12 135	32 760
Queensland	..	..	119	72 653	53 803	..	126 574	109 447
Standard	..	..	..	36 442	4 098	104	40 644	44 200
Total, Other.	350	..	119	320 439	166 638	27 098	514 643	635 842
Total, All Banks	6 555	3 343	11 681	5 433 126	990 465	2 384 109	8 829 279	7 777 599
A.R.D.B	..	..	..	20 851	..	..	20 851	892
C.D.B.	..	..	..	..	..	..	..	357 562

(a) For legend on abbreviations of Bank names see footnote on page 2640. (b) See note (c) on Statement of Assets. (c) See note (d) on Statement of Assets.

Note. Any discrepancies between totals and sums of components are due to rounding.

(\$'000)

Deposits repayable in Australia								Loans (other than loans to authorised dealers in the short-term money market), advances and bills discounted (b)
Commonwealth and State Governments			Other than Commonwealth and State Governments			Total Deposits		
Current		Not Bearing Interest	Current		Not Bearing Interest			
Bank(a)	Fixed		Bearing Interest	Fixed			Bearing Interest	
SOUTH AUSTRALIA								
Major Banks—								
A.N.Z.	..	..	68	468 336	94 056	224 510	786 970	1 047 163
Commonwealth	398	2 805	343	427 965	20 857	122 950	575 318	712 650
National.	1 106	..	33	490 850	59 991	106 359	658 338	583 960
Westpac.	..	..	..	173 948	68 977	156 906	399 831	639 703
Total, Major	1 504	2 805	443	1 561 098	243 881	610 725	2 420 456	2 983 476
Other Banks—								
Barclays	..	..	..	..	..	..	..	400
Chase A.M.P.	..	..	..	25 143	14 364	..	39 506	5 005
Citibank.	..	..	..	..	310	..	310	5 454
Lloyds N.Z.A.	13	..	..	2 311	..	..	2 324	..
Nat. Mutual	..	..	..	4 972	1 691	..	6 663	3 081
NatWest.	..	..	..	36 011	..	..	36 011	52 363
New Zealand	..	..	..	1 441	9 548	726	11 714	16 662
Paris	..	..	..	2 955	22	282	3 259	26 997
P.I.B.A.	..	..	..	18 859	..	..	18 859	20 660
Standard	..	..	..	15 817	8 450	515	24 781	48 697
State Bank S.A. (c)	..	..	..	1 606 588	168 290	73 198	1 848 076	2 906 906
Total, Other.	13	..	..	1 714 097	202 674	74 720	1 991 502	3 086 224
Total, All Banks	1 517	2 805	443	3 275 195	446 555	685 444	4 411 958	6 069 700
A.R.D.B.	..	..	..	21 854	..	..	21 854	11 667
C.D.B.	..	..	..	..	..	..	..	241 645
WESTERN AUSTRALIA								
Major Banks—								
A.N.Z.	1 369	..	35	488 905	31 420	217 508	739 238	628 932
Commonwealth	427	1 489	115	498 695	18 047	216 921	735 692	916 053
National.	4 511	..	..	518 999	72 335	196 557	792 402	895 932
Westpac.	..	..	..	469 955	221 220	338 873	1 030 047	1 015 070
Total, Major	6 307	1 489	150	1 976 554	343 022	969 859	3 297 379	3 455 987
Other Banks—								
America	..	..	..	2 163	..	826	2 988	310
Bankers Trust	..	..	..	9 046	..	..	9 046	..
Barclays	..	..	..	..	..	..	..	22 022
Chase A.M.P.	..	..	..	9 027	4 794	..	13 821	3 413
Citibank	..	..	..	..	51	..	51	4 055
HongKong	..	..	..	4 153	8 022	..	12 175	68 022
I.B.J.	..	..	..	19 156	2 990	69	22 214	53 176
Lloyds N.Z.A.	..	..	..	..	..	..	..	3 600
Nat. Mutual	..	..	..	4 926	..	..	4 926	86
NatWest.	..	..	..	42 864	1 232	1 099	45 195	124 145
New Zealand	..	..	..	39 457	35 057	14 915	89 428	86 481
Paris	..	..	..	13 593	272	3 602	17 468	20 436
P.I.B.A.	..	..	..	1 760	..	..	1 760	68 594
Singapore	..	..	..	..	..	..	..	7 451
Standard	..	..	..	49 529	6 884	97	56 509	43 947
R. & I. of W.A. (c)	45 151	1 470	98	1 758 952	105 817	301 639	2 213 126	2 285 881
Total, Other.	45 151	1 470	98	1 954 624	165 118	322 245	2 488 706	2 791 617
Total, All Banks	51 458	2 958	248	3 931 177	508 140	1 292 104	5 786 084	6 247 604
A.R.D.B.	..	..	..	19 451	..	..	19 451	..
C.D.B.	..	..	..	..	..	..	..	292 727

(a) For legend on abbreviations of Bank names see footnote on page 2640. (b) See note (c) on Statement of Assets. (c) See note (d) on Statement of Assets.

Note. Any discrepancies between totals and sums of components are due to rounding.

(\$'000)

Deposits repayable in Australia								Loans (other than loans to authorised dealers in the short-term money market), advances and bills discounted (b)
Bank(a)	Commonwealth and State Governments			Other than Commonwealth and State Governments			Total Deposits	
	Current		Not Bearing Interest	Current		Not Bearing Interest		
	Fixed	Bearing Interest		Fixed	Bearing Interest			
TASMANIA								
Major Banks—								
A.N.Z.	4	..	26	129 970	25 083	79 040	234 123	332 489
Commonwealth	517	364	1 472	91 591	14 101	44 295	152 339	173 011
National	1 641	..	..	40 527	7 301	17 173	66 643	108 925
Westpac	493	..	..	91 118	36 833	77 529	205 972	253 645
Total, Major	2 655	364	1 499	353 206	83 318	218 036	659 077	868 069
Other Banks—								
Chase A.M.P.	..	..	..	8 563	7 762	..	16 325	882
Citibank	..	..	..	..	..	..	..	252
Lloyds N.Z.A.	..	..	..	..	..	..	..	500
NatWest	..	..	..	2 846	..	..	2 846	20 484
P.I.B.A.	..	..	..	6 723	..	..	6 723	..
Total, Other	..	..	..	18 132	7 762	..	25 894	22 118
Total, All Banks . .	2 655	364	1 499	371 338	91 080	218 036	684 971	890 187
A.R.D.B.	..	..	..	15 787	..	..	15 787	7 801
C.D.B.	..	..	..	..	..	..	..	84 249
NORTHERN TERRITORY								
Major Banks—								
A.N.Z.	4 354	..	28	45 168	6 053	32 620	88 222	111 895
Commonwealth	98	60	16	31 608	2 017	17 964	51 764	56 980
National	2 115	..	..	35 147	10 061	15 097	62 420	57 787
Westpac	..	885	532	21 705	13 924	38 244	75 289	137 486
Total, Major	6 567	945	576	133 628	32 055	103 925	277 695	364 148
Other Banks—								
Chase A.M.P.	..	..	..	100	447	..	547	290
NatWest	..	..	..	..	..	..	..	4 398
P.I.B.A.	..	..	..	12	..	..	12	..
Standard	..	..	..	7 216	2 948	164	10 328	13 500
State Bank S.A. (c) . .	..	..	..	1 977	32 542	..	34 520	43 080
Total, Other	..	..	..	9 305	35 938	164	45 406	61 267
Total, All Banks . .	6 567	945	576	142 933	67 993	104 088	323 101	425 415
C.D.B.	..	..	..	..	..	..	..	22 563
AUSTRALIAN CAPITAL TERRITORY								
Major Banks—								
A.N.Z.	..	..	..	36 366	3 729	31 017	71 112	72 248
Commonwealth	1 839	6 176	..	98 040	39 334	68 093	213 482	281 539
National	2 075	2 500	2	47 829	28 267	36 936	117 607	188 137
Westpac	..	..	..	48 409	98 492	72 079	218 981	202 825
Total, Major	3 914	8 676	2	230 643	169 822	208 124	621 180	744 748
Other Banks—								
Chase A.M.P.	..	..	..	119	96	..	215	496
Citibank	..	..	..	..	12	..	12	951
Nat. Mutual	..	..	..	..	258	..	258	1 402
NatWest	..	..	..	5 052	..	..	5 052	17 225
Paris	..	..	..	1 049	145	905	2 099	2 784

(a) For legend on abbreviations of Bank names see footnote on page 2640. (b) See note (c) on Statement of Assets. (c) See note (d) on Statement of Assets.

Note. Any discrepancies between totals and sums of components are due to rounding.

(\$'000)

<i>Deposits repayable in Australia</i>								<i>Loans (other than loans to authorised dealers in the short-term money market), advances and bills discounted (b)</i>
<i>Commonwealth and State Governments</i>			<i>Other than Commonwealth and State Governments</i>			<i>Total Deposits</i>		
<i>Current</i>			<i>Current</i>					
<i>Bank(a)</i>	<i>Fixed</i>	<i>Bearing Interest</i>	<i>Not Bearing Interest</i>	<i>Fixed</i>	<i>Bearing Interest</i>		<i>Not Bearing Interest</i>	
P.I.B.A.	..	..	..	931	..	..	931	..
State Bank N.S.W. (c)	..	..	..	46 717	2 366	8 546	57 630	213 787
Total, Other	..	..	..	53 868	2 876	9 451	66 195	236 645
Total, All Banks	3 914	8 676	2	284 511	172 698	217 575	687 375	981 393
A.R.D.B.	..	..	..	2 425	..	..	2 425	..
C.D.B.	..	..	..	..	..	..	..	12 665
OTHER TERRITORIES								
Major Banks—								
Commonwealth	..	16	..	18 120	1 036	1 351	20 523	7 185
Westpac	..	..	..	48 264	859	2 757	51 879	9 696
Total, Major	..	16	..	66 385	1 895	4 107	72 403	16 881
Total, All Banks	..	16	..	66 385	1 895	4 107	72 403	16 881

(a) A.N.Z.—Australian and New Zealand Banking Group Limited.

Commonwealth—Commonwealth Bank of Australia.

National—National Australia Bank Limited.

Westpac—Westpac Banking Corporation.

America—Bank of America Australia Limited.

Aust. Bank—Australian Bank Limited.

Bankers Trust—Bankers Trust Australia Limited.

Barclays—Barclays Bank Australia Limited.

Chase A.M.P.—Chase A.M.P. Bank Limited.

China—Bank of China.

Citibank—Citibank Limited.

Deutsche—Deutsche Bank Australia Limited.

HongKong—HongKong Bank of Australia Limited.

I.B.J.—I.B.J. Australia Bank Limited.

Lloyds N.Z.A.—Lloyds Bank N.Z.A. Limited.

Macquarie—Macquarie Bank Limited.

Mitsubishi—Mitsubishi Bank of Australia Limited.

Nat. Mutual—National Mutual Royal Bank Limited.

NatWest—NatWest Australia Bank Limited.

New Zealand—Bank of New Zealand.

Paris—Banque Nationale de Paris.

P.I.B.A.—Primary Industry Bank of Australia.

Queensland—Bank of Queensland Limited.

Singapore—Bank of Singapore (Australia) Limited.

Standard—Standard Chartered Bank Australia Limited.

Tokyo—Bank of Tokyo Australia Limited.

State Bank N.S.W.—State Bank of New South Wales (General Bank Department).

State Bank S.A.—The State Bank of South Australia.

R. & I. of W.A.—The Rural and Industries Bank of Western Australia (General Banking Department).

A.R.D.B.—Australian Resources Development Bank.

C.D.B.—Commonwealth Development Bank of Australia.

(b) See note (c) on Statement of Assets.

(c) See note (d) on Statement of Assets.

Note: Any discrepancies between totals and sums of components are due to rounding.

N.N.—8867368



COMMONWEALTH OF AUSTRALIA

FISHERIES ACT 1952

FISHERIES NOTICE NO. ECC1

EAST COAST DEEP-WATER CRUSTACEAN TRAWL FISHERY: PROHIBITION ON
TRAWLING FOR CRUSTACEANS WITHOUT ENDORSEMENT

I, JOHN CHARLES KERIN, Minister of State for Primary Industries
and Energy, hereby:

- (a) provide that this Notice shall come into force on
15 November 1988;
- (b) provide that, in this Notice, words have the same meaning
as in the Act and -

"licence" means a licence granted to a person, in
respect of a boat, under subsection 9(2) of the Act;
and

"the Act" means the Fisheries Act 1952;

- (c) pursuant to paragraph 8(1)(c) of the Act, prohibit the
taking of fish of the Class Crustacea, in the area of
proclaimed waters specified in Schedule 1, by the method
known as trawling;
- (d) pursuant to paragraph 8(1)(da) of the Act, prohibit a
person from having in the person's possession or in the
person's charge in a boat, in the area of proclaimed
waters specified in Schedule 1, a trawl net the mesh of
which is less than, or equal to, 60 millimetres when
measured in accordance with either Schedule 2 or Schedule
3;
- (e) pursuant to paragraph 8(40)(b) of the Act, declare that
the activities to which the prohibitions contained in
paragraphs (c) and (d) of this Notice relate are
activities in respect of which an endorsement may be made
under subsection 9(4) of the Act; and
- (f) revoke Fisheries Notice No. 44, published in Gazette 57 E
on 15 July 1974, in its application to the taking of fish
by the method known as trawling with the use of a boat,
the licence in respect of which is endorsed under
subsection 9(4) of the Act pursuant to this Notice.

SCHEDULE 1

AREA OF THE EAST COAST DEEP-WATER CRUSTACEAN TRAWL FISHERY

The area of proclaimed waters contained within the area bounded by a line:

- (1) commencing at the point of Latitude 33°35'South, Longitude 153°20'East;
- (2) thence northerly along the geodesic to the point of Latitude 30°South, Longitude 154°45'East;
- (3) thence northerly along the geodesic to the point of Latitude 27°48'South, Longitude 154°40'East;
- (4) thence north along that meridian to its intersection by the parallel of Latitude 22°15'South;
- (5) thence north-westerly along the geodesic to the point of Latitude 18°45'South, Longitude 152°35'East;
- (6) thence westerly along the geodesic to the point of Latitude 18°20'South, Longitude 148°20'East;
- (7) thence north-westerly along the geodesic to the point of Latitude 15°South, Longitude 146°East;
- (8) thence north-westerly along the geodesic to the point of Latitude 13°South, Longitude 145°East;
- (9) thence north along that meridian to its intersection by the outer limit of the Australian fishing zone;
- (10) thence generally southerly along that outer limit to its intersection by the parallel of Latitude 33°35'South; and
- (11) thence west along that parallel to the point of commencement.

SCHEDULE 2

Manner of measuring mesh of net

1. Immediately before a measurement is taken, the part of the net to be measured shall be soaked in fresh or salt water for not less than 5 minutes.

2. The part of the net to be measured shall then be suspended vertically and a weight of 3170 grams shall be suspended from one knot of that part of the net.
3. The distance between the surface of the knot from which the weight is suspended and the surface of the knot in the diagonally opposite corner of the mesh immediately above the first-mentioned knot shall be measured with a metal rule to the nearest millimetre.
4. The measurement of the mesh shall be taken to be the average measurement of 10 adjacent meshes at any place in the net.

SCHEDULE 3

Manner of measuring mesh of net

1. Immediately before a measurement is taken the part of the net to be measured shall be soaked in fresh or salt water for not less than 5 minutes.
2. The part of the net to be measured shall be suspended vertically. The distance between the surface of a knot and the surface of the knot diagonally opposite the first-mentioned knot in the same mesh shall be measured by means of a device designed for the measuring of the mesh of nets by means of two arms, the upper of which, when the device is in use, shall be fixed to the body of the device and the lower of which when the device is in use shall:
 - (a) be directly below the upper arm;
 - (b) move freely in relation to the upper arm; and
 - (c) have a weight of 3170 grams acting on it.
3. The device shall be suspended in such a manner as to ensure that the upper edge shall remain in a fixed position and that the lower edge may move freely in relation to the upper edge, within the confines of the mesh to be measured.

4. The device shall be equipped with a scale from which the distance between the upper edge of the upper arm and the lower edge of the lower arm can be ascertained at any time to the nearest millimetre.

Dated this

Tenth

day of

November

1988.

John Kerin

JOHN KERIN

COMMONWEALTH OF AUSTRALIA

FISHERIES ACT 1952

FISHERIES NOTICE NO. 117D

PROHIBITION ON THE TAKING OF PRAWNS OFF THE EAST COAST OF NEW
SOUTH WALES WITHOUT ENDORSEMENT: VARIATION OF FISHERIES NOTICE
NO. 117

I, JOHN CHARLES KERIN, Minister of State for Primary Industries and Energy, pursuant to section 8 of the Fisheries Act 1952, hereby vary Fisheries Notice No. 117, published in Gazette No. S 272 on 4 November 1983 by omitting all the words after "hereby" and substituting the following:

- " (a) provide that this Notice shall come into force on 15 November 1988;
- (b) provide that, in this Notice, words have the same meaning as in the Act and "the Act" means the Fisheries Act 1952;
- (c) pursuant to paragraph 8(1)(a) of the Act, prohibit the taking, processing or carrying of fish of the family Penaeidae (commonly known as prawns or shrimps) in the area of proclaimed waters specified in the Schedule; and
- (d) pursuant to paragraph 8(4D)(b) of the Act, declare that the activities to which the prohibition contained in this Notice relates are activities in respect of which an endorsement may be made under subsection 9(4) of the Act.

SCHEDULE

AREA OF THE IN-SHORE PRAWN FISHERY OFF THE EAST COAST OF NEW
SOUTH WALES

The area of proclaimed waters contained within the area bounded by a line:

- (1) commencing at the point of intersection of the eastern shore of Australia by the parallel of Latitude 28°10'South;
- (2) thence easterly along the geodesic to the point of Latitude 27°58'South, Longitude 154°East;

- (3) thence north-easterly along the geodesic to the point of Latitude 27°48'South, Longitude 154°22'East;
- (4) thence east along that parallel to its intersection by the meridian of Longitude 154°40'East;
- (5) thence southerly along the geodesic to the point of Latitude 30°South, Longitude 154°45'East;
- (6) thence south-westerly along the geodesic to the point of Latitude 33°35'South, Longitude 153°20'East;
- (7) thence east along that parallel to its intersection by the eastern shore of Australia; and
- (8) thence generally northerly along that shore to the point of commencement."

Dated this *Tenth* day of *November* 1988.

John Kerin
JOHN KERIN

Fisheries Act 1952

Fisheries Notice No. 216.


REVOCATION OF FISHERIES NOTICES

In pursuance of section 8 of the Fisheries Act 1952, I, JOHN CHARLES KERIN, Minister of State for Primary Industries and Energy, hereby revoke the Fisheries Notices specified in the Schedule

SCHEDULE

Notice No.	Gazette No.	Gazette date
17	97	14 November 1963
40	129	20 September 1973
40A	S 1	06 January 1984
46	57 E	15 July 1974
51	103 E	23 December 1974
52	103 E	23 December 1974
53	103 E	23 December 1974
54	103 E	23 December 1974
54A	S 133	11 April 1984
55	103 E	23 December 1974
55A	S 133	11 April 1984
56	G 13	08 April 1975
57	G 13	08 April 1975
58	G 13	08 April 1975
59	G 13	08 April 1975
69	S 191	27 October 1976
75	S 79	03 May 1977
75A	S 133	11 April 1984
75B	S 340	28 August 1985
87	S 144	19 July 1979
90	S 142	27 June 1980
99	S 209	02 October 1981
107	S 229	01 November 1982
109	S 133	11 April 1984
112	S 133	11 April 1984
129	S 470	05 November 1984
136	S 340	28 August 1985
146	S 371	16 September 1985
149	S 413	09 October 1985
153	S 435	24 October 1985
164	S 154	08 April 1986

Dated this *Tenth* day of *November* 1988


JOHN CHARLES KERIN



PROCLAMATION

Commonwealth of
Australia
N. M. STEPHEN
Governor-General

By His Excellency the
Governor-General of
the Commonwealth of
Australia

I, SIR NINIAN MARTIN STEPHEN, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council and pursuant to subsection 2 (9) of the *Statute Law (Miscellaneous Provisions) Act 1987*, hereby fix 1 December 1988 as the day on which amendments to the *Commonwealth Prisoners Act 1967* made by the first-mentioned Act shall come into operation. (L.S.) GIVEN under my hand and the Great Seal of Australia on 8 November 1988

By His Excellency's Command,

LIONEL BOWEN
Attorney-General

GOD SAVE THE QUEEN!

AN ARRANGEMENT BETWEEN HIS EXCELLENCY THE GOVERNOR-GENERAL OF THE COMMONWEALTH OF AUSTRALIA, acting with the advice of the Federal Executive Council, and HIS HONOUR THE ADMINISTRATOR OF THE NORTHERN TERRITORY OF AUSTRALIA, acting with the advice of the Executive Council of the Northern Territory.

IT IS HEREBY ARRANGED, pursuant to section 21 of the *Commonwealth Prisoners Act 1967* of the Commonwealth and all powers thereunto enabling, as follows:

1. Persons who hold office as Stipendiary Magistrates in the Northern Territory of Australia may perform the functions of a prescribed authority under the *Commonwealth Prisoners Act 1967* or that Act as amended from time to time.
2. Officers of the Northern Territory who perform the functions of parole officer or probation officer in that Territory may perform the functions of a parole officer under the *Commonwealth Prisoners Act 1967* or that Act as amended from time to time.

Dated 8 November 1988

N. M. STEPHEN
Governor-General

By His Excellency's Command
LIONEL BOWEN
Attorney-General

E. E. JOHNSTON
Administrator

By His Honour's Command
DONALD F. DALE
Minister for Health and
Community Services



NOTIFICATION OF THE MAKING OF STATUTORY RULES

Notice is hereby given that the undermentioned Statutory Rules have been made. Copies of the Statutory Rules may be purchased at the Commonwealth Government Bookshop, 70 Alinga St, Canberra City, ACT.

<i>Act under which the Statutory Rules were made</i>	<i>Description of the Statutory Rules</i>	<i>Year and number of the Statutory Rules</i>
<i>Superannuation Act 1976</i>	Superannuation (Approved Authorities) Regulations (Amendment)	1988 No. 273
<i>Superannuation Act 1976</i>	Superannuation (Interest) Regulations (Amendment)	1988 No. 274
<i>Superannuation Act 1976</i>	Superannuation (Existing Invalidity Pensioners) Regulations	1988 No. 275
<i>Marriage Act 1961</i>	Marriage Regulations (Amendment)	1988 No. 276
<i>Air Navigation Act 1920</i>	Air Navigation (Aircraft Noise) Regulations (Amendment)	1988 No. 277



AGPS

COMMONWEALTH GOVERNMENT

Publications

A wide selection of government publications is available from Commonwealth Government Bookshops located in Canberra and all State capitals and through the Australian Government Publishing Service Mail Order Service. The range includes most titles published by AGPS for federal departments and agencies and covers all aspects of the Australian land, people and government. In addition to government reports, parliamentary publications, government directories, freedom of information statements, legislation and gazettes, subjects include:

**BUSINESS
FINANCE
INDUSTRY
MANUFACTURING
TRANSPORT
COMMUNICATIONS
EDUCATION
ENVIRONMENT
FAUNA
FLORA
AGRICULTURE
TRADE
FOREIGN POLICY
DEFENCE
HEALTH
HUMAN RIGHTS
ABORIGINAL AFFAIRS
ETHNIC AFFAIRS
IMMIGRATION
WOMEN'S ISSUES
COMMUNITY SERVICES
WELFARE
SAFETY
ARTS
HERITAGE
INDUSTRIAL RELATIONS
TECHNOLOGY
COMMERCE
RESOURCES
ENERGY
SCIENCE
RECREATION
TOURISM**

COMMONWEALTH GOVERNMENT

Bookshops



ADELAIDE

55 Currie Street
Weekdays 8.30 a.m. – 5.00 p.m.
Telephone (08) 237 6955



BRISBANE

294 Adelaide Street
Weekdays 8.30 a.m. – 5.00 p.m.
Telephone (07) 229 6822



CANBERRA

70 Alinga Street
Weekdays 8.30 a.m. – 5.00 p.m.
Telephone (062) 47 7211



HOBART

162 Macquarie Street
Weekdays 8.40 a.m. – 5.00 p.m.
Telephone (002) 23 7151



MELBOURNE

347 Swanston Street
Weekdays 8.30 a.m. – 5.00 p.m.
Telephone (03) 663 3010



PERTH

200 St George's Terrace
Weekdays 8.30 a.m. – 5.00 p.m.
Telephone (09) 322 4737



SYDNEY

120 Clarence Street
Weekdays 8.30 a.m. – 5.30 p.m.
Telephone (02) 29 1940



MAIL ORDERS

Include payment with order to
Mail Order Sales
AGPS
G.P.O. Box 84
Canberra, A.C.T. 2601